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CHAPTER 1 
GENERAL INTRODUCTION 

General Introduction 
INTRODUCTION 
Fatty acids are essential for every living cell. They are a source of energy by their 
oxidation in mitochondria and peroxisomes. Fatty acids are also part of lipids, which form the 
membrane structures to maintain cell integrity. Various cellular processes are affected by their 
interactions with enzymes, ion channels, receptors and genes. The transport of fatty acids has to 
be facilitated by proteins because of their low solubility in aqueous environment. In plasma, 
fatty acids are transported either bound to albumin or esterified in triacylglycerols of chylomi-
crons and very-low-density lipoproteins. The uptake across the plasma membrane occurs 
presumably by diffusion. In cytoplasm of tissues the flux of fatty acids between plasma 
membrane and cellular organelles is thought to be controlled by the low-molecular mass (15 
kDa) fatty acid-binding proteins (FABPs). In the last two decades many reports have been 
published on the presence of the FABPs in all kinds of tissues of various species. The FABPs 
were named after the first tissue, they were isolated from. Up to now seven FABP types have 
definitively been established by the analysis of the amino acid sequence of the isolated protein 
and/or the cDNA sequence. 
In our laboratory studies were devoted to develop adequate methods to assay and isolate 
FABPs from various tissues of rat, pig and human. Especially the FABPs from liver and heart 
or skeletal muscle, representing the liver and heart FABP types were investigated. The liver 
FABP type appeared to be present in liver and intestine, the heart (muscle) FABP type is 
present in heart, skeletal muscle but also in many other tissues. 
In this thesis we devoted especially our attention to the identification and characterization 
of FABP(s) in human kidney, since this organ presents a marked biochemical heterogeneity. 
The human kidney is an excretory organ which consists of about 106 basic units, called 
nephrons. Each nephron is composed of a glomerulus, which is a tuft of capillaries interposed 
between the afferent and the efferent arteriole, and a series of tubules lined by a continuous 
layer of epithelial cells. The glomeruli are located in the outer part of the kidney, called the 
cortex, whereas the tubules are present in both the cortex and the inner part of the kidney, the 
medulla. An ultrafiltrate of plasma formed across the glomerulus passes through the tubules and 
is modified by reabsorption and secretion. The different tubular segments contribute in different 
ways to these processes by their different permeability and transport characteristics. In the 
proximal tubules isosmotic reabsorption of about 70% of filtered water and NaCl takes place 
based on active sodium transport. Active reabsorption of glucose and amino acids and secretion 
of organic cations and anions occur in this nephron segment and low-molecular proteins filtered 
through the glomerulus are reabsorbed and degraded. The proximal tubule forms also the 
primary target for many nephrotoxic drugs, halogenated hydrocarbons, mycotoxins and heavy 
metals. The function of the distal tubules and the collecting ducts is the final adjustment of 
sodium and water excretion. Solute reabsorption in these nephron segments is characterized by 
finely regulated transport processes against gradients in contrast to the bulk absorption in the 
proximal tubule. 
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For the reabsorption and secretion processes the kidney requires much energy which is 
reflected by the oxygen consumption. Although the kidney represents less than 0.5% of total 
body mass, renal oxygen consumption constitutes approximately 8% of whole body mass. In 
general there is a fairly good correlation between the intranephron oxygen consumption and 
mitochondrial density. The mitochondrial density does not differ much between the various 
nephron segments in contrast to the metabolism to obtain the required energy. Segmental 
differences in substrate utilization may reflect differences in cellular uptake and/or mitochondri-
al transport or differences in activity of the enzymes. The proximal tubules are characterized by 
aerobic oxidation of substrates and gluconeogenesis whereas the distal tubules show aerobic and 
anaerobic glycolysis. In the proximal tubules fatty acids serve as energy supply and are 
metabolized by B-oxidation in mitochondria and peroxisomes. The excess of fatty acids is 
incorporated in triacylglycerols. In the distal tubules only mitochondrial oxidation occurs and 
triacylglycerol synthesis is low. 
In view of their different metabolic and transport characteristics the significance of 
F ABP may differ in the various nephron segments. FABP may play a role in the uptake and 
utilization of fatty acids, but possibly also in the transfer and conversion of other hydrophobic 
compounds as steroid hermones, prostaglandins, vitamins and drugs. It may also have a 
protectoryrole against high concentrations of fatty acids or acyl-Coenzyme A esters arising in 
the case of ischemia or anoxia. 
In an additional investigation we describe the primary structure and properties of FABP 
from the flight muscle of a locust, Locusta migratoria for comparison with those of the human 
heart (muscle) FABP type. The flight muscles of locusts are among the most active muscles 
known. They display exceptionally high rates of fuel utilization during migratory flight. Fatty 
acids form then the principal substrate. 
AIM AND OUTLINE OF THIS THESIS 
In these investigations we tried to elucidate novel structural and functional characteristics 
of FABPs by biochemical and molecular biological approaches. We focussed on FABP in the 
kidney, because fatty acids play an important role in the energy supply within this organ and a 
marked biochemical and physiological intranephron heterogeneity exists. 
Chapter 2 gives an overview of the current knowledge of the FABP family. We 
discussed structural and functional aspects of the various FABP types. 
First we studied the presence of FABP in human kidney was studied (Chapter 3). Two 
FABP types were isolated and characterized. Their physicochemical and binding properties and 
their distribution within the kidney were investigated. 
Subsequently we elucidated their primary structure by analysis of cDNA prepared by 
reverse transcriptase polymerase chain reaction on human kidney RNA (Chapter 4). This 
method and immunocytochemistry were also applied to identify and localize the FABP types in 
rat kidney. 
The presence and different localization of two FABP types within the kidney could 
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relate to differences in binding characteristics. Therefore we expressed both proteins in 
Escherichia coli and performed extensive comparative analysis of binding characteristics of both 
FABP types with fatty acids of various chain-length and saturation grade and with various other 
types of hydrophobic ligands (Chapter 5). 
In an additional project we performed a comparative analysis of the primary structure of 
FABP from human muscle and from the flight muscle of Locusta migratoria to study evolutio-
nary aspects of this protein (Chapter 6). We isolated the cDNA of night muscle FABP and 
manipulated E.coli to express the protein. The recombinant protein was compared with 
recombinant human muscle FABP in radiochemical and fluorescent binding studies. 
In the last chapter a summary is given of the results described in this thesis. 

CHAPTER 2 
INTRODUCTION: STRUCTURAL AND FUNCTIONAL ASPECTS 
OF CYTOPLASMIC FATTY ACID-BINDING PROTEINS 
J.H. Veerkamp, T.H.M.S.M. Van Kuppevelt, R.G.H.J. Maatman and C.F.M. Prinsen 
Prostaglandins Leukot. Essent. Fatty Acids (1994) 49, 887-906 
(modified and extended version) 

Introduction 
Introduction 
The solubility and the translocation of hydrophobic ligands is facilitated in intra- and extracel­
lular fluid by so-called lipid-binding or -transfer proteins (1,2). These proteins may catalyze 
intermembrane transfer and exchange of lipids as fatty acids, retinol, retinoic acid, steroids, 
phospholipids, but may also modulate the concentration of the free form of the hydrophobic 
ligand. These proteins may be classified as extra- or intracellular lipid-transfer proteins 
depending on their location. A special class is formed by the plasma membrane lipid-binding 
proteins, of which the existence is equivocal. The proteins can be present in lipid-protein 
complexes (lipoproteins) like in serum, or function as separate lipid carriers. The latter group of 
proteins may non-covalently bind various types of ligands, but generally they have only high 
affinity for one class of ligands or to one ligand. Albumin is the main transporter of fatty acids 
and many other lipophilic ligands in the plasma and the interstitial fluid, but specific binding 
proteins are present for retinol, vitamin D and steroids (3). Besides albumin, α-fetoprotein and 
fetuin can function as carriers of fatty acids in fetal plasma (4). 
From the capillary to the mito­
chondrion, fatty acids have to pass 
through a series of aqueous spaces and 
membranes (Fig.l). Various models 
and systems have been suggested for 
the mechanism of cellular uptake of 
fatty acids (5,6). The presence of al­
bumin receptors and their involvement 
in fatty acid uptake by hepatocytes and 
cardiomyocytes is still a matter of 
investigation and debate (7-9). A frac­
tion of albumin-fatty acid molecules are 
transcytosed by endothelial plas-
malemmal vesicles into the interstitial 
fluid (10). Various groups described the 
presence of plasma membrane proteins 
that may be involved in fatty acid bin­
ding or transmembrane transport, in various cell types as adipocytes, hepatocytes, myocytes, 
and enterocytes (6,11-15). The molecular mass of the proteins was determined to be about 22, 
40-43, or 85 kDa. The first protein was identified by photoaffinity labeling in adipocytes (14), 
the second was isolated by affinity chromatography from various other cell types (6,12,13), the 
third was found by binding of radiolabeled sulfosuccinimidyl long-chain fatty acids (15). 
Antibodies against the 40-43 kDa protein from liver inhibited fatty acid uptake into hepatocytes, 
adipocytes and cardiac myocytes (12,13,16,17), but by never more than 69%. This indicates 
that only a portion of the fatty acid uptake may be mediated by a plasma membrane protein. 
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Fig.l Schematic representation of the way of transport 
of fatty acids from blood to mitochondrion. Abbrevia­
tions: FA, fatty acid; VLDL, very low density lipopro­
teins; chylos, chylomicrons; LPL, lipoprotein lipase; ECF, 
extracellular fluid. 
Chapter 2 
The mediated uptake would especially be the case at low fatty acid concentrations, as in the fed 
condition. Differentiation of adipocytes is accompanied by the expression of a 43-kDa plasma 
membrane fatty acid-binding protein (17). Recent measurements of fatty acid transport through 
the adipocyte plasma membrane with fluorescence microscopy indicate that the uptake of a large 
fraction of long-chain fatty acids is mediated by protein (18). 
Reports about the involvement of plasma membrane proteins in fatty acid uptake do not 
exclude the possibility that the distribution of the ligand into the membrane phospholipids plays 
an important role. Diffusion through the lipid phase together with equilibration between 
extracellular albumin and intracellular cytosolic fatty acid-binding proteins (FABPs) may also 
explain the observed saturation kinetics of the initial rate of fatty acid uptake (19-21). Unionized 
fatty acids move spontaneously and rapidly across phospholipid bilayers (22). The fast "flip-
flop" of uncharged fatty acids across phospholipid bilayers provides a simple and energy-
independent mechanism for rapid entry of fatty acids into cells such as adipocytes, hepatocytes 
and myocytes. 
In heart, skeletal muscle and adipose tissue, fatty acids have to pass capillary en-
dothelium prior to uptake into myocytes or adipocytes. Transcytosis of endothelial plasmalem-
mal vesicles containing albumin-bound fatty acids may play a role (10), but other transcellular 
transport mechanisms may be more important (23). Cooperative interaction between endothelial 
and smooth muscle cells (25) and between liver endothelial and parenchymal cells (26) in fatty 
acid metabolism has been demonstrated. Albumin may play a role in fatty acid transport in the 
interstitial fluid between different cell types. The presence of plasma membrane fatty acid-
binding proteins in endothelial and smooth muscle cells has not been described up to now. Their 
probable role in transendothelial transport of fatty acids is thus an open issue. Scow and 
Blanchette-Mackie postulate, on the basis of electron microscopic studies, that fatty acids can be 
transported across endothelium in an interfacial continuum of membranes composed of the outer 
(luminal) leaflet of plasma and intracellular membranes of endothelial cells (24). According to 
their theory, the outer leaflets of the plasma membrane, endoplasmic reticulum and outer 
mitochondrial membrane form an analogous continuum of cell membranes for fatty acid 
transport in myocytes. Thus, in this model cytosolic FABPs would not be necessary for uptake 
and intracellular transport of fatty acids. Nevertheless, this review is devoted to these molecu-
les, although there is a paucity of experimental evidence and FABPs have many other functions, 
as we will discuss later. 
FABPs form a class of cytosolic proteins with a molecular mass of 14-15 kDa, which 
bind long-chain fatty acids and, depending on type, also other hydrophobic ligands. They have 
been isolated from or identified in various tissues of mammals, birds and fishes (27), insects 
(28-30) and worms (31). The different FABP types are denominated by the first tissue of 
isolation. Generally, these FABPs differ from other cellular lipid-binding proteins as the 
specific acyl-CoA binding protein (32), phospholipid-transfer proteins (33), glycolipid-transfer 
proteins (34) and sterol carrier protein (35) by their structure and also by their relative 
abundance. The cellular retinol-binding proteins (CRBP-I and -II) and retinoic acid-binding 
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proteins (CRABP-I and -Π) belong, on the basis of their primary structure and their confor­
mation to the same superfamily of non-enzymic lipid-binding proteins as the FABPs (36-39). 
For comparison, some data on these proteins are also given in this survey. 
The extracellular lipocalins as ß-lactoglobulin, serum retinol-binding protein, a,-
microglobulin and apolipoprotein D have no sequence similarity with this FABP super-family 
but show a marked degree of conformational identity (3,40,41). Since the first detection of 
FABPs in several rat tissues (42,43), several reviews have described the progress of the 
research on the structure and function of these proteins (5,27,38,39,44-50). Cloning and 
bacterial expression techniques and biophysical methods have led to new information about the 
molecular structure and conformation of these proteins and their interaction with the fatty acid 
ligand (27,51). In this review we will compare and discuss recent data on the structure and 
function of the different FABP types. 
Occurrence of at least 7 FABP types and their cellular and subcellular distribution 
FABPs have been isolated from tissues by a variety of procedures, including gel filtra-
tion, ion-exchange and affinity chromatography, (NH^SC^, precipitation and preparative 
electrophoresis (5). The existence of various tissue-specific FABP molecules was indicated by 
the necessary adaptations of the isolation procedures for different tissues. Amino acid analysis 
and sequencing of FABP preparations and cDNA analysis, have established, up to now, the 
Table 1 Characteristic differences of members of the FABP family. All differences are derived from 
human, except ileal FABP and CRBP II. Methionine on position 1 was not taken into consideration for 
numbering. Positions were indicated after alignment. 
Tyrosme phosphorylation site (15-19): asn-phe-asp-asp-tyr. 
Member 
Liver FABP 
Intestinal FABP 
Heart FABP 
Adipocyte FABP 
Myelin FABP 
Epidermal FABP 
Ileal FABP 
CRBP I 
CRBP II 
CRABPI 
CRABPn 
Tyr 
P-site" 
-
-
+ 
+ 
+ 
+ 
-
+ 
+ 
-
Arg 
•106' 
Ihr 
106 
106 
106 
106 
108 
ala 
gin 
gin 
i l l 
111 
Arg 
'126' 
122 
126 
126 
126 
126 
128 
123 
gin 
gin 
132 
132 
Туг 
"128" 
ser 
phe 
128 
128 
128 
130 
ser 
phe 
phe 
132 
132 
Trp 
-
6,82 
8,97 
8,97 
8,97 
10,99 
48 
8,88,106,109 
8,88,106,109 
87,109 
87,109 
Cys 
68 
-
124 
117 
117,124 
119,126 
68 
95,126 
121,125 
95,130 
95,130 
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existence of 7 FABP types (Tables 1 and 2). The occurrence of liver, intestinal and heart F ABP 
types was first described on base of structural and immunochemical data (see refs in 5 and 27), 
later proved by cDNA sequencing (see 52 and refs in 5 and 27). The large degree of similarity 
of the heart FABP type with the human and bovine myelin P2 protein, and the murine adipocyte 
P2 (p 422) protein was also noted (27,47,52) and reinforced by analysis of the cDNA sequence 
of rabbit and human myelin P2 (53,54), and human adipocyte FABP (55). However, the 
existence of a specific renal FABP (56,57) was recently disproved (58). In the kidney of 
mammals both the liver and the heart FABP type are present (58,59). In the male rat kidney, an 
additional fatty acid-binding a^-globulin molecule is present, which is not a FABP, but a 
lipocalin (3). This protein is secreted from the liver and undergoes endocytosis and proteolytic 
modification in the proximal tubules (57). The occurrence of specific ileal (60-62) and 
epidermal (63,64) FABP types have recently been established by amino acid and cDNA 
sequencing. The ileal FABP type was originally isolated as gastrotropin (60), but later identified 
by others as a cytoplasmic hydrophobic ligand-binding protein (61,62) or a bile acid-binding 
protein (65-67). More FABP types may exist but have to be carefully identified. Table 1 gives 
also, for comparison, some characteristics for the CRBPs and CRABPs. 
The presence of the FABP
 Τ Λ
^ Τ * « ο « ™ « ofFABP«^. 
1
 The identification of α FABP type in a tissue does not mean 
its presence in all cell types of that tissue; the FABP type may 
be limited to specific cells. 
1
 Evidence was obtained both by protein and mRNA analysis. 
types in the tissues given in Table 2 
is based on isolation of the protein, 
on mRNA analysis or on immunohis-
tochemical evidence. Up to now 
adipose tissue, myelin and epidermis 
appear to contain one specific FABP 
type. The immunochemical and/or 
immunohistochemical evidence for 
the presence of some FABP types in 
certain tissues needs to be es­
tablished. The structure of human 
muscle FABP is identical to that of 
human heart FABP (52). The heart 
FABP type appears to be the most 
general one in mammalian tissues (68-71). 
Immunocytochemical investigations show in addition to biochemical data, that some 
tissues express more than one FABP type. Their spatial and cellular distribution, however, 
differs markedly. After birth, only the liver and intestinal FABP types show a comparable 
cellular distribution in the intestine, with the same decreasing protein and mRNA gradient from 
villus top to crypt and from proximal jejunum to colon (65,72-76). The ileal FABP type is 
primarily expressed in the distal small intestine (65). A heterogenous pattern of cell-specific 
expression of the liver and intestinal FABP types is present in the intestinal villi of 18-day old 
rat fetuses (76). The distribution of the liver and heart FABP types in the kidney differs in rat 
Liver type 
Intestinal type 
Heart type 
Adipose type 
Myelin type 
Ileal type 
Epidermal type 
liver3, intestine2, stomach, kidney2 
intestine2, stomach 
heart', kidney2, skeletal muscle2, aorta2, 
lung, mammary gland, placenta2, brain2, 
testes, ovary, adrenals2, stomach 
adipose tissue2 
nervous system2 
intestine2, ovary, adrenals, stomach 
skin2 
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and man and also between both species (58,59). The liver type is limited to the proximal part of 
the nephron (man) (59), or present in proximal, distal and collecting tubules (rat) (58). The 
heart type is mainly (in man) or exclusively (in the rat) present in the distal tubules (58,59,68). 
Three F ABP types (heart, liver, and intestinal) are expressed in the rat stomach, depending on 
the cell type and developmental stage (77). Recently, the ileal FABP was also demonstrated in 
the surface mucous cells of the stomach (78). The heart and the ileal FABP type are present in 
different cells of the ovary (68,78). Discrepancy exists for the presence of the heart FABP type 
and/or its mRNA in adrenals (68,79) and brain (68,79,80). The FABP type in lung and placenta 
has also not been established (27). Immunohistochemical observations on rat skeletal muscles 
show a relation of the distribution of heart FABP type with the muscle fiber type (81). Slow-
oxidative and fast-oxidative-glycolytic fibers react strongly with anti-heart FABP antiserum, 
whereas staining of fast glycolytic fibers is weak or absent (81). Capillary endothelial cells are 
immunostained in heart and skeletal muscle, exocrine pancreas, digestive tract and thymus 
(68,81). 
The subcellular distribution of FABP has been studied by analysis of isolated cell 
fractions or by immunoelectron microscopy. Most data sustain the idea, that FABPs are 
confined to the cytoplasmic matrix outside the membranous organelles. Association with 
mitochondria, microsomes, peroxisomes, endoplasmic reticulum and lysosomes was not detected 
by most investigators (see refs in 5,27). With the immunogold technique especially, more 
locations were observed. The presence of the heart FABP and ileal FABP types were shown in 
rat heart mitochondria (82) and the nuclear matrix of rat enterocytes (76), respectively. Others 
observed the occurrence of the heart FABP type in the mitochondria and nuclei of bovine heart 
by ELISA (83) and isolated FABP from bovine heart mitochondria (84). The FABP from 
bovine heart mitochondria is identical to one of the two cytosolic isoforms (84). FABP was also 
found in nuclei of bovine liver (85) and of locust flight muscle (86), and in a slightly higher 
molecular form in nuclei of rat liver (87,88), but the latter appeared to be histone H } (89). 
Structural data 
The family of FABPs and related proteins contains at least 11 members (Table 1). The 
primary structure is known for the 7 FABP types, for CRBP-I and -II and CRABP-I and -II. 
Information was obtained from amino acid sequencing and cDNA analysis. The proteins contain 
126-137 amino acids and show various degrees of similarity. An orthologous protein (e.g. heart 
FABP type) from different mammalian species displays more similarity than two different 
members (from the same or different tissues) of the same species (27). The aligned amino acid 
sequence for 6 established FABP types, CRBP-I and CRABP-I and -II from man and CRBP-II 
from rat is given in Fig.2. The structure of human ileal FABP type and CRBP-Π is not known 
yet. The human heart FABP type has an amino acid sequence similarity to the bovine, rat and 
mouse orthologue of 99, 89, and 84%, respectively. Its similarity with the human adipocyte, 
myelin, liver and intestinal FABP types are 65, 61, 27, and 25%, respectively. Its similarity 
with human CRBP-I (90) and CRABP-I and CRABP-II (91) are 34, 38, and 37%, respectively. 
-21-
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L-FABP MS FSGK 
I-FABP HA PDSt 
H-FABP MVDA..FLGT 
My-FABP SNK..FLGX 
A-FABP MCDA..*VCT 
E-FABP HATVQO.LEGR 
CRBPI MPVD..FTGY 
CRBPII MTKD..QNGT 
CRABPI MPN...FAGT 
CRABPII HPN...?SGN 
SI 
L-FABP GKHPKFTITA 
I-FABP GNKFÎVRESS 
H-FABP SDILTLKTHS 
My-FABP вОІІТІАТЕЭ 
ÏQEQSQEWFE 
WKVDRSEKYB 
WKLVDSKNFP 
WKLVSSENFD 
WXLVSSBKFO 
WRLVDSKGFB 
WKMLVNERFE 
WEMESNEHFE 
WKMRS8EWFB 
WKIIRSEMFE 
GSKVIQNEST 
AKIHIBVVFE 
TFKOTRISFK 
AFMXftlGLPE 
KFMEKMQVNI 
El.. . IQKGKD 
VKRKXÄAHDN 
DYMRSLGVGF ÄTRQVASMT. 
DÏMKALGVGL 
DYMXEVGVGF 
EÏWKELGVGI 
EÏLRAÜDVNV 
GÏMKALDIDF 
ELLKALGVNA 
ELLRVLGVNV 
VGEEC8. .LE 
LGVTE>i. .YN 
ЬО КПЗЕ. .T 
TFKNTEISFX bGQEFBE..T 
A-FABP GOVITIXSES TFKNTÇJS?! 
E-FABP GKNLTIKtES TLKTTQFSCT 
ЬСОВТОЕ.. 
ÊGEKFB8..T 
CRBPI GDHMIIRTLS ÏFRHYIMDFQ. VGKEfEEDLT 
CRBPII GDNFXTICrNS 
CRABPI ÖOQfYlKTST 
CRABPII GDTFYIKTÎST 
101 
L-FABP TTFKNIKSVT 
I-FABP 
H-FABP 
My-FABP 
ft-FABP 
E-FABP 
CRBPI 
CRBPII 
CRABPI ( 
CRABPII ( 
.GKFKRTON 
TFHHYDLDFT VGVEFDEHTK 
tVRTTEÏNFK VGEGfEB..E 
TVRTTEINFK VGEEF5B..Q 
GNELNTVREI 
...LÖKW0G QETTLVKEtl 
...VQRWNG 
...VQKWDO 
. . . HQ.EWDG 
.QCVO.KGEK 
...VQKGEK 
:TQTLLEGDG 
:EQKLLKGEO 
KETTIKRKLV 
KSTTIKRKRE 
KESTIÎHKLK 
EGRGWE.QWI 
ENRGWK.QWV 
PKTYWTRELA 
PKTSWTRELT 
NGÖIITNTMT 
IGDELVOJTYV 
.OGKblLTLT 
.DGKMVAECK 
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Fig. 3 Alignment of the liver, intestinal, heart, myelin, adipocyte and epidermal FABP types, and of 
CRBP I, CRBP Π (rat), CRABP I and CRABP Π of man. Identical amino acid residues present in at 
least 5 molecules are shaded. 
The main differences are given in Table 1. The alignment shows a marked gap in the C-
terminal part of liver FABP. 
The finding that the FABP isolated from nurse shark liver is structurally far more 
closely related to the mammalian FABP types of heart, adipose tissue and myelin than to the 
mammalian liver FABP type, appears to differ from the conservation of FABP structure 
observed in mammalian tissues (92). Shark liver is, however, metabolically different from 
mammalian liver in that it behaves, in some respects, like adipose tissue. The FABPs from 
flight muscle of two locusts, Schistocerca gregaria and Locusta migratoria, show 41 and 42% 
identity respectively, with the human heart FABP (93, Maatman et al., unpublished data). A 
polypeptide in the flat worm, Schistosoma mansoni, displays a comparable degree of similarity 
with the heart, adipocyte and myelin FABP types of man and less with the liver and intestinal 
FABP types and the CRBPs (31). Two FABPs from the midgut of the tobacco homworm, 
Manduca sexta, show, however, only 20-30% similarity with all FABP types (30). 
A common ancestral gene for the FABPs was already proposed in 1983 on the basis of 
their structural relationship (94). Phylogenetic trees can be constructed on the basis of amino-
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acid and/or nonsynonymous nucleotide substitutions (92,95). Chan et al. (95) suggested a 
divergence of the ancestors of the two major subfamilies of the myelin/adipocyte proteins and 
the liver/intestinal FABPs before the vertebrate-invertebrate divergence 600 million years ago. 
The divergence of the members of the heart/myelin/adipocyte FABP family was at some time 
near the mammal-bird divergence (270 million years; 95). Divergence of the genes for 
mammalian liver FABP, ileal FABP, intestinal FABP, CRABP-I as well as the progenitor for 
CRBPs must have occurred prior to the mammal/fish divergence (92). 
Tertiary structure and ligand-binding site 
Computer analysis and circular dichroism measurements indicate a variable percentage 
(12-38%) of α-helical structure in various FABP types (5,27). Regions of internal similarity, 
tandemly arranged repeats, can be detected in different FABPs, but with variations in length, 
composition and position (5,27). 
The availability of recombinant proteins of FABPs in a larger amount and with a higher 
purity than after isolation from tissues gave a strong impetus to the use of biophysical techni­
ques. Preparations of rat liver (96,97) and intestinal (98,99), murine adipocyte (100,101) and 
bovine (102) and human (103) heart FABP types have been obtained from Escherichia coli 
cultures. Studies with fluorescence spectroscopy, nuclear magnetic resonance and X-ray 
diffraction have given much information about the tertiary structure and/or the lipid-binding site 
of the FABP types. Photo-affinity labeling and site-directed mutagenesis yield additional 
information. 
Fluorescent fatty acids with bulky side chains show, on the basis of fluorescence 
enhancement, a strong interaction with the liver FABP type (104-109), but no (or only a weak 
one) with the heart and adipocyte FABP type (104,109-111). Anthroyloxy-labeled fatty acids 
were reported to bind to liver, heart and adipocyte FABPs in a bent conformation within a 
hydrophobic pocket (109,111). The fatty acid bound to liver FABP demonstrates the highest 
degree of motional constraint, but is present in the most hydrophobic binding site (109,111). 
Adipocyte and heart FABP types are more similar to each other than either is to the liver FABP 
type (111). The binding pocket appears to be less open and more hydrophobic, in the rank 
order: heart FABP, adipocyte FABP, liver FABP (111). The interactions vary with the 
attachment site of the anthroyloxy group along the length of the fatty acid (105,111). 
Cis- and trans-parinaric acids were applied as spectroscopic reporters of the protein-
binding site of FABPs (108,112). Tyrosine and tryptophan are present in the binding pocket of 
liver FABP and intestinal FABP, respectively. The fatty acid-binding site of intestinal FABP is 
much less polar than that of liver FABP. The liver FABP appears to undergo significant 
conformational changes upon parinaric acid binding in contrast to intestinal FABP (112). 
Recently rat intestinal FABP has been covalently modified with the fluorescent com­
pound Acrylodan at Lys77 (113). The shift in fluorescence emission wave length at fatty acid 
binding provides a direct measure of the concentration of fatty acid bound to the protein. This 
shift is likely to be due to displacement of the Acrylodan moiety from the hydrophobic fatty 
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acid binding pocket into the aqueous environment. 
'H-NMR investigations also revealed conformational changes of bovine and rat liver 
FABP upon fatty acid binding (114,115). Sequential Ή resonance assignment obtained by 
homonuclear twodimensional NMR spectroscopy provided the basis for the elucidation of the 
secondary structure of bovine heart FABP (116). NMR spectra were obtained for a 1:1 complex 
of unlabeled palmitate with uniformly 13C-enriched intestinal FABP (51). "F-NMR spectroscopy 
on different 6-fluorotryptophan mutant proteins of CRBP-II showed that two tryptophans (Trp9 
and Trp107) undergo marked changes in their environment upon binding of retinol, while two 
others (Trp89 and Trp110) apparently do not (51,117). " F NMR analysis of recombinant 
isotopically labeled proteins appears a sensitive method for monitoring retinoid flux between 
CRBP-I and CRBP-II (118). The folding of intestinal FABP has been monitored by "F-NMR 
after incorporation of 6-fluorotryptophan into the protein (119). The fluorotryptophan substitu­
tions of tryptophan do not markedly change the interaction of CRBPs or intestinal FABP with 
their ligand (117-119), although minor structural changes occur (120). 
"C-carboxyl enriched fatty acids were applied in NMR studies with rat liver and 
intestinal FABP (121) and porcine ileal FABP (65). The stoichiometry of binding of fatty acid 
to protein was 1:1 for the intestinal and ileal FABP types, but could vary between 1 and 3 for 
liver FABP depending on the physical state of the unbound fatty acid (121). The ionization and 
dissociation behaviour of fatty acids bound to ileal or liver FABP at different pH values was, 
however, very similar and suggested a binding environment more solvent-accessible than that of 
intestinal FABP (65,121). NMR samples of porcine ileal FABP with [13C]chenodeoxycholate 
showed a specific binding interaction, which could be inhibited by fatty acid (65). The 
carboxylate group of fatty acid bound to intestinal FABP appears to be located in a more 
interior region and probably involved in ion-pair electrostatic interactions, whereas the 
carboxylate group(s) of fatty acid(s) bound to liver FABP appear to be present at or near the 
solvent/protein interface and show no or weak electrostatic interactions (121). 
Crystals have been obtained from nearly all members of the FABP family (Table 3). The 
3-dimensional structure was shown first for bovine myelin FABP (PJ (122) and recombinant rat 
intestinal FABP (123). The structure of the latter molecule was analyzed as holoprotein (123), 
as apoprotein (124,125) and as protein with bound palmitate (99,126) or oleate (127). Recently, 
the structures of chicken liver FABP (128), bovine heart FABP (129), recombinant murine 
adipocyte FABP (130), recombinant human muscle FABP (131) and of an intestinal FABP from 
Manduca sexta (132) were also determined. Bovine liver FABP (133) and recombinant rat liver 
FABP (134) have been crystallized, but their tertiary structure is not yet known. The same is 
the case with ileal FABP (65), CRBP-I (135), CRBP-II (136) and CRABP-I (137). 
All these molecules contain 10 anti-parallel β strands and two short a helices. The β 
strands are arranged in two fl-pleated sheets in an orthogonal orientation, giving the protein an 
overall appearance of a clam. The interior of the protein is extensively solvated. Movement or 
displacement of some of these ordered water molecules is necessary for fatty acid binding 
(127,138). The shape of the binding cavity of the intestinal FABP differs from that of human 
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Member 
Bovine liver F ABP 
Ree. rat intestinal F ABP" 
Bovine nerve myelin FABP 
Chicken liver FABP 
Ree. ret liver FABP 
Ree porcine ileal ILBP 
Bovine heart FABP 
Ree. murine adipocyte FABP 
Ree. human muscle FABP 
Manduca sexta gut FABP 
Rat liver CRBP I 
Rat epididymis CRABP I 
Ree. rat CRBP Π 
3-D 
analysis 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Resolution 
(Á) 
1.2-2 0 
2.7 
2 5 
3.5 
2 5 
2.1 
1.8 
Reference 
133 
123-127 
122 
128 
134 
65 
129 
101,130 
131 
132 
135 
137 
136 
heart muscle FABP Table 3 Crystallization of members of the FABP family 
іл 11 ι ->o\ τ» * as apoprotein, holoprotein with undefined fatty acid, with palmitic or with 
(131,138). It is more
 o l e i c a c i d . 
elongated, deep inside 
the protein and allows 
a slightly bent confor­
mation of the fatty 
acid. The hydrocarbon 
tail of the fatty acid 
bound to heart FABP 
type has a U-shaped 
conformation in con­
trast to the extended 
form in intestinal 
FABP (131) (Fig.3). 
Some of the solvent 
molecules in the two 
binding sites are on 
positions occupied by 
the fatty acid in the 
other holoprotein 
(138). The intestinal, 
heart, adipocyte, myelin and epidermal FABP types and the CRABPs share the same arginine 
residues of the binding site (Table 1). These amino acid residues are not present in liver FABP 
and the CRBPs. The fatty acid-binding site of intestinal FABP, however, also lacks Tyr128. The 
carboxylate moiety of the fatty acid ligand binds m the same general position in myelin FABP 
(122) and the FABP from Manduca sexta (132) as in human muscle FABP (131) The structures 
of the FABPs show marked conformational similarities to the extracellular lipocalins, which 
lack however 2 ß-strands (40,99). 
All data of biophysical 
techniques together indicate 
that although the clam structure 
is similar for various members 
of the FABP family, the nature 
of the internal side-chains is 
not highly conserved and re-
sults m differences of the 
volume distribution of the 
cavity, the solvent localization 
and the conformation of the 
bound fatty acid, between the 
Fig. 4 Comparison of the tertiary structures of rat intestinal 
FABP (left) and human muscle FABP (right) with bound fatty 
acid. 
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different FABP types. Table 4 Effect of mutations on binding affinity and thermostability of 
T-i · Λ . ^ _ r *. » ·.• _ members of the FABP family. Elucidation of the tertiary . . . . J . J
 t, decrease; Τ, increase; -, no change. 
structure of the liver 
FABP type and of mutant 
FABPs will give more 
information on the inter­
actions between the fatty 
acid and the different 
FABP types. The align­
ment of amino acid se­
quences of the FABP 
types (Fig.2) indicates for 
liver FABP shortening of 
G and H strands and a 
wider opening between 
their two β-sheets. A 
unique structure may 
explain the large differen­
ces in ligand specificity, fatty acid stoichiometry and ligand binding site between the liver 
FABP and the heart and intestinal FABP types. 
Some studies have already been performed on mutants of the FABP family (Table 4). 
Some mutations affect the thermostability of the protein (119,139). Substitution of Arg106 in rat 
intestinal FABP (140) and human heart FABP type [Prinsen and Veerkamp, unpublished data], 
by glutamine and threonine, respectively markedly decreased the binding affinity for fatty acids 
and increased that for retinol (140). Glutamine substitution of Arg1" or Arg1" in CRABP 
decreased the affinity for retinoic acid (139). The retinol binding affinity was decreased and that 
for fatty acids or retinoic acid increased by replacement of Gin109 by arginine in CRBP-I and 
CRBP-Π (141,142). All these results on mutant proteins underline the importance of electros­
tatic interactions between lipid and binding protein. 
Protein 
I-FABP 
H-FABP 
CRBPI 
CRBPn 
CRABP I 
Mutation 
trp-6-Kyr 
trp-82-»tyr 
arg-106-»gln 
arg-106-Khr 
gln-109-4Tg 
gln-109-4Tg 
gln-129-»arg 
arg-lll-«gln 
arg-131-»gln 
tyr-133-«phe 
FA 
1 
* 
t 
-
Binding affinity 
Retinol 
t 
t 
i 
i 
-
-
-
RA 
t 
-
-
* 
i 
Stability 
1 
t 
t 
Ligand specificity and stoichiometry 
Table 5 gives a survey of the main ligands of the members of the FABP family on base 
of literature (see refs in 5,27,46,47). The binding of ligands other than fatty acids has not been 
fully investigated for all FABP types. The heart FABP type will only bind long-chain fatty acids 
(103,143-146), although binding of acyl-CoA and/or acylcarnitine esters has been reported 
(143,144). The binding of acyl-CoA to liver FABP (104,145,147) and adipocyte FABP (47) is 
disputed (146). The liver FABP type appears to be endogeneously associated with fatty acids, 
but also with heme (148), bilirubin (149) and selenium (150). The liver, intestinal and ileal 
FABP types isolated from rat intestine contained as endogenous ligands besides fatty acids also 
butylated hydroxy-toluene and dibutyl- and di(2-ethylhexyl)-esters of phtalic acid (151). Studies 
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Ligand 
Member 
Liver F ABP 
Intestinal F ABP 
Heart FABP 
Adipocyte FABP 
Myelin FABP 
Epidermal FABP 
Ileal FABP 
CRBP 
CRABP 
Fatty 
acid 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
Retinol 
-
-
-
-
+ 
-
+ 
-
Retinoic 
acid 
-
-
-
+ 
+ 
-
-
+ 
Bile 
acid 
+ 
-
-
+ 
Eicosa-
noids 
+ 
-
with exogenous ligands showed Table 5 Ligands of members of the FABP family, 
that a large señes of hydro-
phobic compounds bound to or 
competed for binding with fatty 
acids to liver FABP (5,27,104-
,147,152-156). These ligands 
include hexachlorophene, 
bilirubin, bromosulfophtalein, 
cholesterol sulfate, oestron 
sulfate, lysophosphatidylcho-
line, carcinogens, thyroid 
hormones, warfarin, a poly-
chlorinated biphenyl derivative, 
bile salts, some peroxisome 
proliferators and inhibitors of 
carnitine palmitoyl transferase, 
and have generally a lower affinity than fatty acids. A large variation exists in the binding 
affinity of a series of peroxisomal proliferators in relation with their structure (155, 
156). Clofibric acid has little or no affinity in contrast to bezañbrate (104,155-157). Liver 
FABP and heart FABP type do not bind long-chain alcohols, retinol and retinoic acid. 
Prostaglandin Et (158) and heme (147,154, 157) appear to be bound to rat liver FABP with 
higher affinity than oleic acid, as are the lipoxygenase metabolites 15-HPETE, 5-HPETE and 5-
ΗΕΓΕ (159). Other lipoxygenase metabolites including 12-H(P)ETE, 15-HETE and leukotriene 
(LT)C4 bind to rat liver FABP to a lesser degree. The cyclooxygenase metabolites PGEj and 
thromboxane Bj as well as the lipoxygenase metabolite leukotriene B4 (LTB4) did not bind to 
liver FABP (159). The results on prostaglandin binding to liver FABP are equivocal. Cyclopen-
tenone Prostaglandines (PGA,, PGAj, PGJ, and A^-PGJJ bound more avidly than oleic acid to 
liver FABP (160). PGD2, PGEj and PGF^ were poor competitors and PGE, was intermediate 
(160). Others found a strong binding of PGE, which was not displaced by other prostaglandins 
(158). Displacement studies could not demonstrate binding of PGE, to liver FABP (104,147). 
Human heart FABP type does not bind prostaglandins or thromboxane B? (103,143). Eicosanoid 
binding to FABPs deserves more attention, especially now recombinant proteins become 
available. 
Liver FABP proved to be identical with a heme-binding protein (161), a selenium-
binding protein (150), a lysophosphatidic acid-binding protein (162,163) and a warfarin receptor 
(153). Bovine myelin FABP also binds retinol and retinoic acid (164). The adipocyte FABP 
type from man and mouse also binds retinoic acid, but no retinol (55,100,165). Ileal FABP has 
a higher affinity for chenodeoxycholate than for oleic acid (65). 
Liver, heart and intestinal FABP types bind C16-C„ saturated and Сц-Сд polyunsatura­
ted) fatty acids with comparable affinity (27,97,103,104,143,147). Saturated fatty acids with a 
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longer chain appear only to be well bound by the liver FABP type (Maatman et al., unpublished 
data). The apparent dissociation constants of these fatty acids are generally less than 1 μΜ 
(5,27). Methodological problems such as aqueous solubility of ligands, aspecific adsorption, 
and concentration of free ligand impede the interpretation of many investigations of these 
binding studies (27,47). Recently a theoretical analysis of the interaction of a fluorescently 
labeled fatty acid with FABP was described as a possible solution for this latter problem (166). 
The stoichiometry of binding is one mol fatty acid per mol protein for all FABP types 
except for the liver FABP type (5,27,167). This FABP type appears to bind 1-3 fatty acids 
depending on the assay procedures and techniques and the physical state of the applied fatty acid 
(108,114,121,167-169). Multiple classes of binding sites for fatty acids have been found for this 
protein (114,169), but not in all cases (108,167). The stoichiometry of fatty acids with bulky 
side chains is also for liver FABP always 1:1 (104,107,108). 
Functions as transfer protein 
The main functions ascribed to FABPs are related to the cellular uptake and trafficking 
of fatty acids to specific cellular compartments or metabolic pools. They may also be involved 
in the modulation of the intracellular concentration of the fatty acids or their CoA or carnitine 
esters, and in this way regulate the activity of enzymes involved in lipid metabolism. FABPs 
may also protect enzymes or membranes from deleterious effects of high fatty acid con­
centrations. In the case of liver FABP, its capacity in the binding of other ligands may be 
relevant to the functions. 
The role of FABPs in fatty acid uptake and transport was theoretically considered for 
hepatocytes (19,170) and recently also for cardiomyocytes (171). Indirect evidence on the basis 
of physiological data and experiments with inhibitors of fatty acid binding to FABP is disputable 
(27). However, using a photoactivatable, radioiodinated fatty acid analogue, FABP of Hep G2 
cells and primary rat hepatocytes and of differentiated 3T3 adipocytes in situ, were labeled in a 
time- and temperature-dependent fashion (14,172-174). The transfer to and the release of fatty 
acids from model and natural membranes by FABP has been observed in many studies 
(107,175-178 and refs in 5 and 27). The transfer does not occur by collision of FABP with 
membranes, but by aqueous diffusion of the fatty acids (175-177). Only in the case with heart 
FABP and anthroyloxy-labeled fatty acids a collision model was postulated (110). The rate of 
transfer of fatty acids from liver FABP to membranes is influenced by aqueous variables, such 
as pH and ionic strength as well as by the structure of the fatty acid (177). In vitro transfer of 
fatty acids by FABP was found between two membrane systems separated by a polycarbonate 
filter (175,178) and between two separated monolayers (175). FABP facilitates also the 
diffusion of oleic acid in a model cytosol system (179). 
The fatty acid exchange rate is much faster on NMR time scale for the intestinal 
FABP/bilayer than for the liver FABP/bilayer system (121). The transfer rate of fluorescent 
anthroyloxy-labeled fatty acids from heart FABP to phospholipid bilayers is an order of 
magnitude greater than the rate of transfer from liver FABP (110,176). The dissociation rates of 
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the anthroyloxy fatty acids from rat liver FABP (176,177) are in the same order as the 
dissociation rates of palmitate and oleate from albumin (180). In combination with the 
comparable dissociation constants of palmitate from albumin (for the three high-affinity sites) 
and liver FABP, these data suggest that fatty acid uptake in the hepatocyte may be regulated by 
changes in the level of FABP and the fatty acid/albumin molar ratio. The fatty acid distribution 
between blood and cytosol may be similar to that of retinol. The distribution of retinol between 
serum retinol-binding protein and CRBP appears to be at equilibrium and intracellular levels of 
retinol are regulated by the levels of CRBP (181). 
Modulatory functions 
FABPs may influence, by supply and modulation of availability of substrate, the activity 
of enzymes involved in fatty acid and lipid metabolism as mitochondrial and microsomal acyl-
CoA synthase and acyl-CoA: glycerol 3-phosphate acyltransferase, acetyl-CoA carboxylase, 
acyl-CoA: cholesterol acyltransferase, diacylglycerol acyltransferase (see refs in 5,44-46). Some 
of these results have been related to binding of acyl-CoA by FABP, but acyl-CoA binding 
protein appears therefore a more real candidate by virtue of its higher affinity for acyl-CoA 
(146). 
FABPs present fatty acids and acyl-CoA to mitochondria and peroxisomes for oxidation 
(82,175,182,183) and to microsomes for acyl-CoA synthesis (145,178). The use of a holo-
FABP as a substrate has not yet been proven. Recently, evidence was obtained for such a role 
of holo-CRBP in microsomal retinal synthesis (184) and holo-CRABP in retinoic acid meta-
bolism (185). 
The binding of different ligands by liver FABP may have various consequences. The 
sulfation of glycolithocholate by bile salt sulfotransferases was inhibited by liver FABP, in 
contrast to that of the weaker ligands glycodeoxycholate and glycochenodeoxycholate (186). The 
presence of heme-binding protein (= FABP) facilitates the heme efflux from rat liver mitochon-
dria (187). The binding of lysophosphatidylcholine (188) and lyso-phosphatidic acid (163) to 
liver FABP indicate an important role of this protein in regulation of metabolism and utilization 
of these lysophospholipids in the liver. The involvement of lysophospholipids in signal 
transduction (189-191) could also be influenced by FABP. 
Fatty acids, their CoA and carnitine esters and other lipid mediators, such as eicosanoids 
and lysophospholipids, influence directly or indirectly various cellular processes by their 
interaction with enzymes, membranes, ion channels, receptors or genes. Table 6 gives an 
exemplary survey for the effects of fatty acids. FABPs may have a modulatory role by their 
influence on the synthesis or the intracellular transport of fatty acids and lipid mediators or by 
their effect on the availability of the unbound ligand. The availability of the ligand may depend 
on its affinity to FABP, the presence of competitive ligands and possibly conditions as pH and 
specific ion concentrations. Fatty acids modulate many steps of the cascade of reactions 
involved in signal transduction. They may represent modulators, but also first or second 
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messengers (192). Enzymes of both cyclic AMP Table 6 Effects of fatty acids, 
and protein kinase С pathways are regulated by 
fatty acids or in some cases by eicosanoids Disturbance of mebrane structure and function 
(192,193). Inhibition of enzymes: Na\ K+-ATPase, 
Arachidonic acid and Other fatty acids «denme nucleoüde translocase 
directly regulate K+, Ca2+ and CI' ion channels Modulation of receptor binding: nuclear T„ 
„m inox u * ·. · * ι t. »u 4.· · angiotensm, glucocorticoid, insulin, opioid 
(194-198), but it is not known whether this is 
caused by interaction with the ion channel pro- Activation of soluble protem kinase с 
tein 0Г by modulation Of its lipid environment Regulation of ion channels: K+, Ca1*, er 
(194). Metabolites of arachidonic acid or protein Modulation of gene expression: F ABP, acyl-
kinase С activity were not involved in these C o A ^*1""*· « * " * ' - О » А desaturase 
cases, but the former may also stimulate the G-
protein of some ion channels in a receptor-independent way (199). Recently, a significant 
degree of similarity was established between a 131-residue domain of the N-methyl-D-aspartate 
(NMDA) receptor (residues 263-393 inclusive) and various members of the FABP family (200). 
Arachidonic acid potentiates the NMDA-receptor current, when glutamate activates the receptor 
in isolated cerebellar granule cells (201). Arachidonic acid accumulation in pancreatic β cells 
may play a role in the signaling process which leads to insulin secretion (202). 
Receptor-mediated release of unsaturated fatty acids and diacylglycerol contribute 
synergistically to the activation of protein kinase С (191,203). This activation may form a part 
of the signal-induced degradation cascade of various membrane phospholipids which is initiated 
by the action of phospholipase A2 and phospholipase C. Due to their difference in structure and 
localization, the isoforms of the protein kinase С family show differences in their sensitivity for 
fatty acids and other lipid mediators (191). Soluble protein kinase С would be a primary target 
for unsaturated fatty acids, membrane-associated protein kinase С for diacylglycerols (204). 
Fatty acids may interfere with the binding of ligands to their binding proteins, e.g. the 
binding of retinoic acid to CRABP (205) and the binding of insulin (206), angiotensin (207), or 
opioids (208) to their receptor. Binding of fatty acid to glutathione S-transferase Ρ noncom-
petitively inhibited the activity of this enzyme (209). 
Fatty acids and/or eicosanoid metabolites amplify the signals from growth factor 
receptors in mammary epithelial cells (210). Fatty acids can interact with nuclear or cytoplasmic 
steroid or thyroid hormone receptors to modulate positively or negatively the binding of these 
hormones (211-216). They can also influence in this way the transfer of steroid or thyroid 
hormone information from one binding protein to another. Fatty acylation of proteins has also 
been suggested as an event involved in second messenger action (217). FABP may modulate all 
these actions of fatty acids. 
A protective role of FABP in ischemia of tissues as heart, intestine, kidney and liver 
appears also probable. The intracellular rise of fatty acid concentration at ischemia can perturb 
functions of enzymes, membranes and ion channels (218-222) and in this way e.g. interfere 
with heart function (23). 
-30-
Introduction 
A phosphorylated form of adipocyte FABP may be an intermediate in the insulin 
signaling pathway (223-225). This form accumulates, though in a very low percentage of total 
FABP, in adipocytes in the presence of insulin or vanadate and phenylarsine oxide, an inhibitor 
of tyrosine phosphatases (226). In vitro, adipocyte FABP can be phosphorylated on Tyr" by the 
insulin receptor tyrosine kinase with a positive effect of the presence of a bound fatty acid 
(100,227,228). The presence of a bound fatty acid on adipocyte FABP increases the affinity of 
the insulin receptor for this FABP (228). The same phosphorylation site for tyrosine kinases is 
apparently present in heart, myelin and epidermal FABP, and in CRBP-I and -Π (Table 1). A 
slight amount of the phosphorylated form of the heart FABP type ( < 1 % of total FABP) could 
be isolated from insulin-stimulated cardiomyocytes (229), but not from insulin-stimulated rat 
soleus muscle or cultured rat muscle cells (Prinsen and Veerkamp, unpublished data). 
Recently, evidence was obtained for the involvement of fatty acids in gene regulation 
(230-236) as was earlier established for retinoids. A role for FABPs as trans factors in the 
expression of lipogenic enzymes was suggested by Clarke and Armstrong (48). In fully 
differentiated adipocytes a high level of adipocyte FABP gene transcription can be supported by 
fatty acid supply (230,231). Long-chain fatty acids are able to activate, in preadipose cells, the 
expression of the genes encoding adipocyte FABP and acyl-CoA synthetase (232,233). Fatty 
acids dramatically activate the expression of mRNA for adipocyte FABP and the Fos-related 
gene Fral in 3T3 preadipocytes, without initiating the general program of adipocyte differen­
tiation (234). The process of activation of the FABP gene by fatty acids was not found in non-
adipose cells (233,234). Activation of the genes of adipocyte FABP and acyl-CoA synthetase by 
fatty acids does not appear to be mediated by the CCAAT enhancer binding protein (233). The 
increase of the steady state levels of adipocyte FABP mRNA in preadipocytes is likely to be the 
result of post-transcriptional mechanisms, most likely, message stabilization (234). Induction of 
adipocyte FABP in preadipocytes appears to be exerted by unprocessed fatty acid (232). Recent 
fmdings implicate arachidonic acid as an important inhibitory regulator of stearoyl-CoA 
desaturase gene expression in lymphoid cells (235). Selected fatty acids modulate gene 
expression in human breast cancer cells (236). 
The involvement of FABPs in growth and cell replication is suggested by various 
investigations. The level of liver FABP (237,238) and the activity of the liver FABP promoter 
(239) were markedly enhanced in normal hepatocytes during mitosis. Linoleic acid specifically 
stimulated the growth and DNA synthesis of hepatoma cell clones that were stably transfected 
with the coding sequence of liver FABP and expressed this protein (240). Metabolism of 
linoleic acid to oxygenated derivatives was apparently necessary. Growth stimulatory and 
growth inhibitory eicosanoids bind well to liver FABP and even with higher affinity than fatty 
acids (159,160). Liver FABP is the principal early target protein of the reactive metabolites of 
the carcinogen N-(2-fluorenyl)acetamide (241). 
An isoform of bovine heart FABP was originally isolated from bovine lactating 
mammary gland (242). This compound was named mammary-derived growth inhibitor since it 
had inhibitory action on growth of various normal and transformed mammary epithelial cell 
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lines. Its expression is highest in lactating mammary gland (243). Bovine heart FABP had no 
inhibitory effect on cell proliferation. The heart FABP type was also isolated from, and 
identified in, mammary gland of lactating rat and mouse (244,245). 
Gene structure and regulation of expression 
Table 7 Chromosomal location of genes of lipid-binding 
proteins of the FABP family. 
Protein 
Adipocyte FABP 
Haut FABP 
Intestinal FABP 
Liver FABP 
CRBPI 
CRBPII 
CRABPI 
CRABPn 
Chromosome ireinoni 
Human 
? 
1 
4(q28Hq31) 
2(pl2-qll) 
3 (q2H22) 
3 
15 
2 or 11 ? 
Mouse 
3 
4,8 and 10 or IS 
3 
6 
9 
9 
9 
2 
Screening of genomic libraries 
with specific cDNAs revealed the genes 
for nine members of the FABP family: 
adipocyte, myelin, heart, intestinal and 
liver FABP types, CRBP I and Π and 
CRABP I and Π. Only the genes for 
epidermal and ileal FABP types have 
not been identified up to now. All 
genes except the intestinal and heart 
FABP and the CRABP Π genes were 
identified in one species (Table 7). The 
intestinal FABP gene was elucidated in 
mouse (246), rat (247) and human 
(247), the heart FABP gene in mouse 
and cattle (248,249) and the CRABP Π gene in mouse (250) and human (251). Most of the 
genes were however detected in other species by low stringency Southern hybridization. The 
overall organization of the genes is identical, four exons and three introns (Fig.4). The exon/in-
tron boundaries are similar in all genes but the length of the intron sequences varies markedly. 
The CRBP genes have relatively large introns. 
Using somatic cell-hybrids and Table 8 Identified genes of the FABP family. 
restriction fragment length polymor-
phisms the chromosomal localization of 
most of these genes was determined in 
human and mouse (Table 8). The last 
few years detailed studies on the 5' 
promoter region revealed much infor­
mation about the regulatory elements 
for the tissue-specific expression of 
these genes. We will separately discuss 
the structure and regulation of the ex­
pression of the different genes. 
Species 
Member Mouse Rat Bovine Human 
Adipocyte FABP 
Myelin FABP 
Heart FABP 
Intestinal FABP 
Liver FABP 
CRBPI 
CRBP Π 
CRABPI 
CRABPΠ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Adipocyte FABP gene 
The mouse adipocyte FABP or aP2 gene has a total length of 4.2 kb containing 4 exons 
encoding 25, 57, 34 and 16 amino acids, respectively separated by 3 introns of 2.2, 0.5 and 0.7 
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kb (252,253) (Fig. 4). The mouse gene is localized on chromosome 3 within 2.2 cM of the 
carbonic anhydrase 2 locus (79). 
Adipocyte FABP \ H — \ 
24 82 I 13 
11« 
Myelin FABP I |_i 1 
24 81 I 131 
118 
Heart FABP \ ] — | — 
Liver FABP 
Intestinal FABP 
i-i—и 
22 80 m l 
127 
I ! II 
22 79 118 1Э1 
CRBP 1 
CRBP II 
CRABP 
CRABP II 
H" 
24 
24 83 
-H 
- ι — t 
Hi ~ 
24 83 138 
121 
Fig. 4 Comparison of the structures of FABP genes. The exon/intron structures of the mouse adipocyte, 
myelin, intestinal FABP, CRABP I and П, rat liver FABP, CRBP П, bovine heart FABP and human 
CRBP I genes. The locations of the splice sites are indicated by the number of the amino acid. 
Most studies on the regulation of adipocyte FABP gene expression have been performed 
with 3T3, Ob 1771 and BCFC-1 cell lines. All cells exhibit, as preadipocytes, the properties of 
growing fibroblasts. When the confluent cells are treated with appropriate media and hormones, 
growth factors or pharmacologic agents they undergo adipocyte differentiation (254-256). Dif­
ferentiation can be induced by various combinations of dexamethasone, insulin and methylisc-
butylxanthine (257). Addition of retinoic acid, together with these compounds, to preadipocytes 
inhibited differentiation (257). De novo synthesis of fatty acids and triacylglycerol formation 
increase at differentiation and the cells accumulate large lipid droplets. Activities of enzymes 
involved in lipogenesis, lipolysis and glycolysis increase due to increased synthesis. Levels of 
other proteins, e.g. cytoskeletal proteins decrease. Examples of enzymes which increase in 
activity '10- to 100-fold are glycerol 3-phosphate dehydrogenase, fatty acid synthase, glycerol 3-
phosphate acyltransferase, malic enzyme, lipoprotein lipase, stearoyl-CoA desaturase and also 
serine protease (adipsin) (255). Also the content of acyl-CoA binding protein (258), adipocyte 
FABP (259,260) and a 88 kDa membrane protein implicated in fatty acid-binding (261) increase 
markedly. The genes of these differentiation-dependent proteins have been shown to be 
regulated by various adipogenic and antiadipogenic factors. A number of cis-acting regulatory 
elements within the promoters of these genes have been identified together with various trans­
acting nuclear factors, that activate or derepress transcription (255,262). We will discuss in the 
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ARF2 ШШ 
АЯР2 ШШ -
ЦП 
ш 
ARE1 (-5.342 -5,3481 
АЯЕ6 (-5.296-5,308) 
ARE2 (-5.267-5.2791 
ARE7 (-5.220-5.2321 
ARE4I-5.187-5.197I 
Glucocorticoid 
гееропее element 
1-365 -3931 
following especially those, which influence the expression of the adipocyte FABP gene. All cis-
regulatory elements in the 5' flanking region of the adipocyte FABP gene and their possible 
trans-acting factors are depicted in Fig. 5. Adipocyte FABP 
Hunt et al. (253) compared the 5' 
promoter region of genes of which expression 
is induced upon adipocyte differentiation, the 
glycerol 3-phosphate dehydrogenase, the 
serine protease (adipsin) and the adipocyte 
FABP gene, and looked for cis-regulatory 
sequences. A fat-specific element of 13 bp 
with a consensus sequence 5'-GGCT/ACTG-
GTCAG/TG-3', called FSE1, was found in 
multiple copies in all three genes. An ad­
ditional element, FSE2, 5'-ACTC-/GAGAG-
GAAAAG-3', was only found in the adipo­
cyte FABP and glycerol 3-phosphate de­
hydrogenase genes (253). The first 168 bp of 
the 5' flanking sequence of the adipocyte 
FABP gene appeared to be sufficient to drive 
differentiation-dependent expression. Within 
this sequence a 28 bp element is located 
which inhibits expression in preadipocytes 
and binds a fos-like protein (263). Fusion 
products of 858 or 248 bp of the 5' flanking 
sequence of the adipocyte FABP gene with 
the bacterial chloramphenicol acetyltrans-
ferase (CAT) gene were transfected into 
preadipocytes. Differentiation induced by 
adipogenic agents revealed only expression of 
the longer construct with dexamethasone, which indicates the presence of a glucocorticoid-
regulatory element. Expression of both constructs was induced by 8-bromoadenosine 3',5'-
cyclic monophosphate which suggests a response element for с AMP in the first 248 bp (264). 
Deletion analysis of the short construct established the presence of a sequence containing an 
overlapping positive and negative regulatory element. The positive regulatory element contains a 
consensus activator protein 1 (AP-1) binding sequence (265) which is activated by the trans-
activating fos and jun proteins (263,266). The inhibitory effect of the negative regulatory 
element in confluent preadipocytes is relieved by с AMP (265). 
A binding sequence for the trans-activating CCAAT/enhancer binding protein (C/EBP) is 
located directly upstream of the AP-1 sequence, within the negative regulatory element. This 
sequence is also present in the promoter region of the differentiation-induced stearoyl-CoA 
c/EBP m (-130-1491 
API (-116-1221 I "" (re 
! 
Neoetivo regulatory element 
relieved by CAMPI 
FSE1 
FSE1 
• FSEI 
Fig. 5 Cis-acting dements and trans-acting 
factors in the 5' flanking region of the adipocyte 
FABP gene. 
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desaturase 1 gene (267). The role of AP-1 and C/EBP was analyzed by deletions and point 
mutations in their binding sequences. These sequences appear to regulate gene expression 
during adipocyte differentiation (268). In a cell-free transcription system it was also shown that 
the expression driven by promoters of adipocyte differentiation-induced genes is activated by 
C/EBP (269). Antibodies against C/EBP and oligonucleotides with the C/EBP consensus 
binding sequence drastically decreased this in vitro transcription. Additional evidence for the 
role of C/EBP in adipocyte differentiation was demonstrated by transfecting preadipocytes with 
a vector expressing antisense C/EBP RNA (270). The cells did not show C/EBP expression on 
RNA and protein level and no cytoplasmic triglyceride accumulation. The C/EBP region and 
adjacent sites also regulate A-FABP expression in human adipocytes (271). Cao et al. (272) 
showed the existence of three C/EBP isoforms which are all regulated during differentiation. 
These trans-activating factors and their way of interaction with cis-acting elements in the 
upstream region of the adipocyte F ABP gene were recently reviewed (262). 
The far upstream region of the 5' flanking region of the adipocyte F ABP gene appeared 
to have a adipocyte-specific enhancer (273). Transgenic mice containing 168 bp, 247 bp, 1.7 kb 
or 5.4 kb of 5' flanking sequence of the adipocyte FABP gene linked to the CAT gene did not 
show high levels of chloramphenicol transferase in their adipose tissue until the extension 
amounted to 5.4 kb (273). More detailed analysis of this enhancer revealed five cis-acting 
adipocyte regulatory elements designated ARE1, ARE2, ARE4, ARE6 and ARE7 (274,275). 
The ARE1 site binds a member of the nuclear factor-1 (NF-1) family. Multimers of this site 
have no activity on their own; nevertheless, when this site is mutated, there is a significant 
reduction in enhancer activity. Multimers of ARE2 and ARE4 stimulate promoter acitvity in 
several cell types. These elements share a common motif and appear to be recognized by 
adipocyte regulatory factor 2 (ARF2). By contrast, multimers of ARE6 and ARE7 stimulate 
promoter activity only in adipocytes. These elements also share a common motif which is bound 
by adipocyte regulatory factor 6 (ARF6). The binding of this factor to both elements is 
differentiation dependent. Mutational analysis established that ARE6 is critical for enhancer 
activity. 
The differentiation from preadipocytes to adipocytes is controlled by several factors 
which also affect the expression of adipocyte FABP. Insulin growth factor-1 (IGF-1) and in 
higher concentrations also insulin are able to induce preadipocyte differentiation (276). Both 
increase the mRNA expression level of the fatty acid synthase and the adipocyte FABP gene. 
Pioglitazone, an antidiabetic drug showed a similar effect on the expression of adipocyte FABP 
(277). It was suggested that this agent sensitizes the 3T3-L1 cells for insulin. Incubation of fully 
differentiated 3T3-L1 adipocytes with tumor necrosis factor-α (TNF-α) resulted in an insulin 
resistance (278). The expression of differentiation-induced genes encoding glucose transporters 
1 and 4 (GLUTI and 4), C/EBP and proteins involved in fatty acid metabolism (stearoyl Co A 
desaturase, acyl-CoA synthase and adipocyte FABP) was completely or markedly repressed. 
The effect is probably due to the lower expression of C/EBP which controls the expression of 
the other genes (279). Transforming growth factor-fl, TNF-a and retinoic acid increase the 
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expression of mRNA of transcription factors c-fos, jun-B and c-jun, but inhibit C/EBP mRNA 
expression (280). Both the increase and the inhibition may cause the attenuation of differen-
tiation of preadipocytes. 
Since preadipocytes and adipocytes are exposed to changing levels of fatty acids these 
substrates may regulate the expression of genes during adipogenesis. Oleate addition to 
confluent preadipocytes potentiated the effect of dexamethasone in inducing expression of 
adipocyte FABP mRNA (230,233). After differentiation, the level of expression in adipocytes 
could be maintained by fatty acids (230,231). Especially long-chain fatty acids are able to 
activate adipocyte FABP gene expression (232-234). In fully differentiated adipocytes impair-
ment of fatty acid synthesis by glucose deprivation leads to an inhibition of expression of the 
genes of adipocyte FABP, adipsin and glycerol 3-phosphate dehydrogenase (231). Supplemen-
tation of the culture medium with fatty acids prevents the decrease of adipocyte FABP gene 
expression, whereas the expression of adipsin and glycerol 3-phosphate dehydrogenase is 
unaffected (231). The activation of FABP gene expression by dexamethasone and fatty acids in 
3T3 preadipocytes does not appear to be mediated by C/EBP, since C/EBP is not expressed 
(233). Besides the effect on the adipocyte FABP gene, fatty acids also induce the expression of 
the acyl-CoA synthase gene and the Fos-related Fra-1 gene in preadipocytes (234). The 
mechanism by which fatty acids induce gene expression is unclear but seems to differ from 
C/EBP mediated expression during adipogenesis (233). 
Myelin FABP gene 
The mouse myelin FABP or myelin P2 gene with a length of 3.2 kb contains four exons 
encoding 25, 57, 34 and 16 amino acids, respectively separated by 3 introns of 1.2, 0.2 and 1.3 
kb in length (281)(Fig.4). 
Myelin P2 protein is one of the major proteins of peripheral nervous system myelin 
besides the P0 glycoprotein and myelin basic protein (53,54). It is not detected in central 
nervous system myelin. 
In the 5' flanking region two AP-1 binding sites are present besides a candidate TATA 
element and 2 CAAT sequences. A band shift of labeled myelin FABP promoter DNA was seen 
after incubation with nuclear extracts containing c-jun. These results suggest that c-jun may 
regulate expression of myelin FABP (281). 
Heart FABP gene 
The heart FABP gene was detected in the chicken, rat, mouse and human DNA using 
the rat heart FABP cDNA as a probe in Southern blot analysis (79). Three loci in the mouse 
genome located on different chromosomes (4, 8 and 10 or 12) reacted with this probe under 
stringent conditions. The loci may represent pseudogenes and/or genes encoding proteins with a 
high similarity to the heart FABP. Two FABP isoforms were found in bovine heart (84). Two 
bovine heart FABP mRNAs with the codon for Asn or Asp at position 98, respectively were 
isolated, which may derive from different genes (282). Recently the bovine heart FABP gene 
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has been isolated and sequenced (248). It consists of four exons encoding 22, 57, 37 and 17 
amino acids respectively separated by 3 introns of 2.5, 1.1 and 0.8 kb (Fig. 4). Also the mouse 
heart FABP gene has been identified, including some part of its 5' flanking region (249). The 
mouse heart FABP gene is located on chromosome 4. 
At fetal age from day 16 on heart FABP is present at a low level in rat heart, but after 
birth it increases in rat heart and skeletal muscle up to 70 days (70, 283-285). Heart FABP 
mRNA levels rise rapidly in rat heart during the 2 days prior to and after birth, reaching peak 
levels by the early weaning period (79). Immunohistochemical studies on the ontogeny of heart 
FABP type demonstrated a more extensive tissue distribution and earlier ontogenic expression in 
the rat (68) than might be expected from mRNA analyses. Rat kidney shows a postnatal 
increase of the content of the heart FABP type (283). Heart FABP mRNA showed in this tissue 
biphasic alterations with peaks in late gestation and at 8 days of postnatal age (79). Rat brain 
and testis show an increase of heart FABP mRNA after weaning (79). A rapid increase in heart 
FABP mRNA was also observed in the late gestation placenta (79). 
The main FABP present in mammary gland of rat, mouse and cattle appears to be the 
heart FABP type (244,245,287,288). A growth inhibitor isolated from bovine mammary gland 
(MDGI) appeared to be an isoform of heart FABP (242). The expression of the protein is 
highest in terminally differentiated lactating mammary gland and absent in virgin mammary 
gland (243,287,288). C-terminal amino acids seem to carry the signal for inhibition of tumor 
cell proliferation (289). A MDGI form at nine amino acid positions not identical with heart 
FABP was detected by screening of a cDNA library derived from the mammary gland of a 
pregnant mouse (290). Also the rat mammary gland contains an additional FABP, which is 
presumably an isoform of heart FABP (244). MDGI may be a protein in low abundance and/or 
localized to a specific group of mammary epithelial cells. 
In brain the main FABP type appears also to be the heart type (69-71), although both the 
presence (79) and absence (80) of heart FABP mRNA were reported. The presence of more 
FABP types in bovine brain was suggested on base of amino acid sequence heterogeneity of 
isolated preparations (291,292). Under relatively relaxed stringency employed for primer 
extension experiments two products were found with brain mRNA in contrast to with heart, 
muscle and kidney mRNA (79). Recently a mouse gene coding for a new type of FABP was 
identified by a homology-based PCR approach (293). Using mRNA from brain as template its 
DNA sequence was confirmed by reverse transcriptase PCR. On base of the localisation of the 
transcript and the protein in the olfactory nerve layer, the new FABP is called olfactory FABP. 
It has 88% similarity with heart FABP type and 70% with adipocyte and myelin FABP types. 
Epidermal FABP gene 
The gene for the epidermal FABP type (63,64) has not yet been identified. Expression 
levels of this FABP are low in normal epidermis, higher in cultured keratinocytes and still 
higher in psoriatic skin (63,64). Krieg et al. (294) described the cDNA for a mal-1 protein, a 
keratinocyte lipid-binding protein, which is up-regulated in both benign papilloma and malignant 
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squamous cell carcinomas stages during tumor development. The derived amino acid sequence 
is most identical with the mouse myelin FABP and adipocyte FABP types. In Southern blot 
analysis the gene was detected in DNA from mouse epidermis and from papillomas and 
squamous cell carcinomas. It was suggested that more copies of the gene were present in the 
mouse genome. Ал additional band was observed in DNA from tumors indicating rearrange­
ments or changes in the methylation pattern of the mal-1 gene. 
Intestinal FABP gene 
The complete intestinal FABP gene was elucidated for human and mouse (246,247). For 
the rat intestinal FABP gene only the first two exons, the first intron and 11 kb of 5' flanking 
sequence were isolated (247). The human and mouse intestinal FABP gene consist of four exons 
encoding 23, 57, 36 and 16 amino acids, respectively separated by 3 introns of 1.2, 1.0-1.8 and 
0.4 kb (Fig. 4). In the second intron of the human gene a trinucleotide repeat of (TTA)i3 is 
present (247,295). Using the rat intestinal FABP cDNA as a probe a restriction fragment length 
polymorphism was demonstrated after Taq I digestion of genomic DNA from various cattle 
species (296). The gene is located on human chromosome 4 in the q28-q31 region and on 
mouse chromosome 3 between the amylase 1,2 and alcohol dehydrogenase 3 loci (246,247) 
(Table 8). 
The regulatory elements of the 5' flanking region of the intestinal FABP gene are 
depicted in Fig. 6. Alignment of the 5' flanking sequences of the mouse, rat and human 
intestinal FABP genes revealed the presence of three conserved domains and of more copies of 
a 14 bp consensus sequence (5'-TGAACi"i"i'GAACTT). The positioning of these sequence 
elements is well conserved among the intestinal FABP genes of mouse, rat and human despite 
the difference in the relative position of elements Ι, Π and Ш. In the mouse and rat genes three 
copies are present. The human intestinal FABP gene is missing 180 bp between the conserved 
domains I and Π, but has an additional partial fourth copy at a position analogous to the most 5' 
14-bp element of the rat and mouse genes (246). This consensus sequence or parts of it are also 
found in the 5' flanking region of the CRBP II and the apolipoprotein Α-I gene (247,297). 
These genes are expressed in the small intestine like the intestinal FABP gene. Only the rat 
intestinal FABP gene contains a B2 repetitive element. All intestinal FABP genes have the 
transcription-regulatory CCAAT and TATA box sequences (246,247). Several cAMP-reponsive 
elements are also present. The latter contains a 24 bp element that binds nuclear factors which 
are present in colon but not in small intestine epithelial cells. Directly downstream this element 
the consensus sequence for C/EBPa is located. Between nucleotides -103 to +28 one copy of 
the 14 bp element is present. This element binds two transcription factors, hepatic nuclear 
factor4 (HNF4) and apolipoprotein regulatory protein-1 (ARP-1), both belonging to the steroid 
hormone receptor superfamily (298). 
Study of the regulation of the intestinal FABP gene is of large interest. This gene is only 
expressed in the enterocytes in mouse, rat and human (246,299,300), one of the four principal 
epithelial cell types originating from the multipotent stem cell in the base of the intestinal crypt. 
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Expression is activated during their translocation from 
the upper crypt to the base of the intestinal villi and 
continues dunng migration to the apical extrusion 
zone. In this way a crypt-to-villus (vertical) gradient 
of intestinal FABP and intestinal FABP mRNA of 
mouse, rat and human is formed (72,247,299-301) 
The level of the protein and its mRNA vary also 
along the cephalo-caudal (horizontal) axis of the gut. 
The highest concentrations are present in the jejunum 
and ileum of mouse and rat (65,72,76,299,300). It is 
also present in the proximal colon, but absent from 
stomach and distal colon. 
The mouse intestinal FABP gene is activated 
m the gut epithelium between embryonic days 15 and 
16 (246). In the rat the intestinal FABP mRNA was 
first detectable m small intestine and between the 19th 
and 21st day of gestation (286). The rat enterocytes 
of jejunum and ileum do not demonstrate uniform 
staining for intestinal FABP until postnatal day 1 
(76). This mosaic cellular pattern starts m the proxi-
mal small intestine by fetal day 18 and occurs 1-2 
days later in distal small intestine. In the mouse a 
mosaic pattern of intestinal FABP is observed up to 
the fourth postnatal day only in cells located in the 
mtervillus region, but not in the villus-associated 
enterocytes (246). In adult animals the intestinal 
FABP gene is activated in mouse and rat enterocytes 
after they complete passage through the cell cycle and exit the crypt (246). The cell-specific and 
regional differences of intestinal FABP evident at the early life are maintained throughout 
adulthood m rat and mouse (246,299). 
Gordon and his associates have used transgenic mice containing fusion genes of the 5' 
nontranscnbed domain of intestinal FABP and the coding region of the human growth hormone 
gene to map the cis-acting elements which regulate the developmental stage- and cell lineage-
specific and the regional patterns of expression (299,300). Analyses of intestinal isografts have 
shown that the differentiation-dependent of intestinal FABP synthesis and the horizontal 
variations in enterocyte intestinal FABP levels do not relate to luminal signals (301). 
Studies m transgenic mice indicated that nucleotides -1178 to +28 of rat intestinal FABP gene 
contain all information to direct cellular and regional patterns of expression of reporters hGH 
(299) and SV-40 Τ antigen (73) which are comparable to intestinal FABP m late fetal life. 
Nucleotides -103 to +28 of the rat intestinal FABP gene are sufficient to direct lineage-
24 bp elementi 18Θ 212) 
I 167 Ιβθ) 
14 bp element { 69 Θ2) 
CCAAT bo« 
TATA bOK 
Fig. 6 Cis-acting elements and uans-acung 
(actors ш the 5' flanking region of (be intes­
tinal FABP gene. 
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appropriate expression and to establish a duodenal-colonic distribution of reporter hGH mRNA 
accumulation in enterocytes which mimics that of mouse intestinal F ABP mRNA (300). They 
lack however elements, that sustain expression beyond the suckling/weaning period. Elements 
between nucleotides -1077 and -277 appear to function as positive transcriptional elements for 
expression during postnatal life. They also support expression in ileum and colon but a domain 
located between -277 and -185 suppresses this activation of ileal and colonic expression (300). 
Removal of this domain yielding a -184 to +28 construct caused inappropriate expression of the 
transgene in stomach and in nonproliferating and proliferating epithelial cells of the upper half 
of the crypts (300). 
Transfection of Caco-2 cells with fusion genes of elements of intestinal FABP promoter 
and hGH gene caused expression of hGH in these cells, which usually do not produce intestinal 
FABP (298). The highest expression was obtained with the shortest construct, of nucleotides 
-103 to +28, which did not give FABP expression in colon. 
Liver FABP gene Liver FABP 
The transcription unit of the liver FABP gene 
spans a region of 3.8 kb encoding 4 exons of 23, 57, 
31 and 16 amino acids, respectively separated by 
three exons of 1.5, 1.2 and 0.6 kb (302)(Fig. 4). 
Using the rat liver FABP cDNA as a probe the mouse 
gene was detected in Southern hybridization ex­
periments. This gene is localized on mouse chromoso­
me 6 within 3 cM of the lymphocyte antigen-2 (Ly-2) 
(247,303) (Table 8). The human gene is localized on 
chromosome 2 in the pl2-qll region (247, 304). 
Fig. 7 shows some of the regulatory elements 
of the rat liver FABP gene as revealed by studies of 
Gordon and his coworkers (302,305). Survey of the 
first 600 nucleotides of the 5'-nontranscribed domain 
shows besides one TATA-box, a purine-rich region 
located at nucleotides -53 to -47 which contain the 
core recognition sequence for members of the Ets 
superfamily. A peroxisome proliferator response 
element (PPRE) is present at nucleotides -76 to -66. It 
differs by one nucleotide from an hepatic nuclear 
factor 2 (HNF2) binding site in other promoters. The 
PPRE element will be discussed later. Two additional 
HNF1 binding sites can be observed. A putative 
"GATA" binding site is present at nucleotides -245 to 
-240. C/EBP a protects three regions of the promoter 
С/ЕВРО 
HNF1 
HNF1 
PPAR 
(-345 -3561 
1-329 -342) 
SATA (-240 -2451 
(-102-115) 
CCAAT Ьож 
РРЯЕ (HNF2K-SS.75) 
EH (-47 -53) 
TATA bOM 
Fig. 7 Cis-acting dements and trans­
acting factors in the 5' flanking region 
of the liver FABP gene. 
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of the rat liver F ABP from DNase I digestion, but these regions do not contain any of the 
highly diverse C/EBP α binding sites characterized previously. 
Expression of the liver FABP gene is confined in the mouse to hepatocytes of the liver 
(239) and to enterocytes and a subset of enteroendocrine cells of the small intestine (65,73,299, 
305). In rat and human liver the liver FABP type is also only present in hepatocytes (88,306-
308) but in the intestine of these species it is besides in small intestine also present in the 
epithelial cells of the cecum and colon (305,309). The liver FABP type was also found in cells 
of the rat stomach, depending on developmental stage (77,310). In the rat and human kidney 
also expression of liver FABP type is present with a marked difference in cellular distribution 
(58, 59). The liver FABP type and its mRNA show a declining gradient of expression from 
periportal to pericentral hepatocytes in mouse (239), rat (88,237,238,306,311,312) and human 
(307). All species show besides zonal variations in liver, also a crypt to villus tip gradient in 
their intestine (72-75,239,301,309). The liver FABP-positive enteroendocrine cells of the mouse 
intestine appear to represent a small subpopulation of serotogenic cells (313). 
The temporal and regional patterns of liver FABP type expression are similar in the rat 
intestine to that of the intestinal FABP type, although the prenatal mosaic pattern of cellular 
expression was different (76). Immunoreactive liver FABP and its mRNA are first detectable at 
fetal day 17 in mouse liver and small intestine and exhibit variations along the cephalo-caudal 
axis from late fetal life through adulthood (73,301,314). A vertical gradient in cellular liver 
FABP is also established with the first emergence of nascent villi (73). The content of liver 
FABP in rat liver increases from fetal day 16 up to adulthood (70,283,284,286). FABP-
immunoreactive hepatocytes and enterocytes are present in human at week 7 and 23 of 
gestation, respectively (307,309). The FABP mRNA level, low in prenatal rat liver and 
intestine rises markedly around birth and again between 35 and 70 days (286). Liver FABP 
mRNA was present in similar concentrations in human liver between the 8th through 25th 
weeks of gestation (315). Studies of fetal and adult intestinal implants into the subcutaneous 
tissues of adult nude mouse recipients have shown that exposure to luminal contents is not 
necessary to obtain region- and differentiation-dependent expression of liver FABP type (301). 
Liver FABP type appeared to be the only FABP type present in a human colon carcino­
ma (CaCo-2) cell line (316,317) and to increase with differentiation (91,316). These cells only 
contain liver FABP mRNA and no intestinal FABP mRNA (247,318). 
Analysis of the 5' flanking region of the liver FABP gene was performed in a similar 
approach as for the intestinal FABP gene by use of fusion genes of sequential deletions of this 
region and a reporter gene in mice (239,305). A fusion product of nucleotides -596 to +21 with 
the coding region of hGH or human decay-accelerating factor/HLA-B44 appeared to be 
sufficient to direct expression of the reporter to hepatocytes and to enterocytes of intestinal 
epithelium (239,319). However, anomalous expression was observed in cecum, colon, renal 
proximal tubular epithelial cells and intestinal crypts and in many enteroendocrine cells of 
young adult mice (239,305,313,319). In fetal mice, nucleotides -596 to +21 are however 
sufficient to reproduce an appropriate temporal, cellular and regional pattern of reporter 
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expression (316) like nucleotides -4000 to +21 (73). This larger construct did not give hGH 
expression in adult mice in colon, kidney and some enteroendocrine cells (239,305,313). It 
directed a proper horizontal gradient of hGH expression in the intestine, but inappropriate 
expression occurred in the crypt epithelium, where liver F ABP normally is not present. 
In liver of adult mice, nucleotides -4000 to +21 produced a pattern of cell-specific and 
intralobular expression (hepatocytes with a gradient from portal triads to central veins)(299), but 
the temporal partem of induction of hGH expression in fetal liver appears to be different from 
that of liver FABP (73). The nucleotides -132 to +21 of the rat liver FABP gene are sufficient 
to confine expression to hepatocytes (305). In addition, nucleotides -246 to +21 direct ap-
propriate regional patterns of reporter expression in the hepatic acinus and cell-cycle-dependent 
variations like for liver FABP were observed (305). 
Nucleotides -103 to +21 are already sufficient to direct a pattern of reporter hGH 
mRNA in villus-associated enterocytes along the duodenal-to-ileal axis of the gut of adult mice 
that sembles the pattern of the endogenous liver FABP gene (305). This transgene is also 
expressed in the stomach mucous cells and the colonocytes of the surface epithelium, like the 
endogenous donor liver FABP gene of the rat, but not the mouse liver FABP gene. It is 
precociously activated in the intestinal crypt cells and is also expressed in proximal tubular 
epithelial cells. 
Analysis of mice containing different transgenes with sequential deletions of the 5 ' non-
transcribed domain of the liver FABP gene indicated that cis-acting suppressors and activators 
of cecal and colonic expression are located between nucleotides -4000 and -1600 and between 
nucleotides -597 and -351, respectively (305). Sequences located outside of -4000 to +21 of the 
liver FABP gene are necessary to suppress the precocious activation of hGH production along 
the crypt-to-villus and crypt-to surface epithelial cuff axis (239,305). 
The nucleotides -186 to -133 cause a relative suppression of renal expression. The 
transgene with the -132 to +21 construct showed a marked increase of hGH mRNA in kidney 
relative to in proximal jejunum, if it was compared with the -186 to +21 construct (305). The 
region of -4000 to -597 contains cis-acting suppressor elements of renal expression (299) but 
also more distal sequences appear to be necessary for complete suppression in the mouse (305). 
At least seven functionally distinguishable cis-acting elements, located between nucleoti-
des -4000 and +21 influence the number and type of enteroendocrine cells that support liver 
FABP gene expression (305). Distinct cis-acting sequences appear to be responsible for 
regulating transcription of this gene in enterocytes and enteroendocrine cells (313). 
The content of the liver FABP type appears to be more affected by changes of physiolo-
gical and pharmacological conditions than the other FABP types (90,283,284,320). Sex and 
Clofibrate affect the content of liver FABP but not of intestinal FABP in intestine (320). 
Peroxisomal proliferators increase the liver FABP content in liver and intestine of rodents 
(70,283,320,321) but have no effect on heart FABP content in rat heart and skeletal muscle 
(283). They rise the liver FABP mRNA level (320,322) by an enhanced transcription rate of the 
liver FABP gene (322). High-fat diets increase the FABP content of rat liver (46,283,323-325), 
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adipose tissue (283) and intestine (326). Only one study was reported on liver F ABP mRNA 
during high-fat diet (327). In rat intestine no change of this mRNA was observed and a slight 
increase of intestinal FABP mRNA. 
The upregulaüon of liver FABP content and FABP mRNA by peroxisomal proliferators 
and high fat diet in liver and intestine is accompanied by a marked increase of total and 
especially peroxisomal fatty acid oxidation (283,320,321,328). A significant correlation was 
observed between the FABP content and peroxisomal oxidation capacity of liver of rats fed with 
various peroxisomal proliferators (321). 
Time courses of induction of liver FABP and peroxisomal oxidation were only studied in 
cultured hepatocytes. The first studies showed that the induction of FABP and peroxisomal 
oxidation are temporally consecutive processes (156). Others reported a coordinate increase of 
FABP, acyl-CoA binding protein and peroxisomal ß-oxidation after three days of treatment with 
clofibric acid (329). The same was observed for liver FABP, its mRNA, peroxisomal fl-
oxidation and cytochrome P450 Г АІ-activity (330). Induction of the latter activity measured as 
lauric acid ω-hydroxylase activity preceded induction of both FABP and peroxisomal oxidation. 
Hexadecanedioic acid that is poorly metabolized in hepatocytes and non-oxidizable dicarboxylic 
analogs induce peroxisomal ß-oxidation and liver FABP but not lauric acid ω-hydroxylase, via a 
pretranslational mechanism, that was not inhibited by inactivators of cytochrome P-450 IVAl 
(330,331). These results indicate that the induction is mediated, to a significant extent, by 
poorly metabolized dicarboxylic acids formed via the cytochrome P450-IVA pathway (330). 
The cellular response to peroxisome proliferators in liver and to a less extent in kidney 
is characterized by an increase in the transcription of several genes that are involved in 
peroxisomal fatty acid oxidation (332, 333) and of the genes of microsomal cytochrome P450 
IVA1 enzymes (330,334,335) and liver FABP (320,322,331). Peroxisomal proliferators as 
fibrates reduced the expression of mRNAs for the apolipoproteins Α-I, A-II and A-IV in rat 
liver, not in intestine and affected in different directions the expression of enzymes involved in 
lipoprotein metabolism (336). Non-ß-oxidazable fatty acids (337) and high-fat diets, especially 
those containing certain poorly metabolizable fatty acids (338-341) also induce the peroxisomal 
oxidation enzymes, although the mechanism is not known. The common feature of all diverse 
reagents inducing peroxisomal proliferation is the presence of an acid function or easy conver-
sion to a compound with an acid function (342,343) The mechanisms by which all these 
chemically distinct compounds work is unclear. 
Recently good evidence is arising, that peroxisomal-proliferator-activated receptors 
(PPARs) mediate the biological action of these compounds. After the first description of murine 
PPARa (344) several other forms of PPARs have been demonstrated, one in rat, a (345), three 
in Xenopus, a, ß and γ (346,347) and one human form, Nucl (348). The PPARs show 
considerable sequence similarity, especially in the DNA-binding С domain and the ligand-
binding E/F domain. Based on the amino acid sequence of the P-box, which determines DNA 
recognition specificity (349) they belong to the nuclear hormone receptor subgroup, which 
comprises receptors for all-trans-retinoic acid (RAR), 9-cis-retinoic acid (retinoic X receptor; 
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RXR), thyroid hormone, vitamin D3 and several orphan receptors. All of these receptors 
recognize the canonical DNA response element AGGTCA (346,349), that is complementary to 
the peroxisome proliferator réponse element (PPRE) TGACCT (350-353). Such PPRE 
sequences have been identified in the 5' flanking regions of the genes of rat acyl-CoA oxidase 
(347,352, 
354), of peroxisomal bifunctional enzyme enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydroge-
nase (355) and of liver FABP (305,356). 
The similarity of the PPAR with other receptors of the nuclear hormone receptor family 
enabled the investigation of PPAR activators (but not necessary their ligands). By the use of 
chimeric receptors containing the putative ligand-binding domain of PPAR and the N-terminal 
and DNA-binding domain of a steroid hormone (oestrogen or glucocorticoid) receptor, specific 
activators of PPAR could be detected as saturated, monounsaturated and polyunsaturated fatty 
acids (345,347,353,357) and various peroxisome proliferators, among which Wy-16,343 was 
most active (347,353,358). Polyunsaturated fatty acids and a synthetic archidonic acid analogue, 
5,8,11,14-eicosatetraynoic acid were very effective activators (357). The natural PPAR ligands 
are still not known. The strong activation of PPAR by a metabolically stabilized fatty acid as 
tetradecylthioacetic acid, indicates that the weak activity of fatty acids is due to their rapid 
metabolism within the cell (353). Hexadecanedioic acid was equally potent as the most active 
fatty acids (353,359). 
Diverse PPARs bind to the PPREs of the genes of rat hydratase/dehydrogenase and acyl-
CoA oxidase but differentially induce expression (360). Heterodimerization with the RXR 
causes cooperative and strongly enhanced binding of PPAR and more stimulation of the acyl-
CoA oxidase gene promoter (353,357,360). PPAR a binding on PPRE and cooperativity with 
RXR and other cellular factors appear to be obligatory, but not necessarily sufficient for 
peroxisome proliferator-dependent transcription induction (360). Distinct PPREs can selectively 
mediate induction by specific PPARs. Since the presence of 9-cis retinoic acid enhances 
synergistically with RXR the activity of PPAR, RXR contributes to stimulation of transcription, 
not only DNA binding (353). The induction of peroxisomal 0-oxidation genes by retinoic acid 
in cultured hepatocytes (361) suggests also a coupling between PPARs and RARs. Peroxisome 
proliferators and thyroid hormone appear to operate by way of distinct nuclear receptors (362). 
In relation with FABP it is important that many peroxisome proliferators (155-157,363), 
all fatty acids and also hexadecanedioic acid (363) are competing ligands for liver FABP. PPAR 
activators (ligands) may originate from or are controlled by FABP. In this way FABP may 
indirectly regulate gene expression. This may involve expression of its own gene. 
Since FABP appears also to bind steroid hormones (363,364) an indirect influence on the 
steroid hormone receptor appears also possible. Oestrogens increase the concentration of FABP 
in rat liver (365) and of liver FABP mRNA in cultured human hepatoma (HepG2) cells (366). 
Other indications for involvement of FABP in growth are the increase of liver FABP (237,238) 
and of the activity of the liver FABP promoter (239) in hepatocytes during mitosis. The growth 
of hepatoma cells transfected with the coding sequence of liver FABP could be stimulated by 
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linoleic acid but conversion of this acid to oxygenated metabolites was apparently necessary 
(240). Growth-stimulatory and -inhibitory eicosanoids bind well to liver FABP, some with 
higher affinity than fatty acids (156-160,363). Liver FABP was identified as the target protein 
of the metabolites of the liver carcinogens 2-acetylaminofluorene (238,241) and 4-dimethyl-
amino-3-methylazobenzene (364). In mouse, liver FABP is identical with a selenium-binding 
protein (150). Selenium compounds block cell multiplication and inhibit carcinogenesis. All 
these findings indicate that liver FABP may be involved in growth and differentiation of 
hepatocytes. 
CRBP I 
RARE (-997-1009) 
CRBP I and Π genes 
The human CRBP I gene harbors 4 exons 
encoding 24, 59, 33 and 16 amino acids, respectively 
separated by 0.4, 18.3 and 0.7 kb of intron sequences 
(90) (Fig. 4). The gene was identified in bovine, 
chicken and frog (90). The gene is located in the 
segment pll-qter of human chromosome 3 and on 
mouse chromosome 9 (90,297) (Table 8). 
CRBP I mRNA is first expressed in mouse 
intestinal and liver RNA at fetal day 16 (367). The 
following days of development and immediately after 
birth CRBP I mRNA is also detectable in lung, kid­
ney, testes, seminal vesicle, colon, adrenal, spleen, 
brain and heart RNA (367,368). The level of expres­
sion is highest in lung. During postnatal life CRBP I 
mRNA levels in the various tissues do not show a 
coordinate expression (367). 
The cis-acting elements and trans-acting fac­
tors of the 5' upstream region of the CRBP I gene are 
depicted in Fig. 8. In the 5' flanking region of the 
CRBP I gene a high number of CpG dinucleotides is 
present which is the most common site for methyla-
tion in mammalian cells (90). The other members of 
the FABP family do not contain this high content of 
CpGs in the 5' flanking region of their gene. The 
TATA box is absent but 6 to 8 copies of the CCG-
CCC sequence, the core sequence for the SP-1 tran­
scription factor binding site, are present. Furthermore a 9 bp sequence element which is similar 
with the SV40 enhancer was found. Smith et al (369) found additional Krox-20 or Krox-24 and 
two NF-1 binding sites. In the more upstream region a retinoic acid response element (RARE) 
was found which sequence closely resembled that of the RARE in the RAR ^ promoter. CRBP 
г — , (-171-1831 
H . (-158-166) 
iÜ± Λ 1-1 CC . I M I 
4-153-1471 
[(-141 -1351 
((-134-1281 
4-114-1081 
Fig. 8 Cis-acting elements and trans­
acting factors in the 5' flanking region 
of the CRBP I gene. 
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I expression seems to be activated by RAR, since three RAR isoforms α, β and 7 are able to 
bind to the RARE in the 5' flanking region of the CRBP I gene (369,370). 
The gene for CRBP Π was isolated from rat (297). The four exons encoding 24, 59, 34 
and 16 amino acids, respectively are interspersed by 3 introns of 5.3, 9.2 and 1.4 kb in length 
(297) (Fig.4). The gene was identified in human and mouse DNA, but was not detected in 
chicken and fish DNA (297). The mouse gene is located on chromosome 9 and the human 
homolog on chromosome 3 (297) (Table 8). In both species the CRBP Π gene is closely linked 
to the CRBP I gene. 
In contrast to CRBP I mRNA, expression of CRBP Π mRNA is less widely spread. In 
fetal mouse high mRNA levels were found in intestine and only trace amounts in liver and lung 
(367). CRBP Π transcript expression is first detectable at fetal day 19 simultaneously with the 
appearance of a proliferative intestine absorptive columnar epithelium (367,371). The expression 
in intestine declines dramatically after birth, remains low during the weaning period and rises 
again during adulthood (367,371,372). Expression in liver disappears completely after birth 
(367,371). 
The transcription-regulatory elements, the CAAT- and TATA-box, are both present in 
the CRBP Π gene. As mentioned for intestinal FABP, the CRBP II gene also contains a 14-bp 
element in the 5' flanking region (297). This element binds the transcription factors HNF4 and 
ARP-1, which might direct expression of the gene in the intestine (298). The expression of the 
CRBP II gene is dramatically upregulated by 9-cis retinole acid by RXR (but not by RAR) via a 
retinoid X réponse element (RXRE) in the gene promoter region (373). Between nucleotides 
-639 to -605 five nearly perfect tandem repeats are present which form the RXRE (373). 
CRABP I and Π genes 
The mouse CRABP I gene spans 10.5 kb containing 4 exons encoding 24, 59, 38 and 16 
amino acids, respectively which are separated by 3 introns 0.5, 3.5 and 5.5 kb in length (374) 
(Fig. 4). The gene was detected by Southern hybridization in bovine, human, chicken, frog and 
fish (368,375,376). The human CRABP I gene is localized on chromosome 3 like CRBP I and 
Π. Since no linkage studies were done it is not known if the CRABP I gene forms a cluster with 
the CRBP genes (375). 
CRABP I mRNA is expressed in testis, seminal vesicle, brain, kidney and skin of adult 
rat (377). The expression pattern is similar in neonatal rats but in general the transcription level 
is higher. In mouse, CRABP mRNA was only detected in seminal vesicle RNA (368). 
Analysis of the 5' flanking region of the CRABP I gene revealed that no TATA box was 
present. A high GC content and multiple copies of the putative SPI transcription factor binding 
sequence were found identical with CRBP I and housekeeping genes (374). 
The CRABP Π gene was isolated for mouse and man with a length of 4.6 and 6 kb, 
respectively. The length of the three introns are 3-4, 0.2 and 0.5 kb, respectively (250,251). 
The gene has been mapped to mouse chromosome 2, approximately 4.2 cM distal to the muscle 
nicotinic acetylcholine receptor α-chain gene and 4.5 cM proximal to the catalase-1 gene (250). 
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For human it could therefore be located on chromosome 2 or 11 (Table 8). 
CRABP Π mRNA is only expressed in skin of neonatal rats. Its level is approximately 
5% of CRABP I expression in the same tissue. In adult rats no transcripts were detected in skin 
and only trace amounts of mRNA in adrenal (377). 
The cis-acting elements and trans-acting fac­
tors controling CRABP Π gene expression are shown 
in Fig. 9. The 5' flanking region of the mouse 
CRABP Π gene contains a TATA-box, a GC-rich 
region with two overlapping SP-1 recognition motifs, 
an AP-1 consensus and an AP-2 consensus (250). In 
addition a direct repeat spaced by 1 bp was found 
with similarity to the RARE in the RAR ßj gene 
(251). Two potential AP-2 binding sites, one SP-1 
site and two Krox-24 binding sites are present in the 
upstream region of the human gene (251). Durand et 
al. (378) found more upstream a second RARE. 
Since we focus on FABPs in this review we 
will only briefly discuss the interaction of the 
CRABPs with nuclear retinole acid receptors. For an 
extensive discussion see refs 39 and 379-382. These 
receptors belong to the steroid/thyroid hormone nu-
clear receptor superfamily and can be divided in 
receptors with high affinity for all-trans retinoic acid, 
the RAR and for 9-cis retinoic acid, the RXR. Both 
have three subtypes α, β and γ, which have several 
isoforms generated by alternative splicing (382). 
Upon activation the RAR and RXR form dimers and 
recognize specific cis-acting elements RARE and 
RXRE in the 5' upstream region of genes which are 
transcriptionally activated. RAR and RXR form ho-
modimers but also heterodimers, both among themselves and with other members of the 
hormone nuclear receptor super family (353,357,360,373,379,383). Heterodimer RAR and RXR 
(RAR-RXR) bind more efficiently than homodimers to the RAREs (378). Dollé and coworkers 
(384) showed a differential and tissue-specific expression of the three RAR genes and the genes 
of CRBP I and CRABP I. They suggested that this spatio-temporally regulated expression 
during development may account for the diversity of retinoic acid effects. Due to this differen-
tial expression the activation of gene transcription of developmental genes also varies in the 
cells. The role of CRBP and CRABP in embryonal development may be controlling the free 
retinoid concentration and thereby the activity of the RAR and RXR (384). CRBP may regulate 
the concentration of free retinol and its conversion to retinoic acid. CRABPs may sequester 
4 putative SP-1 binding 
Site» 1-41 -62) 
TATA-boi 
Fig. 9 Cis-acting dements and trans-
acting factors in the 5' flanking region 
of the CRABP Π gene. 
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retinole acid which leads to a difference in availability of retinoic acid for RAR and RXR in the 
various cells where CRABPs are expressed (380,385). Retinoic acid induces the expression of 
the genes of CR ABP I and II, RAR β, laminin Bl and collagen type IV in F9 teratocarcinoma 
cells (385). Stably transfected cell lines expressing elevated levels of CR ABP I showed a 80-
90% reduction in the retinoic acid induced expression of RAR β, laminin Bl and collagen type 
IV. 
The CRBP and CRABP levels themselves are also regulated by retinoic acid. Response 
elements for RAR and RXR are present in the 5' upstream region of the CRBP I (369) and the 
CRBP II gene (373), respectively. The CRABP II gene promoter has a response element which 
is recognized by a heterodimer of RAR and RXR (378). The promoter activation of the CRABP 
II gene is more efficiently increased by 9-cis retinoic acid than by all-trans retinoic acid (378). 
The CRABP II gene expression in F9 teratocarcinoma cells is not directly regulated by retinoic 
acid as was shown by nuclear run on experiments and the posttranscriptional inhibition of 
induction by cycloheximide (250,251). It was suggested that a newly synthesized regulatory 
protein is involved in induction of CRABP II expression (251). 
Conclusions 
The abundance of FABP and FABP mRNA in the cytosol of various cells of vertebrates 
and invertebrates indicates the importance of these molecules. Seven FABP types have been 
identified on the protein and/or RNA level. Some are present in only one cell type or tissue, 
other, especially the heart type, have a more broad tissue distribution. The existence of different 
types can be explained by tissue-specific or functional adaptations. The tertiary structure of the 
investigated FABP types shows a similar ß-clam, but the fatty acid-binding site appears to 
differ. The structure of the liver FABP type is not known, but appears rather unique, since this 
molecule has a different primary structure and also shows different properties with biophysical 
techniques and various ligands. The liver FABP type binds, in contrast to the heart type, 
besides long-chain fatty acids also many other hydrophobic ligands, including haem, some 
prostaglandins, leukotrienes, bile acids and peroxisomal proliferators. 
The function of FABPs in fatty acid uptake and intracellular transport and in fatty acid 
metabolism needs more conclusive evidence. Recent observations indicate also a direct or 
indirect role in complex processes as cellular growth, differentiation and signal transduction as 
well as a protective role with respect to membranes and enzyme systems. A primary role of 
FABPs in pathology has not been reported. 
The increasing knowledge on the structure of FABPs, their mRNAs and genes and the 
use of sophisticated molecular-biological, cell-biological and biophysical techniques will allow 
in the near future a better understanding of the biologic significance of the different FABP 
types. 
-48-
η traduction 
leferences 
1. Hüderson HJ. Intracellular transfer of lipid molecules. Subcellular Biochemistry, vol 16, Plenum Press. 
New York and London, 1990 
!. Rueclcert DG, Schmidt K. Lipid transfer proteins. Chem Phys Lipids 1990; 56: 1-20 
I. Godovac-Zimmerman J. The structural motif of B-lactoglobulin and retmol-bmdmg protein: A basic 
framework for binding and transport of small hydrophobic biomolecules? Trends Biochem Sci 1988; 13: 
64-66 
I. Subbiah MTR. Newly recognized lipid earner proteins m fetal life. Proc Soc Exp Biol Med 1991; 198: 
495-499 
¡. Paulussen RJA, Veerkamp JH. Intracellular fatty acid-binding proteins. Characteristics and function. In: 
Hilderson HJ, ed. Intracellular transfer of lipid molecules. Subcellular Biochemistry, vol 16, Plenum 
Press, New York and London, 1990: 175-226 
ι. Potter HJ, Sorrentino D, Berk PD. Mechanisms of cellular uptake of free fatty acids. Annu Rev Nutr 
1989; 9: 253-270 
'. Weisiger RA, Ma W-L. Uptake of oleate from albumin solutions by rat liver. Failure to detect catalysis 
from the dissociation of oleate from albumin by an albumin receptor. J Clin Invest 1987; 79: 1070-1077 
i. Rose H, Hennecke Τ, Kammermeier Η. Is fatty acid uptake m cardiomyocytes determined by physicoche-
mical fatty acid partition between albumin and membranes? Mol Cell Biochem 1989; 88: 31-36 
). Popov D, Hasu M, Ghinea Ν, Simionescu Ν, Sinuonescu M. Cardiomyocytes express albumin binding 
proteins. J Mol Cell Cardiol 1992; 24: 989-1002 
10. Simionescu M, Ghitescu L, Fixman A, Simionescu N. How plasma macromole-cules are transported by 
vascular endothelium. News Physiol Sci 1987; 2: 97-100 
II. Abumrad NA, Park JH, Park CR. Permeation of long-chain fatty acid into adipocytes. Kinetics, 
specificity, and evidence for involvement of a membrane protein. J Biol Chem 1984; 259 8945-8953 
12. Sorrentino D, Stump D, Potter BJ et al. Oleate uptake by cardiac myocytes is earner mediated and 
involves a 40 kD plasma membrane fatty acid-binding protein similar to that m liver, adipose tissue, and 
gut. J Clin Invest 1988; 82: 928-935 
13. Stremmel W. Fatty acid uptake by isolated rat heart myocytes represents a camer-mediated transport 
process. J Clm Invest 1988; 81: 844-852 
14. Tngaro. BL, Mangroo D, Gerber GE. Photoaffinity labeling and fatty acid permeation in 3T3-L1 
adipocytes. J Biol Chem 1991; 266: 22621-22625 
15. Harmon CM, Luce P, Beth AH, Abumrad NA. Labeling of adipocyte membranes by sulfc-N-succinimidyl 
derivatives of long-chain fatty acids: inhibition of fatty acid transport. J Membrane Biol 1991; 121: 261-
268 
16. Stremmel W, Kleinert H, Fttscher BA et al. Mechanism of cellular fatty acid uptake. Biochem Soc Trans 
1992; 20: 814-817 
17. Zhou S-L, Stump D, Sorrentino D, Potter BJ, Berk PD. Adipocyte differentiation of 3T3-L1 cells involves 
augmented expression of a 43-kDa plasma membrane fatty acid-bmdmg protein. J Biol Chem 1992; 267· 
14456-14461 
18. Storch J, Lechene C, Kleinfeld AM. Direct determination of free fatty acid transport across the adipocyte 
plasma membrane using quantitative fluorescence microscopy. J Biol Chem 1991; 266: 13473-13476 
19. Noy Ν, Donnelly TM, Zakim D. Physical-chemical model for the entry of water-insoluble compounds into 
cells. Studies of fatty acid uptake by the liver. Biochemistry 1986; 25: 2013-2021 
20. Brönng К, Haest CWM, Deuticke В. Translocation of oleic acid across the erythrocyte membrane. 
Evidence for a fast process. Biochim Biophys Acta 1989; 986: 321-331 
21. Cooper RB, Noy Ν, Zakim D. Mechanism for binding of fatty acids to hepatocyte plasma membranes. J 
-49-
Chapter 2 
Lipid Res 1989; 30: 1719-1726 
22. Kamp F, Hamilton JA. pH gradients across phospholipid membranes caused by fast flip-Лор of un-iomzed 
fatty acids. Proc Nad Acad Sci 1992; 89- 11Э67-11Э70 
23. Van der Vusse GJ, Glatz JFC, Stam HCG, Reneman RS. Fatty acid homeostasis in the normoxic and 
ischemic heart. Physiol Revs 1992; 72: 881-940 
24. Scow RO, Blancbette-Mackie ET. Endothelium, the dynamic interface in cardiac lipid transport. Mol Cell 
Biochem 1992; 116: 181-191 
25. Stoll LL, Spector AA. Lipid transfer between endothelial and smooth muscle cells in coculture. J Cell 
Physiol 1987; 133: 103-110 
26. Nagelkerke JF, Van Berkel TJC. Rapid transport of fatty acids from rat liver endothelial to parenchymal 
cells after uptake of cholesteryl ester-labeled acetylated LDL. Biochim Biophys Acta 1986; 87S: S93-598 
27. Veerkamp JH, Peelers RA, Maatman RGHJ. Structural and functional features of different types of 
cytoplasmic fatty acid-binding proteins. Biochim Biophys Acta 1991; 1081: 1-24 
28. Haunerland NH, Chisholm JM. Fatty acid binding protein ш flight muscle of the locust Schistocerca 
gregaria. Biochim Biophys Acta 1990; 1047: 233-238 
29. Van der Horst DJ, Van Doom JM, Passier PCCM, Vork MM, Glatz JFC. Role of fatty acid-binding 
protein m lipid metabolism of insect flight muscle. Mol Cell Biochem 1993; 123: 145-152 
30. Smith AF, Tsuchida K, Hanneman E, Suzuki TC, Wells MA. Isolation, characterization and cDNA 
sequence of two fatty acid-binding proteins from the midgut of Manduca sexta larvae J Biol Chem 1992; 
267: 380-384 
31. Moser D, Tendier M, Griffiths G, Klinkert M-Q. A 14-kDa Schistosoma mansoni polypeptide is 
homologous to a gene family of fatty acid binding proteins. J Biol Chem 1991; 266: 8447-84S4 
32. Knudsen J. Acyl-CoA-buiding protein (ACBP) and its relation to fatty acid-binding protein (FABP): An 
overview. Mol Cell Biochem 1990; 98: 217-223 
33. Wirtz KWA. Phospholipid transfer proteins. Annu Rev Biochem 1991; 60: 73-99 
34. Sasaki T, Abe A, Roennk F. Glycolipid transfer protein in animal cells. In: Hilderson Ш, ed. Intracel­
lular transfer of lipid molecules. Subcellular Biochemistry Vol 16. Plenum Press, New York and London, 
1990: 113-127 
35. Billheimer JT, Reinhart MP. Intracellular sterol transport. In: Hilderson HJ, ed. Intracellular transfer of 
lipid molecules. Subcellular Biochemistry Vol 16. Plenum Press, New York and London, 1990° 69-111 
36. Blomhoff R, Green MH, Berg T, Norum KR. Transport and storage of vitamin A. Science 1990; 250· 
399-404 
37. Wolf G. The intracellular vitamin A-brnding proteins: an overview of their functions. Nutr Revs 1991; 49: 
1-12 
38. Bemier I, Jolles P. A survey on cytosohc nonenzyme proteins involved m the metabolism of lipophilic 
compounds: From organic anion binders to new protein families. Biochimie 1987; 69- 1127-1152 
39. Ross AC. Cellular metabolism and activation of retinoids: roles of cellular retinoid-brnding proteins. 
FASEBJ 1993; 7: 317-327 
40. Papiz MZ, SawyerL, Eliopoulos ЕЕ et al. The structure of fi-lactoglobulm and its similarity to plasma 
retinol-binding protein. Nature 1986; 324- 383-385 
41. Pervaiz S, Brew K. Homology and structure-function correlations between a,-acid glycoprotein and serum 
retinol-binding protein and ite relatives. FASEB J 1987; 1: 209-214 
42. Mishkin S, Stem L, Gatmaitan Z, Anas IM. The binding of fatty acids to cytoplasmic proteins: Binding to 
Ζ protein in liver and other tissues of the rat. Biochem Biophys Res Commun 1972; 47: 997-1003 
43. Ockner RK, Manning JA, Poppenhausen RB, Ho WKL. A binding protein for fatty acids in cytosol of 
intestinal mucosa, liver, myocardium, and other tissues. Science 1972; 177: 56-58 
44. Glatz JFC, Veerkamp JH. Intracellular fatty acid-binding proteins. Int J Biochem 1985; 17: 13-22 
-5П-
Introduction 
45. Sweetser DA, Heuckeroth RO, Gordon JI. The metabolic significance of mammalian fatty acid-binding 
proteins: Abundant proteins ш search of a function. Annu Rev Nutr 1987; 7: 337-359 
46. Bass NM. The cellular fatty acid binding proteins: Aspects of structure, regulation and function. Int Rev 
Cytol 1988; 111: 143-183 
47. Matarese V, Stone RL, Waggoner DW, Bemlohr DA. Intracellular fatty acid trafficking and the role of 
cytosolic lipid binding proteins. Prog Lipid Res 1990; 28: 245-272 
48. Clarke SD, Armstrong MK. Cellular lipid binding proteins: expression, function and nutritional regulation. 
FASEB J 1989; 3: 2480-2487 
49. Kaikaus RM, Bass NM, Ockner RK. Functions of fatty acid binding proteins. Expenentia 1990, 46. 617-
630 
50. Glatz JFC, Van der Vusse GJ. Cellular fatty acid-binding proteins: Current concepts and future directions. 
Mol Cell Biochem 1990; 98: 237-251 
51. Gordon Л, Sacchettuu JC, Ropson U et al. Intracellular fatty-acid-binding protein and their genes: useful 
models for diverse biological questions. Current Opinion Lipidol 1991; 2: 125-137 
52. Peters RA, Veerkamp JH, Kanda T, Ono T, Geurts van Kessel A. Cloning of the cDNA encoding human 
skeletal muscle fatty acid-binding protein, its peptide sequence and chromosomal localization Biochem J 
1991; 276: 203-207 
53. Narayanan V, Barbosa E, Reed R, Tennekoon G. Characterization of a cloned cDNA encoding rabbit 
myelin P, protein J Biol Chem 1988; 263: 8332-8337 
54. Hayasaka K, Nanao K, Tahara M et al. Isolation and sequence determination of cDNA encoding P
:
 protein 
of human peripheral myelin. Biochem Biophys Res Commun 1991; 181: 204-207 
55. Baxa CA, Sha RS, Buelt MK, Smith AJ, Matarese V, Chinander LL, Boundy KL, Bemlohr DA Human 
adipocyte lipid binding protein: Purification of the protein and cloning of its complementary DNA. 
Biochemistry 1989; 28: 8683-8690 
56. Lam KT, Borkan S, Claffey KP, Schwartz JH, Chobanian AV, Brecher Ρ Properties and differential 
regulation of two fatty acid-binding proteins m the rat kidney. J Biol Chem 1988; 263. 15762-15768 
57. Kimura H, Odani S, Nishi S, Sato H, Arakawa M, Ono T. Primary structure and cellular distribution of 
two fatty acid-binding proteins in adult rat kidney. J Biol Chem 1991; 266: 5963-5972 
58. Maatman RGHJ, Van de Westerlo EMA, Van Kuppeveit THMSM, Veerkamp JH. Molecular identification 
of the liver- and the heart-type fatty acid-binding protein in human and rat kidney. Use of the reverse 
transcriptase polymerase chain reaction. Biochem J 1992; 288: 285-290 
59. Maatman RGHJ, Van Kuppevelt THMSM, Veerkamp JH. Two types of fatty acid-binding protein m 
human kidney. Biochem J 1991; 273: 759-766 
60. Walz DA, Wider MD, Snow JW, Dass С, Desiderio DM. The complete ammo acid sequence of porcine 
gastrotropin, an ileal protein which stimulates gastric acid and pepsinogen secretion. J Biol Chem 1988, 
263: 14189-14195 
61. Gantz I, Nothwehr SF, Lucey M et al. Gastropin: Not an enterooxyntin but a member of a family of 
cytoplasmic hydrophobic ligand bmding proteins. J Biol Chem 1989; 264: 20248-20254 
62. Kanda T, Odani S, Tomoi M, Matsubara Y, Ono T. Primary structure of a 15-kDa protein from rat 
intestinal epithelium. Sequence similarity to fatty-acid-binding proteins. Eur J Biochem 1991; 197: 759-768 
63. Madsen P, Rasmussen HH, Leffers H, Honoré В, Celis JE. Molecular cloning and expression of a novel 
keratinocyte protein (Psonasis-associated fatty acid-binding protein [PA-FABP]) that is highly up-regulated 
m psoriatic skin and that shares similarity to fatty acid-binding proteins. J Invest Dermatol 1992; 99: 299-
305 
64. Siegenthaler G, Hotz R, Chatellard-Gruaz D, Jaconi S, Saurat J-Η. Characterization and expression of a 
novel human fatty acid-binding protein: the epidermal type (E-FABP). Biochem Biophys Res Commun 
1993; 190: 482-487 
-51-
Chapter 2 
65. Sacchettuu JC, Häuft SM, Van Camp SL, Cistola DP, Gordon JI. Developmental and structural studies of 
an intracellular lipid binding protein expressed in the ileal epithelium. J Biol Chem 1990; 265: 19100-
19207 
66. Lin MC, Kramer W, Wilson FA. Identification of cytosolic and microsomal bile acid-binding proteins in 
rat ileal enterocytes. J Biol Chem 1990; 265: 14986-14995 
67. Lin MC, Gong Y, Geoghegan KF, Wilson FA. Characterization of a novel 14 kDa bile acid-binding 
protein from rat ileal cytosol. Biochim Biophys Acta 1991; 1078: 329-335 
68. Watanabe M, Ono T, Kondo H. Immunohistochemical studies on the localization and ontogeny of heart 
fatty acid binding protein in the rat. J Anal 1991; 174: 81-95 
69. Bass NM, Manning JA. Tissue expression of three structurally different fatty acid binding proteins from 
rat heart muscle, liver and intestine. Biochem Biophys Res Commun 1986; 137: 929-935 
70. Paulussen RJA, Geelen MJH, Beynen AC, Veerkamp JH. Immunochemical quantitation of fatty acid-
binding proteins. I. Tissue and intracellular distribution, postnatal development and influence of physiologi-
cal conditions on rat heart and liver FABP. Biochim Biophys Acta 1989; 1001: 201-209 
71. Paulussen RJA, Van Moerkerk НТВ, Veerkamp JH. Immunological quantification of fatty acid-binding 
proteins. Tissue distribution of liver and heart FABP types m human and porcine tissues. Int J Biochem 
1990; 22: 393-398 
72. Shields HM, Bates ML, Bass NM, Best CJ, Alpers DH, Ockner RK. Light microscopic ïm-
munocytochemical localization of hepatic and intestinal types of fatty acid-binding proteins in rat small 
intestine. J Lipid Res 1986; 27: 549-557 
73. Häuft SM, Sweetser DA, Rotwein PS et al. A transgenic mouse model that is useful for analyzing cellular 
and geographic differentiation of the intestine during fetal development. J Biol Chem 1989; 264: 8419-
8429 
74. Iseki S, Hitomi M, Ono T, Kondo H. Immunocytochemical localization of hepatic fatty acid-binding 
protein m the rat intestine: effect of fasting. Anat Ree 1989; 223: 283-291 
75. Iseki S, Kondo H. Light microscopic localization of hepatic fatty acid buiding protein mRNA in jejunal 
epitheha of rats using m situ hybridization, immunohistochemical, and autoradiographic techniques. J 
Histochem Cytochem 1990; 38: 111-115 
76. Rubm DC, Ong DE, Gordon JI. Cellular differentiation in the emerging fetal rat small intestinal 
epithelium: mosaic patterns of gene expression Proc Natl Acad Sci USA 1989; 86. 1278-1282 
77. Iseki S, Kanda T, Hitomi M, Ono T. Ontogenic appearance of three fatty acid binding proteins in the rat 
stomach. Anat Ree 1991; 229: 51-60 
78. Amano О, Kanda Τ, Ono Τ, Iseki S. Immunocytochemical localization of rat intestinal 15 kDa protein, a 
member of cytoplasmic fatty acid-binding proteins. Anat Ree 1992; 234: 215-222 
79. Heuckeroth RO, Bierkenmeier EH, Levin MS, Gordon JI. Analysis of the tissue-specific expression, 
developmental regulation and linkage relationships of a rodent gene encoding heart fatty acid-binding 
protein. J Biol Chem 1987; 262: 9709-9717 
80. Claffey KP, Herrera VL, Brecher Ρ, Ruiz-Opaza N. Cloning and tissue distribution of rat heart fatty acid-
binding protein mRNA: Identical forms in heart and skeletal muscle. Biochemistry 1987; 26 7900-7904 
81. Veerkamp JH, Paulussen RJA, Peeters RA, Maatman RGHJ, Van Moerkerk НТВ, Van Kuppeveit 
THMSM. Detection, tissue distribution and (subjcellular localization of fatty acid-binding protein types. 
Mol Cell Biochem 1990; 98: 11-18 
82. Foumier NC, Rahim M. Control of energy production m the heart: a new function for fatty acid-binding 
protein. Biochemistry 1985; 24: 2387-2396 
83. Borchers Τ, Unterberg С, Rudel Η, Robenek Η, Spener F. Subcellular distribution of cardiac fatty acid-
binding protein m bovine heart muscle and quantitation with an enzyme-linked immunosorbent assay. 
Biochim Biophys Acta 1989; 1002: 54-61 
-52-
Introduction 
84. Unterberg С, Borchers Τ, Herjrup Ρ, Roepstorff Ρ, Knudsen J, Spener F. Cardiac fatty acid-bmding 
proteins: Isolation and charactenzation of the mitochondrial fatty acid-binding protein and its structural 
relationship with the cytosohc isofonns. J Biol Chem 1990; 265: 16255-16261 
85. Bordewick U, Heese M, Borchers Τ, Robenek Η, Spener F. Compartmentation of hepatic fatty acid-
binding protein in liver cells and its effect on microsomal phosphatide acid biosynthesis. Biol Chem 
Hoppe-Seyler 1989; 370: 229-238 
86. Haunerland NH, Andol fatto P, Chisholm JM, Wang Z, Chen X. Fatty acid-binding protem in locust flight 
muscle. Developmental changes of expression, concentration and intracellular distribution. Eur J Biochem 
1992; 210: 1045-1051 
87. Vinores SA, Churey JJ, Haller JM, Schnabel SJ, Custer RP, Sorof S. Normal liver chromatin contains a 
firmly bound and larger protem related to the principal cytosohc target polypeptide of a hepatic car­
cinogen. Proc Nad Acad Sci USA 1984; 81: 2092-2096 
88. Fammi HD, Vöelkl A, Vincent SH, Muller-Eberhard U. Localization of the heme-binding protem ш the 
cytoplasm and of a heme-bmding protein-like lmmunoreac-tive protem m the nucleus of rat liver 
parenchymal cells: lmmunocytochemical evidence of the subcellular distribution corroborated by 
radioimmunoassay and immunoblottmg. Hepatology 1990; 11: 859-865 
89. Munir KM, Custer RP, Sorof S. Normal hepatocytes exhibiting historie H3 with antibody accessible sites 
that are cryptic in carcinogen-altered hepatocytes. Cancer Res 1989; 49: 424-432 
90. Nilsson MH, Spurr NK, Lundvall J, Rask L, Peterson PA Human cellular retinol-binding protein gene 
organization and chromosomal location. Eur J Biochem 1988; 173: 35-44 
91. Âstrom A, Tavakkol A, Petterson U, Cromie M, Elder JT, Voorhees JJ. Molecular cloning of two human 
cellular retinole acid-binding proteins (CRABP). J Biol Chem 1991; 266. 17662-17666 
92. Medzthradszky KF, Gibson BW, Kaur S et al. The primary structure of fatty acid-binding protem from 
nurse shark liver. Eur J Biochem 1992; 203: 327-339 
93. Pnce HM, Ryan RO, Haunerland NH Primary structure of locust flight muscle fatty acid-binding protem. 
Arch Biochem Biophys 1992; 297: 285-290 
94. Takahashi K, Odani S, Ono T. Isolation and charactenzation of the three fractions (DE-I, DE-1I and DE-
UT) of rat liver Ζ protem and the complete primary structure of DE-I. Eur J Biochem 1983; 136 589-601 
95. Chan L, Wei C-F, Li W-Η, et al. Human liver fatty acid-binding protem cDNA and ammo acid sequence. 
Functional and evolutionary implications. J Biol Chem 1985; 260: 2629-2632 
96. Lowe JB, Strauss AW, Gordon JI. Expression of a mammalian fatty acid-bindmg protem in Escherichia 
coli. J Biol Chem 1984, 259: 12696-12704 
97. Worrall AF, Evans C, Wilton DC. Synthesis of a gene for rat liver fatty-acid-binding protem and its 
expression m Escherichia coll. Biochem J 1991; 278: 365-368 
98. Lowe JB, Sacchettini JC, Laposata M, McQuillan JJ, Gordon JI. Expression of rat intestinal fatty acid-
binding protem m Eschenchia coll. Purification and comparison of ligand bmdmg characteristics with that 
of Eschenchia coh-denved rat liver fatty acid-bmdmg protem J Biol Chem 1987; 262: 5931-5937 
99. Sacchettini JC, Banaszak Li, Gordon JI. Expression of rat intestinal fatty acid-binding protem in E. coli 
and its subsequent structural analysis, a model system for studying the molecular details of fatty acid-
protein interaction. Mol Cell Biochem 1990; 98: 81-93 
100. Chinander LL, Bemlohr DA. Cloning of murine adipocyte lipid bmdmg protem in Eschenchia coll Its 
purification, ligand bmdmg properties, and phosphorylation by the adipocyte insulin receptor. J Biol Chem 
1989; 264: 19564-19572 
101. Xu Z, Buelt MK, Banaszak LJ, Bemlohr DA. Expression, punRcation, and crystallization of the adipocyte 
lipid bmdmg protem. J Biol Chem 1991; 266: 14367-14370 
102. Oudenampsen E, Kupsch E-M, Wissel Τ, Spener F, Lezius A. Expression of fatty acid-binding protem 
from bovine heart m Eschenchia coli. Mol Cell Biochem 1990; 98: 75-79 
-53-
Chapter 2 
103. Peeteis RA, Ena JM, Veerkamp JH. Expression ш Escherichia coli and characterization of the fatty-acid-
binding protein from human muscle. Biochem J 1991; 278: 361-364 
104. Peelers RA, In 't Groen MAPM, De Moei MP, Van Moerkerk НТВ, Veerkamp JH. The binding affinity 
of fatty acid-binding proteins from human, pig, and rat liver for different fluorescent fatty acids and other 
ligands. Int J Biochem 1989; 21: 407-418 
105. Storch J, Bass NM, Kleinfeld AM. Studies of the fatty acid-binding site of rat liver fatty acid-binding 
protein using fluorescent fatty acids. J Biol Chem 1989; 264: 8708-8713 
106. Wilkinson TCI, Wilton DC. Studies on fatty acid-binding proteins. The detection and quantitation of the 
protein from rat liver using a fluorescent fatty acid analo-gue. Biochem J 1986; 238: 419-424 
107. Reers M, Elbracht R, Rudel H, Spener F. Rapid methods for the characterization of unilamellar 
phospholipid vesicles. Application to studies on fatty acid donor and acceptor properties of membranes and 
fatty acid binding proteins. Chem Phys Lipids 1984; 36: 15-28 
108. Keuper HJK, Klein RA, Spener F. Spectroscopic investigations on the binding site of bovine hepatic fatty 
acid-binding protein. Evidence for the existence of a single binding site for two fatty acid molecules. Chem 
Phys Lipids 1985; 38: 159-173 
109. Storch J. A comparison of heart and liver fatty acid-binding proteins: interactions with fatty acids and 
possible functional differences studies with fluorescent fatty acid analogues. Mol Cell Biochem 1990; 98: 
141-147 
110. Kim U-K, Storch J. Mechanism of free fatty acid transfer from rat heart fatty acul-binding protein to 
phospholipid membranes. Evidence for a colhsional process. J Biol Chem 1992; 267: 20051-20056 
HI. Wootan MG, Bass NM, Bernlohr DA, Storch J. Fatty acid bmding sites of rodent adipocyte and heart fatty 
acid bmding proteins: characterization using fluorescent fatty acids. Biochemistry 1990; 29: 9305-9311 
112. Nemcz, G, Jefferson JR, Schroeder F. Polyene fatty acid interactions with recombinant intestinal and liver 
fatty acid-binding proteins. J Biol Chem 1991; 266: 17112-17123 
113. Richieri GV, Ogata RT, Klemfeld AM. A fluorescently labeled intestinal fatty acid bmding protein. 
Interactions with fatty acids and its use in monitoring free fatty acids. J Biol Chem 1992; 267: 23495-
23501 
114. Schulenberg-Schell H, Schäfer Ρ, Keuper HJ et al. Interactions of fatty acids with neutral fatty acid 
binding protein from bovine liver. Eur J Biochem 1988; 170: 565-574 
115. Li M, Ishibashi T. Reversible conformational changes of rat liver fatty acid binding protein following lipid 
binding: circular dichroic and nuclear magnetic resonance analysis. Biomed Res 1992; 13: 335-341 
116. Lücke С, Lassen D, Kreienkamp Η-J, Spener F, Ruterjans H. Sequence-specific 'H-NMR assignment and 
determination of the secondary structure of bovine heart fatty-acid-binding protein. Eur J Biochem 1992; 
210: 901-910 
117. Li E, Qian S, Yang N, d'Avignon A, Gordon JI. "F nuclear magnetic resonance studies of 6-fluorotryp-
tophan-substituted rat cellular retinol bmding protein Π produced in Escherichia coli. J Biol Chem 1990; 
265: 11549-11554 
118. Li E, Qian S, Winter NS, d'Avignon A, Levin MS, Gordon JI. Fluorine nuclear magnetic resonance 
analysis of the ligang binding properties of two homologous rat cellular relmol-bmdmg proteins 
expressed in Escherichia coll. J Biol Chem 1991; 266: 3622-3629 
119. Ropson LI, Frieden С. Dynamic NMR spectral analysis and protein folding: Identification of a highly 
populated folding intermediate of rat intestinal fatty acid-binding protein by "F NMR. Proc Natl Acad Sci 
USA 1992; 89: 7222-7226 
120. Locke ВС, Maclnnis JM, Qian S et al. Fluorescence studies of rat cellular retinol bmding protein Π 
produced ш Escherichia coli: An analysis of four tryptophan substitution mutants. Biochemistry 1992; 31: 
2376-2383 
121. Cistola DP, Saccbettini JC, Banaszak LI, Walsh MT, Gordon JI. Fatty acid interactions with rat intestinal 
-54-
Introduction 
and liver fatty acid-binding proteins expressed ш Escherichia coli. A comparative "C NMR study. J Biol 
Chem 1989; 264: 2700-2710 
122. Jones ТА, Bergfors T, Sedzik J, Unge T. The three-dimensional structure of P2 myelin protein. EMBO J 
1988; 7: 1597-1604 
123. Secchettuu JC, Gordon Л, Banaszak U. The structure of crystalline Escherichia coli-denved rat intestinal 
fatty acid-binding protein at 2.S-Á resolution. J Biol Chem 1988; 263: 5815-5819 
124. Sacchettuu JC, Gordon Л, Banaszak U . Refined apoprotein structure of rat intestinal fatty acid binding 
protein produced in Escherichia coli. Proc Natl Acad Sci USA 1989, 86- 7736-7740 
125. Scapin G, Gordon JI, Sacchettuu JC. Refinement of the structure of recombinant rat intestinal fatty acid-
binding apoprotein at 1.2-Ä resolution. J Biol Chem 1992; 267: 4253-4269 
126. Sacchettuu JC, Scapin G, Gopaul D, Gordon JI. Crystal structure of rat intestinal fatty-acid-binding 
protein. Refinement and analysis of the Escherichia coli-denved protein with bound palmitate. J Mol Biol 
1989; 208: 327-339 
127. Sacchettuu JC, Scapin G, Gopual D, Gordon JI. Refinement of the structure of Escherichia coli-denved rat 
intestinal fatty acid binding protein with bound oleate to 1.75-À resolution. Correlation with the structures 
of the apoprotein and the protein with bound palmitate. J Biol Chem 1992; 267: 235Э4-23545 
128 Scapin G, Spadon P, Mammi M, Zanotti G, Monaco HL. Crystal structure of chicken liver basic fatty 
acid-binding protein at 2.7 À resolution. Mol Cell Biochem 1990; 98: 95-99 
129. Muller-Fahmow A, Egner U, Jones A, Rudel H, Spener F, Saenger W. Three-dimensional structure of 
fatty acid-binding protein from bovine heart. Eur J Biochem 1991, 199: 271-276 
130. Xu Z, Bemlohr DA, Banaszak LI Crystal structure of recombinant mure adipocyte lipid-binding protein. 
Biochemistry 1992, 31' 3484-3492 
131. Zanotti G, Scapin G, Spadon P, Veerkamp JH, Sacchettuu JC. Three-dimensional structure of recombinant 
human muscle fatty acid-binding protein. J Biol Chem 1992; 267: 18541-18550 
132. Benning MM, Smith AF, Wells MA, Holden HM. Crystallization, structure determination and least-
squares refinement to 1.75 A resolution of the fatty-acid-binding protein isolated from Manduca sexta L. J 
Mol Вюі 1992; 228: 208-219 
133. Pähler A, Maslowska M, Parge HE et al. X-ray studies on tncluuc crystals of fatty acid binding protein. 
Example of an extremely X-ray resistant protein. FEBS Letters 1985; 184: 185-187 
134. Winter NS, Gordon JI, Banaszak LI. Characterization of crystalline rat liver fatty acid binding protein 
produced m Escherichia coli J Biol Chem 1990; 265: 10955-10958 
135. Newcomer ME, Liljas A, Eriksson U, Rask C, Peterson PA. Crystallization of and preliminary X-ray data 
for an intracellular vitamin A-bindmg protein from rat liver. J Biol Chem 1981; 256- 8162-8163 
136. Sacchettuu JC, Stockhausen D, Li E, Banaszak LI, Gordon JI. Crystallization of rat cellular retinol 
binding protein II: preliminary X-ray data obtained from the apoprotein expressed ш Escherichia coli. J 
Biol Chem 1987; 262: 15756-15757 
137. Newcomer ME, Ong DE. Purification and crystallization of a retinole acid-binding protein from rat 
epididymis. Identity with the major androgen-dependent epididymal proteins. J Biol chem 1990; 265: 
12876-12879 
138. Scapin G, Young ACM, Kromnunga A, Veerkamp JH, Gordon JI, Sacchettuu JC. High resolution X-ray 
studies of mammalian intestinal and muscle fatty acid binding proteins provide an opportunity for defining 
the chemical nature of fatty acid:prolein interactions. Mol Cell Biochem 1993; 123: 3-13 
139. Zhang J, Du Z-P, Jones TA, Gierasch LM, Sambrook JF. Mutating the charged residues in the binding 
pocket of cellular retinole acid-binding protein simultaneously reduces its binding affinity to retinole acid 
and ulereases its thermostability. Proteins. Structure, Function, and Genetics 1992; 13: 87-99 
140. Jakoby MG, Miller KR, Toner JJ et al. Ligand-protein electrostatic interactions govern the specificity of 
retino!- and fatty acid-binding proteins. Biochemistry 1993; 32: 872-878 
-55-
Chapter 2 
141. Stump DG, Lloyd RS, Chytil F. Site-directed mutagenesis of ral cellular retinol-bmdmg protein. Alteration 
in binding specificity resulting from mutation of gluUmme 108 to arginine. J Biol Chem 1991; 266: 4622-
4630 
142. Cheng L, Qian S, Rothschild С et al. Alteration of the binding specificity of cellular retinol-binding 
protein Π by site-directed mutagenesis. J Biol Chem 1991; 266: 24404-24412 
143. Paulussen RJA, Van Der Logt CPE, Veerkamp JH. Characterization and binding properties of fatty acid-
binding proteins from human, pig and rat heart. Arch Biochem Biophys 1988; 264: 533-545 
144. Unterberg С, Heidi G, Von Bassewitz D-B, Spener F. Isolation and characterization of the fatty acid-
binding protein from human heart. J Lipid Res 1986; 27: 1287-1293 
145. Burner RE, Mansson CR, Brecher P. Binding of acyl-CoA to liver fatty acid-binding protein: Effect on 
acyl-CoA synthesis. Biochim Biophys Acta 1987; 919- 211-230 
146. Rasmussen JT, Borchers Τ, Knudsen J. Comparison of the binding affinities of acyl-CoA-binding protein 
and fatty-acid-binding protein for long-chain acyl-CoA esters. Blechern J 1990; 265: 849-855 
147. Wilkinson TCI, Wilton DC. Studies on tatty acid-binding proteins. The binding properties of rat liver fatty 
acid-binding proteins. Blechern J 1987, 247: 485-488 
148. Billheimer JT, Gaylor JL. Cytosolic modulators of activities of microsomal enzymes of cholesterol 
biosynthesis. Role of a cytosolic protein with properties similar to Ζ protein (fatty acid-binding protein). J 
Biol Chem 1980; 255: 8128-8135 
149. Levi AJ, Gatmaitan Z, Anas IM. Two hepatic cytoplasmic proteins fractions, Y and Z, and their possible 
role ш the hepatic uptake of bilirubin, sulfobromophtbalein, and other anions. J Clm Invest 1969; 48: 
2156-2167 
150. Bansal MP, Cook RG, Danielson KG, Medina D. A 14-kilodalton selenium-binding protein in mouse liver 
is fatty acid-binding protein. J Biol Chem 1989; 264: 13780-13784 
151. Kanda T, Ono T, Matsubara Y, Muto T. Possible role of rat fatty acid-binding proteins ш the intestine as 
earners of phenol and phtalate derivatives. Blechern Biophys Res Commun 1990; 168: 1053-1058 
152. Larsen GL, Bergman A, Klasson Wehler E, Bass NM. A methylsulfonyl metabolite of a polychlonnated 
biphenyl can serve as a hgand for fatty acid binding protein in rat intestinal mucosa. Chem Biol 
Interactions 1991; 77: 315-323 
153. Myszka DG, Swenson RP. Identification by photoaffinity labeling of fatty acid-binding protein as a 
potential warfarin receptor in rat liver. J Biol Chem 1991; 266: 20725-20731 
154. Takikawa H, Kaplowitz N. Binding of bile acids, oleic acid, and organic anions by rat and human hepatic 
Ζ protein. Arch Biochem Biophys 1986; 251: 385-392 
155. Cannon JR, Eacho PI. Interaction of LY171883 and other peroxisosome prohferators with fatty acid-
brnding protein isolated from rat liver. Biochem J 1991; 280: 387-391 
156. Brandes R, Kaikaus RM, Lysenko N, Ockner RK, Bass NM. Induction of fatty acid binding protein by 
peroxisome prohferators in primary hepatocyte cultures and its relationship to the induction of peroxisomal 
ß-oxidaüon. Biochim Biopys Acta 1990; 1034: 53-61 
157. Vincent S, Muller-Eberhard U. A protein of the Ζ class of liver cytosolic proteins in the rat that 
preferentially binds heme. J Biol Chem, 1985; 260: 14521-14528 
158. Dutta-Roy AK, Gopalswamy N, Trulzsch DV. Prostaglandin E, binds to Ζ protein of rat liver. Eur J 
Biochem 1987; 162: 615-619 
159. Raza Η, Pongubala JR, Sorof S. Specific high affinity binding of lipoxygenase metabolites of arachidonic 
acid by liver fatty acid binding protein. Biochem Biophys Res Commun 1989; 161: 448-455 
160. Khan H, Sorof S. Preferential binding of growth inhibitory prostaglandins by the target protein of a 
carcinogen. Proc Natl Acad Sci USA 1990; 87: 9401-9405 
161. Vincent SH, Bass NM, Snider JM, Muller-Eberhard U. Are the rat liver cytosolic fatty acid-binding (L-
FABP) and heme-binding (HBP) proteins identical? Biochem Arch 1987; 3: 443-451 
-56-
Introduction 
162. Vancura A, Carroll MA, Haldar D. A lysophosphatidic acid-bindmg cytosohc protein stimulates 
mitochondrial glycerophosphate acyltnnsfcrase. Biochem Biophys Res Commun 1991; 175: 339-343 
163. Vancura A, Haldar D. Regulation of mitochondrial and microsomal phospholipid synthesis by liver fatty 
acid-binding protem. J Biol Chem 1992. 267: 14353-14359 
164. Uyemura K, Yoshimura K, Suzuki M, Kitamura K. Lipid-binding activities of the P2 protein in peripheral 
nerve myelin. Neurochem Res 1984; 9- 1509-1514 
165. Matarese V, Bemlohr DA. Purification of murine adipocyte hpid-binding protem. Characterization as a 
fatty acid- and retinole acid-bindmg protem. J Biol Chem 1988; 263: 14544-14551 
166. Van Zoelen EM, Kramer RH, Van Reen МММ, Veerkamp JH, Ross HA. An exact general analysis of 
ligand binding displacement and saturation curves. Biochemistry 1993; 32: 6275-6280 
167. Nemecz G, Hubbell T, Jefferson JR, Lowe IB, Schroetter F. Interaction of fatty acids with recombinant 
rat intestinal and liver fatty acid-binding proteins. Arch Biochem Biophys 1991; 286: 300-309 
168. Haunerland Ν, Jagschies G, Schulenberg H, Spener F. Occurrence of two fatty acid-binding proteins m 
bovine liver cytosol and their binding of fatty acids, cholesterol, and other lipophilic ligands. Hoppe-
Seyler's Ζ Physiol Chem 1984; 365: 365-376 
169. Fukai F, Kase T, Shidotam T, Nagai T, Katayama T. Multiple classes of binding sites for palmitic acid on 
the fatty acid-binding protem molecule. Biochem Int 1989; 18: 1101-1105 
170. Tipping E, Ketterer B. The influence of soluble binding proteins on lipophile transport and metabolism in 
hepatocytes. Biochem J 1981; 195: 441-452 
171. Vork MM, Glatz JFC, Van Der Vusse GJ. On the mechanism of long chain fatty acid transport in 
cardiomyocytes as facilitated by cytoplasmic fatty acid-binding protem. J Theor Biol 1993; 160: 207-222 
172. Waggoner DW, Bemlohr DA. In situ labeling of the adipocyte lipid binding protem with 3-['aI]Iodo-4-
azido-N-hcxadecylsalicylamide. J Biol Chem 1990; 265: 11417-11420 
173. Waggoner DW, Manning JA, Bass NM, Bemlohr DA. In situ binding of fatty acids to the liver fatty acid 
binding protem: analysis using 3-(l2Sr)Iodo-4-azido-N-hexadecylsalicylamide. Biochem Biophys Res 
Commun 1991; 180: 407-415 
174. StoU GH, Voges R, Gerok W, Kurz G. Synthesis of a metabohcally stable modified long-chain fatty acid 
salt and its photolabile derivative. J Lipid Res 1991; 32: 843-857 
175. Peelers RA, Veerkamp JH, Demel RA. Are fatty acid-binding proteins involved ш fatty acid transfer? 
Biochim Biophys Acta 1989; 1002: 8-13 
176. Storch J, Bass NM. Transfer of fluorescent fatty acids from liver and heart fatty acid-bmdmg proteins to 
model membranes. J Biol Chem 1990; 265: 7827-7831 
177. Kim Η-K, Storch J. Free fatty acid transfer from rat liver fatty acid-binding protem to phospholipid 
vesicles. Effect of ligand and solution properties. J Biol Chem 1992; 267: 77-82 
178. McCormack M, Brecher P. Effect of liver fatty acid-bmdmg protem on fatty acid movement between 
liposomes and rat liver microsomes. Biochem J 1987; 244: 717-723 
179. Stewart JM, Dnedzic WR, Berkelaar JAM. Fatty acid-bmdmg protem facilitates the diffusion of oleate m a 
model cytosol system. Biochem J 1991; 275: 569-573 
180. Daniels C, Noy Ν, Zakim D. Rates of hydration of fatty acids bound to unilamellar vesicles of phosphati­
dylcholine or to albumin. Biochemistry 1985; 24: 3286-3292 
181. Noy Ν, Blaner WS. Interactions of retinol with binding proteins: studies with rat cellular retinol-binding 
protein and with rat retinol-binding protein. Biochemistry 1991; 30: 6380-6386 
182. Glatz JFC, Paulussen RJA, Veerkamp JH. Fatty acid-bmdmg proteins from heart. Chem Phys Lipids 
1985; 38: 115-129 
183. Reubsaet FAG, Veerkamp JH, Brückwilder MLP, Tnjbels JMF, Monnens LAH. The involvement of fatty 
acid binding protem m peroxisomal fatty acid oxidation. FEBS Lett 1990; 267- 229-230 
184. Posch КС, Boerman HEM, Bums RD, Napoli JL. Holocellular retinol binding protem as a substrate for 
-S7-
Chapter 2 
microsomal retinal synthesis. Biochemistry 1991; 30: 6224-6230 
185. Fiorella PD, Napoli JL. Expression of cellular retmoic acid binding protein (CRABP) in Escherichia coli. 
Characterization and evidence that holc-CRABP is a substrate in retmoic acid metabolism. J Biol Cbem 
1991; 166: 16572-16579 
186. Singer SS, Dräns D, Henkels К. Tnilzsch DV. Fatty acid binding inhibits glycolithocholate sulfation. 
Biochem Int 1992; 27: Э7Э-Э8Э 
187. Liem HH, Grasso JA, Vincent SH, Muller-Eberhard U. Protein-mediated efflux of heme from isolated rat 
liver mitochondria. Biocbem Biophys Res Commun 1990; 167: 528-534 
188. Burner RE, Brecher P. Binding of lysophosphatidylcholine to the rat liver fatty acid-binding protein. 
Biochim Biophys Acta 1986; 879: 229-239 
189. Van Corven EJ, Van Rijswijk A, Jalink K, Van der Bend RL, Van Blitterswijk WJ, Moolenaar WH. 
Mitogenic action of lysophosphatidic acid and phosphatidic acid on fibroblasts. Dependence on acyl-chain 
length and inhibition by suramin. Biochem J 1992; 281: 163-169 
190. Asaoka Y, Oka M, Yoshida K, Sasaki Y, Nishizuka Y. Role of lysophosphatidylcholine in T-lymphocyte 
activation: involvement of phospholipase A, in signal transduction through protein kinase C. Proc Natl 
Acad Set USA 1992; 89: 6447-6451 
191. Asaoka Y, Nakaraura S, Yoshida К, Nishizuka Y. Protein kinase C, calcium and phospholipid degrada­
tion. Trends Biochem Sci 1992; 17: 414-417 
192. Sumida С, Graber R, Nunez E. Role of fatty acids in signal transduction: modulators and messengers. 
Prostaglandins Leukot Essent Fatty Acids 1993; 48: 117-122 
193. Naor Z. Is arachidonic acid a second messenger in signal transduction? Mol Cell Endocrinol 1991; 80: 
C181-C186 
194. Ordway RW, Singer JJ, Walsh JV. Direct regulation of ion channels by fatty acids. Trends Neurosa 1991; 
14: 96-100 
195. Huang JM-C, Xian H, Bacaner M. Long-chain fatty acids activate calcium channels in ventricular 
myocytes. Proc Natl Acad Sci USA 1992; 89: 6452-6456 
196. Kirber MT, Ordway RW, Chap LH, Walsh JV, Singer JJ. Both membrane stretch and nitty acids activate 
large conductance Ca2*-activated K* channels in vascular smooth muscle cells. FEBS Lett 1992; 297: 24-
28 
197. Rouzaire-Dubois B, Gérard V, Dubois J-M. Modification of K+ channel properties induced by fatty acids 
in neuroblastoma cells. Pflügen Arch Eur J Physiol 1991; 419: 467-471 
198. Ют D, Duff, RA. Regulation of K* channels ш cardiac myocytes by free fatty acids. Circulation Res 
1990; 67: 1040-1046 
199. Kurachi Y, Ito H, Sugimoto Τ, Shimizu Τ, Miki I, Ui M. Arachidonic acid metabolites as intracellular 
modulators of the G protein-gated cardiac K+ channel. Nature 1989; 337: 555-557 
200. Petrou S, Ordway RW, Singer JJ, Walsh JV. A putative fatty acid-binding domain of the NMDA receptor. 
Trends Biochem Sci 1993; 18: 41-42 
201. Miller B, Saranlis M, Traynelis SF, Atrwell D. Potentiation of NMDA receptor currents by arachidonic 
acid. Nature 1992; 355: 722-725 
202. Wolf В A, Pasquale SM, Turk J. Free fatty acid recumulation in secretagogue-stimulated pancreatic islets 
and effects of arachidonale on depolarization-induced insulin secretion. Biochemistry 1991; 30: 6372-6379 
203. Shinomura T, Asaoka Y, Oka M, Yoshida K, Nishizuka Y. Synergistic action of diacylglycerol and 
unsaturated fatty acid for protein kinase С activation: its possible implications. Proc Natl Acad Sci USA 
1991; 88: 5149-5153 
204. Khan WA, Blobe GC, Hannun YA. Activation of protein kinase С by oleic acid. Determination and 
analysis of inhibition by detergent micelles and physiologic membranes: requirement for free oleate. J Biol 
Chem 1992; 267: 3605-3612 
-58-
Introduction 
205. Sani BP, Allen RD, Mooser CM, McGee BW. Interference of retinole acid binding to its binding protein 
by omega-6 fatty acids. Biochem Biophys Res Commun 1987; 147: 25-30 
206. Svedberg J, Bjoratorp P, Smith U, Lônnroth P. Free-fatty acid inhibition of insulin binding, degradation 
and action in isolated rat hepatocytes. Diabetes 1990; 39: 570-574 
207. Goodfnend TL, Ball DL. Fatty acid effects on angiotensin receptors. J Cardiovasc Pharmacol 1986; 8: 
1276-1283 
208. Remmers AE, Nordby GL, Medzihradslcy F Modulation of opioid receptor binding by cis and trans fatty 
acids. J Neurochem 1990; 55: 1993-2000 
209. Nishihihara J, Ishibashi T, Sakai M, Nisht S, Kondo U, Malata A. Identification of the fatty acid binding 
site on glutathione S-transferase Ρ Biochem Biophys Res Commun 1992; 189: 197-205. 
210. Bandyopadhyay GK, Hwang S, Imagawa W, Nandi S. Role of polyunsaturated fatty acids as signal 
transducers: amplification of signals from growth factor receptors by fatty acids in mammary epithelial 
cells. Prostaglandins Leukot Essent Fatty Acids 1993; 48: 71-78 
211. Vallette G, Vanet A, Sumida С, Nunez EA. Modulatory effects of unsaturated fatty acids on the binding 
of glucocorticoids to rat liver glucocorticoid receptors. Endocrinology 1991; 129. 1363-1369 
212. Nunez EA. Free fatty acids as modulators of the steroid hormone message. Prostaglandins Leukot Essent 
Fatty Acids 1993; 48: 63-70 
213. Felden F, Martin M-E, Gueant J-L, Benassayag C, Nunez EA. Free fatty acid-induced alterations in the 
steroid-binding properties of rat androgen-binding protein. Biochem Biophys Res Commun 1993, 190. 602-
608 
214. Inoue A, Yamamoto Ν, Monsawa Y, Uchimoto T. Yukioka M, Monsawa S. Unestenfied long-chain fatty 
acids inhibit thyroid hormone binding to the nuclear receptor. Solubihzed receptor and the receptor in 
cultured cells. Eur J Biochem 1989; 183: 565-572 
215. Van der Klis FRM, Wiersinga WM. Inhibition of nuclear T, buiding via PLA2-induced release of fatty 
acids from nuclear membranes. Bicchim Biophys Acta 1990; 1047' 131-134 
216. Mazzachi ВС, Kennedy JA, Wellby ML, Edwards AM. Effect of fatty acids on rat liver nuclear T
r 
receptor binding. Metabolism 1992; 41: 788-792 
217. James G, Olson EN. Fatty acylated proteins as components of intracellular signaling pathways Bioche­
mistry 1990; 29: 2623-2634 
218. Gutknecht J. Proton conductance caused by long-chain fatty acids ш phospholipid bilayer membranes. J 
Membr Biol 1988; 106: 83-93 
219. Schönfeld Ρ, Schild L, Kunz W. Long-chain fatty acids act as protonophonc uncouplers of oxidative 
phosphorylation in rat liver mitochondria. Biochim Biophys Acta 1989; 977: 266-272 
220. Burt JM, Massey KD, Minnich BN. Uncoupling of cardiac cells by fatty acids: structure-activity 
relationships. Am J Physiol 1991; 260: С4Э9-С448 
221. Hutter JF, Soboll S. Role of fatty acid metabolites m the development of myocardial ischemic damage. Int 
J Biochem 1992; 24: 399^03 
222. Anel A, Richten GV, Kleinfeld AM. Membrane partition of fatty acids and inhibition of Τ cell function. 
Biochemistry 1993; 32: 530-536 
223. Bernier M, Laird DM, Lane MD. Insulin-activated tyrosine phosphorylation of a 15-kilodalton protein ш 
intact 3T3-L1 adipocytes. Proc Natl Acad Sci USA 1989; 84: 1844-1848 
224. Hresko RC, Bemier M, Hoffman RD et al. Identification of phosphorylated 422 (aP2) protein as ppl5, the 
15-kilodalton target of the insulin receptor tyrosyne lañase in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 
1988; 85: 8835-8839 
225. Liao K, Hoffman RD, Lane MD. Phosphotyrosyl turnover in insulin signalling Characterization of two 
membrane-bound ppl5 protein tyrosine phosphatases from 3T3-L1 adipocytes J Biol Chem 1991, 266. 
6544-6553 
-59-
Chapter 2 
226. Benuer M. Laird DM, Lane MD. Effect of vanadate on the cellular accumulation of pplS, an apparent 
product of insuline receptor tyrosine kinase action. J Biol Chem 1988; 263: 13626-13634 
227. Hresko RC, Hoffman RD, Flores-Riveros JR, Lane MD. Insulin receptor tyrosine lonase-catalyzed 
phosphorylation of 422(aP2) protein. Substrate activation by long-chain fatty acid. J Biol Chem 1990; 265: 
21075-21085 
228. Buelt MK, Shekels LL, Jarvis BW, Bemlohr DA. In vitro phosphorylation of the adipocyte hpid-bmdmg 
protein (pi5) by the insulin receptor. Effects of fatty acid on receptor kinase and substrate phosphoryla­
tion. J Biol Chem 1991; 266: 12266-12271 
229. Nielsen SU, Spener F. Fatty acid-binding protein from rat heart is phosphorylated on Туг" m response to 
insulin stimulation. J Lipid Res 1993; 34:1355-1366 
230. Abumrad NA, Forest CC, Regen DM, Sanders S. Increase m membrane uptake of long-chain fatty acids 
early during preadipocyte differentiation. Proc Natl Acad Sci USA 1991; 88: 6008-6012 
231. Amn E-Z, Bertrand В, Ailhaud G, Grimaldi P. Regulation of adipose cell differentiation. I. Fatty acids 
are inducers of the aP2 gene expression. J Lipid Res 1991; 32: 1449-1456 
232. Grimaldi PA, Knobel SM, Whitesell RR, Abumrad NA. Induction of aP2 gene expression by non-
metabolized long-chain fatty acids. Proc Nat] Acad Sci USA 1992; 89: 10930-10934 
233. Amn E-Z, Ailhaud G, Grimaldi P. Regulation of adipose cell differentiation. II. Kinetics of induction of 
the aP2 gene by fatty acids and modulation by dexamethasone. J Lipid Res 1991; 32: 1457-1463 
234. Distel RJ, Robinson GS, Spiegelman BM. Fatty acid regulation of gene expression. Transcriptional and 
post-transcnptional mechanisms. J Biol Chem 1992; 267: 5937-5941 
235. Tebbey PW, Buttke TM. Arachidonic acid regulates unsaturated fatty acid synthesis m lymphocytes by 
inhibiting stearoyl-CoA desaturase gene expression. Biochim Biophys Acta 1992; 1171. 27-34 
236. Tiwan RK, Mukhopadhay B, Telang NT, Osborne MP. Modulation of gene expression by selected fatty 
acids in human breast cancer cells. Anticancer Res 1991; 11: 1383-1388 
237. Custer RP, Sorof S. Target polypeptide of a carcinogen is associated with normal mitosis and carcinogen-
induced hyperplasias in adult hepatocytes. Proc Natl Acad Sci USA 1984; 81: 6738-6742 
238. Bassuk JA, Tsichlis PN, Sorof S. Liver fatty acid-binding protein is the mitosis-associated polypeptide 
target of a carcinogen in rat hepatocytes. Proc Natl Acad Sci USA 1987; 84: 7547-7551 
239. Sweetser DA, Birkenmeier EH, Hoppe PC, McKeel DW, Gordon JI. Mechanisms underlying generation 
of gradients in gene expression within the intestine: an analysis using transgeme mice containing fatty acid 
binding protein-human growth hormone fusion genes. Genes Dev 1988; 2: 1318-1332 
240. Keler T, Barker CS, Sorof S. Specific growth stimulation by linoleic acid in hepatoma cell Unes 
transfected with the target protein of a liver carcinogen. Proc Natl Acad Sci USA 1992; 89: 4830-4834 
241. Blackburn GR, Schnabel SJ, Danley JM, Hogue-Angeletti RA, Sorof S. Principal polypeptide target of 
carcinogen at the beginning of liver carcinogenesis by three carcinogens. Cancer Res 1982, 42: 4664-4672 
242. Böhmer F-D, Kraft R, Otto A et al. Identification of a polypeptide growth inhibitor from bovine mammary 
gland. Sequence homology to fatty acid- and retinoid-bmding proteins. J Biol Chem 1987; 262: 15137-
15143 
243. Spener F, Unterberg С, Borchers Τ, Grosse R. Characteristics of fatty acid-binding proteins and their 
relation to mammary-derived growth inhibitor. Mol Cell Biochem 1990; 98: 57-68 
244. Jones PD, Саше A, Bass NM, Gngor MR. Isolation and characterization of fatty acid-binding proteins 
from mammary tissue of lactating rats. Biochem J 1988; 251: 919-925 
245. Bansal MP, Medina D. Expression of fatty acid-binding proteins in the developing mouse mammary gland. 
Biochem Biophys Res Commun 1993; 191: 61-69 
246. Green RP, Cohn SM, Sacchettini JC, Jackson KE, Gordon JI. The mouse intestinal fatty acid-binding 
protein gene: nucleotide sequence, partem of developmental and regional expression, and proposed 
structure of ite protein product. DNA Cell Biol 1992; 11: 31-41 
-60-
Introduction 
247. Sweetser DA, Birkenmeier EH, Klisak U, Zollman S, Spaikes RS, Mohandas T, Lusis AJ, Gordon JI. 
The human and rodent intestinal fatty acid binding protein genes. A comparative analysis of their structure, 
expression, and linkage relationships. J Biol Chem 1987; 262: 16060-16071 
248. Paproth C, Spener F. The bovine heart fatty acid binding protein gene, MDC FABP Muuworkshop Berlin 
1993 
249. Treuner M, Müller T. Characterization of the mouse MDGI/H-FABP encoding gene, MDC FABP 
Muuworkshop Berlin 1993 
250. MacGregor TM, Copeland NG, Jenkins NA, Giguère V. The murine gene for cellular retinole acid-
binding protein type II. Genomic organization, chromosomal localization, and post-transcnptional 
regulation by retinole acid. J Biol Chem 1992; 267: 7777-7783. 
251. Aström A, Pettersson U, Voorhees JJ. Structure of the human cellular retinole acid-bindmg protein II 
gene. Early transcriptional regulation by retinole acid. J Biol Chem 1992; 267: 252S1-2S25S 
252. Phillips M, Djian P, Green H. The nucleotide sequence of three genes participating m the adipose 
differentation of 3T3 cells. J Biol Chem 1986; 261: 10821-10827 
253. Hunt CR, Ro JH-S, Mm Η-Y, Spiegelman BM. Adipocyte P2 gene: developmental expression and 
homology of 5 'flanking sequences among fat cell-specific genes. Biochemistry 1986; 83: 3786-3790 
254. Smyth MJ, Sparks RL, Wharton W. Proadipocyte cell lines: models of cellular proliferation and 
differentiation. J Cell Sci 1993; 106: 1-9 
255. Sul HS. Adipocyte differentiation and gene expression. Current Opinion Cell Biol 1989; 1: 1116-1121 
256. Sul HS, Smas CM, Moustald N. Positive and negative regulators of adipocyte differentiation. J Nutr 
Biochem 1993; 4: 554-562 
257. Stone RL, Bemlohr DA. The molecular basis for inhibition of adipose conversion of murine 3T3-L1 cells 
by retinole acid. Differentiation 1990; 45: 119-127 
258. Hansen HO, Andreasen PH, Mandrup S, Knstiansen K, Knudsen J. Induction of acyl-CoA-binding and its 
mRNA m 3T3-L1 cells by insulin during preadipocyte-to-adipocyte differentiation. Biochem J 1991; 277' 
341-344 
259. Bemlohr DA, Angus CW, Lane MD, Bolanowski MA, Kelly TJ. Expression of specific mRNAs during 
adipose differentiation: identification of an mRNA encoding a homologue of myelin P2 protein. Proc Natl 
Acad Sci USA 1984; 81: 5468-5472 
260. Bemlohr DA, Bolanowski MA, Kelly TJ, Lane MD. Evidence for an increase in transcription of specific 
mRNAs during differentiation of 3T3-L1 adipocytes. J Biol Chem 1985; 260: 5563-5567 
261. Abumrad NA, Raafat El-Maghrabi M, Amn E-Z, Lopez E, Grimaldi PA. Cloning of a rat adipocyte 
membrane protein implicated in binding or transport of long-chain fatty acids that is induced during 
preadipocyte differentiation. J Biol Chem 1993; 268: 17665-17668 
262. Vasseur-Cognet M, Lane MD. Trans-acting factors involved m adipogenic differentiation. Current Opinion 
Genet Dev 1993; 3: 238-245 
263. Distel RJ. Nucleoprotein complexes that regulate gene expression m adipocyte differentiation: direct 
participation of c-fos. Cell 1987; 49: 835-844 
264. Cook JS, Lucas JJ, Sibley E, Bolanowski MA, Chnsty RJ, Kelly TJ, Lane MD. Expression of the 
differentiation-induced gene for fatty-acid-binding protein is activated by glucocorticoid and cAMP. Proc 
Natl Acad Sci USA1988; 85: 2949-2953 
265. Yang VW, Chnsty RJ, Cook JS, Kelly TJ, Lane MD. Mechanism of regulation of the 422(aP2) gene by 
cAMP during preadipocyte differentiation. Biochemistry 1989; 86: 3629-3633 
266. Rauscher FJ, Sambucetti LC, Curran Τ, Distel RJ, Spiegelman BM. Common DNA binding site for fos 
protein complexes and transcription factor AP-1. Cell 1988; 52: 471-480 
267. Chnsty RJ, Yang VW, Ntambi JM, Geiman DE, Landchulz WH, Friedman AD, Nakkabeppu Y, Kelly 
TJ, Lane MD. Differentiation-induced gene expression m 3T3-L1 preadipocytes: CCAAT/enhancer 
-61-
Chapter 2 
binding protein interacts with and activates the promoters of two adipocyte-specific genes. Genes Dev 
1989; 3: 1323-1335 
268. Herrera R, Ro HS, Robinson GS, Xanthopoulos KG, Spiegelman BM. A direct role for C/EBP and the 
AP-I-bmding site in gene expression linked to adipocyte differentiation. Mol Cell Biol 1989; 9: S331-S339 
269. Cheneval D, Christy RJ, Geiman D, Cornelius P, Lane MD. Cell-free transcription directed by the 422 
adipose P2 gene promoter: activation by the CCAAT/enhancer binding protein. Proc Natl Acad Sci USA 
1991; 88: 8465-8469 
270. Lin F-T, Lane MD. Antisense CCAAT/enhancer-bindmg protein RNA suppresses coordinate gene 
expression and triglyceride accumulation during differentiation of 3T3-L1 preadipocytes. Genes Dev 1992; 
6: 533-544 
271. Ro Η-S, Roncan DAK. The C/EBP-bmding region and adjacent sites regulate expression of the adipose P2 
gene ш human adipocytes. Mol Cell Biol 1991; 11: 2303-2306 
272. Cao Ζ, Umek RM, McKnight SL. Regulated expression of three C/EBP isoforms during adipose 
conversion of 3T3-L1 cells. Genes Dev 1991; 5: 1538-1552 
273. Ross SR, Graves RA, Greenstein A, Piatt KA, Shyu H-L, Mellovitz B, Spiegelman BM. A fat-specific 
enhancer is the primary determinant of gene expression for adipocyte P2 in vivo. Proc Natl Acad Sci USA 
1990; 87: 9590-9594 
274. Graves RA, Tontonoz P, Ross SR, Spiegelman BM. Identification of a potent adipocyte-specific enhancer 
involvement of an NF-1-like factor. Genes Dev 1991, 5: 428437 
275. Graves SR, Tontonoz P, Spiegelman BM. Analysis of a tissue-specific enhancer: ARF6 regulates 
adipogenic gene expression. Mol Cell Biol 1992; 12: 1202-1208 
276. Blake WL, Clarke SD Induction of adipose fatty acid-binding protein (a-FABP) by insulin-like growth 
factor-1 (IGF-1) in 3T3-L1 preadipocytes. Biochera Biophys Res Commun 1990; 173: 87-91 
277. Kletnen RF, Foellmi LA, Hams PKW, Wyse BM, Clarke SD. Adipocyte fatty acid-binding protein: 
regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent. Mol Pharmacol 1992; 42: 
558-562 
278. Stephens Ш , Pekela PH. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 
adipocytes by tumor necrosis factor-or. J Biol Chem 1991; 266:21839-21845 
279. Weiner FR, Smith PJ, Wertheimer S, Rubin CS. Regulation of gene expression by msulm and tumor 
necrosis factor-α m 3T3-L1 cells. Modulation of the transcription of genes encoding acyl-CoA synthetase 
and stearoyl-CoA desaturase-1. J Biol Chem 1991; 266: 23525-23528 
280. Stephens JM, Butts M, Stone R, Pekala PH, Bemlohr DA. Regulation of transcription factor mRNA 
accumulation during 3T3-L1 preadipocyte differentiation by antagonists of adipogenesis. Mol Cell Biochem 
1993; 123: 63-71 
281. Narayanan V, Kaestner KH, Tennekoon GI. Structure of the mouse myelin P2 protein gene. J Neurochem 
1991; 57: 75-80 
282. Bartetzko N, Lezius AG, Spener F. Isoforms of fatty-acid-binding protein in bovine heart are coded by 
distinct mRNA. Eur J Biochem 1993; 215: 555-559 
283. Veerkamp JH, Van Moerkerk НТВ. Fatty acid-binding protein and its relation to fatty acid oxidation. Mol 
Cell Biochem 1993; 123· 101-106 
284. Veerkamp JH, Van Moerkerk НТВ. The fatty acid-binding protein content and fatty acid oxidation 
capacity of rat tissues. In:Coates PM, Tanaka K,eds. New developments m fatty acid oxidation. Wiley-
Liss, New York. Prog Clin Biol Res 1992; 375: 205-210 
285. Crisman TS, Claffey KP, Saouaf R, Hanspal J, Brecher P. Measurement of rat heart fatty acid-binding 
protein by ELISA. Tissue distribution, development changes and subcellular distribution. J Moll Cell 
Cardiol 1987; 19: 423-431 
286. Gordon JI, Elshourbagy N, Lowe JB, Liao S, Alpers DH, Taylor JM. Tissue specific expression and 
-62-
Introduction 
developmental regulation of two genes coding for rat fatty acid-binding proteins. J Biol Chem 1985; 260: 
1995-1998 
287. Kurtz A, Vogel F, Fuña К, Heldin C-Η, Grosse R. Developmental regulation of mammary-denved growth 
inhibitor expression in bovine mammary tissue. J Cell Biol 1990; 110: 1779-1789 
288. Erdmann B, Breter H. Irregular distribution of mammary-denved growth inhibitor in the bovine mammary 
epithelium. Cell Tissue Res 1993, 272: Э8Э-389 
289. Spener F, Borchers T. Structural and multifunctional properties of cardiac fatty acid-bindrng protein: from 
fatty acid binding to cell growth inhibition. Biochem Soc Trans 1992; 20: 806-811 
290. Binas В, Spitzer E, Zschiesche W, Erdmann B, Kurtz A, Müller Τ, Niemann С, Blenau W, Grosse R 
Hormonal induction of functional differentiation and mammary-denved growth inhibator expression m 
cultured mouse mammary gland expiants. In Vitro Cell Dev Biol 1992; 28A: 625-634 
291. Schoentgen F, Pignède G, Bonanno LM, Jolles P. Fatty acid-binding protein from bovine brain: ammo 
acid sequence and some properties. Eur J Biochem 1989; 185. 35-40 
292. Schoentgen F, Bonanno LM, Pignède G, Jolies P. Amino acid sequence and some ligand binding 
properties of fatty acid-binding protein from bovine bram. Mol Cell Biochem 1990; 98' 35-39 
293. Muller Τ, Kurtz A, Schnütgen F, Borchers Τ, Spener F. Olfactory fatty acid-binding protein: gene 
cloning, expression analysis and expression of recombinant protein 1993 Proc 34th Int Conf Biochem 
Lipids, Noordwijkerhout 1993, P85 
294. Kneg P, Feil S, Fürstenberger G, Bowden GT. Tumor-specific overexpression of a novel keratinocyte 
lipid-binding protein. Identification and characterization of a cloned sequence activated during multistage 
carcinogenesis ш mouse skin. J Biol Chem 1993; 268: 17362-17369 
295. Polymeropoulos M, Rath DS, Xiao H, Memi CR. Trinucleotide repeat polymorphism at the human 
intestinal fatty acid binding protein gene (FABP2) Nucl Acids Res 1990, 18' 7198 
296. Barendse W, Armitage SM, Hetzel DJS. Taq I reveals a polymorphism in cattle when probing with the rat 
fatty acid-binding protein (I-FABP). Animal Genet 1991; 22: 443 
297 Demmer LA, Birkenmeier EH, Sweetser DA, Levin MS, Zollman S, Sparkes RS, Mohandas T, Lusis AJ, 
Gordon JI. The cellular retinol binding protein II gene. Sequence analysis of the rat gene, chromosomal 
localization m mice and humans, and documentation of its close linkage to the cellular retinol binding 
protein gene. J Biol Chem 1987; 262: 2458-2467 
298. Rottman JN, Gordon JI. Comparison of the patterns of expression of rat intestinal fatty acid binding 
protein/human growth hormone fusion genes in cultured intestinal epithelial cell lines and m the gut 
epithelium of transgeme mice. J Biol Chem 1993, 268: 11994-12002 
299. Sweetser DA, Häuft SM, Hoppe PC, Birkenmeier EH, Gordon JI. Transgeme mice containing intestinal 
acid-binding protein-human growth hormone fusion genes exhibit correct regional and cell-specific 
expression of the reporter gene in their small intestine. Proc Natl Acad Sci USA 1988; 85: 9611-9615 
300. Conn SM, Simon TC, Roth KA, Birkenmeier EH, Gordon JI. Use of transgeme mice to map cis-acting 
elements in the intestinal fatty acid binding protein gene (FABPi) that control its cell lineage-specific and 
regional patterns of expression along the duodenal-colomc and crypt-villus axes of the gut epithelium. J 
Cell Biol 1992; 119:27-44 
301. Rubin DC, Swietlicki E, Roth KA, Gordon JI. Use of fetal intestinal lsografts from normal and transgeme 
mice to study the programming of positional information along the duodenal-to-colomc axis. J Biol Chem 
1992; 267: 15122-15133 
302. Sweetser DA, Lowe JB, Gordon JI. The nucleotide sequence of rat liver fatty acid-binding protein. Evi-
dence that exon 1 encodes an oligopeptide domain shared by a family of proteins which bind hydrophobic 
ligands. J Biol Chem 1986; 261: 5553-5561 
303. Fowler KJ, Bruce Mann G, Dunn AR. Linkage of the murine transforming growth factor a gene with Igk, 
Ly-2, and Fabpl on chromosome 6. Genomics 1993; 16: 782-784 
-63-
Chapter 2 
304. Chen SH, Van Turnen Ρ, Ledbetter DH, Smith LC, Chan L. Human liver fatty acid-binding protein gene 
is located on chromosome 2. Somat Cell Mol Genet 1986; 12: 303-306 
305. Simon TC, Roth KA, Gordon JI. Use of transgenic mice to map as-acting elements m the liver forty acid-
binding protein gene (Fabpl) that regulate its cell lineage-specific, differentiation-dependent, and spanai 
patterns of expression in the gut epithelium and m the liver acinus. J Biol Chem 1993; 268: 18345-18358 
306. Bass NM, Barker ME, Manning JA, Jones AL, Ockner RK. Acinar heterogeneity of fatty acid binding 
protein expression m the livers of male, female and Clofibrate treated rats. Hematology 1989; 9: 12-21 
307. Suzuki T, Ono T. Immunohistochemical studies on the distribution and frequency of fatty acid-binding 
protein positive cells in human fetal, newborn and adult bver tissues. J Pathol 1987; 153° 385-394 
308. Iseki S., Kondo H, Hitomi, Ono T. Immunocytochemical localization of hepatic fatty acid binding protein 
ш the liver of fed and fasted rats. Histochem 1988; 89: 317-322 
309. Suzuki T, Ono T. Ontogeny of hepatic fatty acid-binding protein immunoreactivity in human liver and 
intestinal tract. Acta Pathol Jpn 1988; 38: 979-987 
310. Isela S, Kondo H. An immunocytochemical study on the occurrence of liver fatty-acid-binding protein in 
the digestive organs of rats: specific localization in the D-cells and brush cells. Acta Anat 1990; 138: 15-
23 
311. Bass NM. Fatty acid-binding protein expression in the liver: its regulation and relationship to the zonation 
of fatty acid metabolism. Mol Cell Biol 1990; 98: 167-176 
312. Isela S, Kondo H, Hitonn M, Ono T. Localization of liver fatty acid-binding protein and its mRNA in the 
liver and jejunum of rats: an immunohistochemical and in situ hybridization study. Mol Cell Biochem 
1990; 98: 27-34 
313. Roth KA, Hertz JM, Gordon JI. Mapping enteroendocnne populations m transgenic mice reveals and 
unexpected degree of complexity in cellular differentiation within the gastrointestinal tract. J Cell Biol 
1990; 110: 1791-1801 
314. Roth KA, Rubin DC, Birkenmeier EH, Gordon JI. Expression of liver fatty acid-binding protein/human 
growth hormone fusion genes within the enterocyte and enteroendocnne cell populations of fetal transgenic 
mice. J Biol Chem 1991; 266: 5949-5954 
315. Levin MS, Pitt AJA, Schwartz AL, Edwards PA, Gordon JI. Developmental changes in the expression of 
genes involved m cholesterol biosynthesis and lipid transport in human and rat fetal and neonatal livers. 
Biochim Biophys Acta 1989; 1003: 293-300 
316. Trotter PJ, Storch J. Fatty acid uptake and metabolism in a human intestinal cell line (Caco-2): comparison 
of apical and basolateral incubation. J Lipid Res 1991, 32: 293-304 
317. Levin MS, Talkad VD, Gordon Л, Stenson WF. Trafficking of exogenous fatty acid within Caco-2 cells. J 
Lipid Res 1992; 33: 9-19 
318. Mallordy A, Besnard P, Carher H. Research of an in vitro model to study the expression of fatty acid-
btnding proteins m the small intestine. Mol Cell Biochem 1993; 123: 85-92 
319. Hansbrough JR, Lublin DM, Roth KA, Birkenmeier EA, Gordon JI. Expression of a liver fatty acid 
binding protein/human decay-accelerating factor/ HLA-B44 chimeric gene in transgenic mice. Am J 
Physiol 1991; 260: G929-G939 
320. Bass NM, Manning JA, Ockner RK, Gordon JI, Seetharam S, Alpers DH. Regulation of the biosynthesis 
of two distinct fatty acid-binding proteins ш rat liver and intestine. Influence of sex difference and of 
Clofibrate. J Biol Chem 1985; 260: 1432-1436 
321. Kawashima Y, Nakagawa S, Tachibana Y, Kozuka H. Effects of peroxisome proliferators on fatty acid-
binding protein m rat liver. Biochem Biophys Acta 1983; 754: 21-27 
322. Besnard P, Mallordy A, Carlter H. Transcriptional induction of the fatty acid binding protein gene in 
mouse liver by bezafibrate. FEBS Lett 1993; 327: 219-223 
323. Haq RU, Shrago E. Dietary and nutritional aspects of fatty acid binding proteins. Chem Pbys Lipids 1985; 
-64-
Introduction 
38: 131-135 
324 St John LC, Rule DC, Knabe DA, Metsmann HJ, Smith SB. Fatty acid-binding protein activity in tissues 
from pigs fed diets containing 0 and 20% high oleate oil. J Nutr 1987; 117- 2021-2026 
325. Malewiak M-I, Bass NM, Griglio S, Oclcner RK. Influence of genetic obesity and of fat-feeding on hepatic 
FABP concentration and activity. Int J Obesity 1988; 12: 543-546 
326. Oclcner RK, Manning JA. Fatty acid-binding protein in small intestine. Identification, isolation and 
evidence for its role in cellular fatty acid transport. J Clin Invest 1974; 54: 326-338 
327. Besnard P, Bernard A, Carher H. Quantification of mRNA encoding rat enterocyte fatty acid binding 
proteins (FABP): effect of a high fat diet and starvation. CR Acad Sci Pans 1991; 312: 407-413 
328. Veerkamp JH, Van Moerkerk НТВ. Peroxisomal fatty acid oxidation in rat and human tissues. Effect of 
nutritional state, Clofibrate treatment and postnatal development with the rat. Biochim Biophys Acta 
1986;875: 301-310 
329. Vanden Heuvel, JP, Sterchele PF, Nesbit DJ, Peterson RE. Coordinate induction of acyl-CoA buiding 
protein, fatty acid binding protein and peroxisomal 0-oxidation by peroxisome prohferators. Biochim 
Biophys Acta 1993; 1177: 183-190 
330. Kaikaus RM, Chan WK, Lysenko N, Ray R, Ortiz de Montellano P, Bass NM Induction of peroxisomal 
fatty acid 0-oxidation and liver fatty acid-binding protein by peroxisome prohferators J Biol Chem 1993; 
268: 9593-9603 
331. Kaikaus RM, Chan WK, Ortiz de Montellano PR, Bass NM. Mechanisms of regulation of liver fatty acid-
binding protein. Mol Cell Biochem 1993, 123- 93-100 
332. Reddy JK, Goel SK, Nemali MR, Camno JJ, Laffler TG. Kumudavalli Reddy M, Sperbeck SJ, Osumi T, 
Hashimoto T, Lalwani ND, Rao MS. Transcriptional regulation of peroxisomal fatty acyl-CoA oxidase and 
enoyl-CoA hydrolase/ 3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome prohferators. Proc 
Natl Acad Sci USA 1986; 83- 1747-1751 
333 Hijikata M, Wen J-K, Osumi T, Hashimoto T. Rat peroxisomal 3-ketoacyl-CoA thiolase gene. Occurence 
of two closely related but differentially regulated genes. J Biol Chem 1990; 265: 4600-4606 
334. Hardwick JP, Song BJ, Huberman E, Gonzalez FJ. Isolation, complementary DNA sequence, and 
regulation of rat hepatic launc acid ω-hydrolase (cytochrome P-450^) Identification of a new cytochrome 
P-450 gene family J Biol Chem 1987; 262: 801-810 
335. Shanna RK, Lake BG, Makowski R, Bradshaw T, Eamshaw D, Dale JW, Gibson GG. Differential 
induction of peroxisomal and microsomal fatty-acid-oxidising enzymes by peroxisome prohferators in rat 
liver and kidney. Characterisation of renal cytochrome P-450 and implications for peroxisome prolifera­
tion. Eur J Biochem 1989; 184: 69-78 
336. Auwerx J. Regulation of gene expression by fatty acids and fibnc acid derivatives: an integrative role for 
peroxisome proliferato activated receptors. Hormone Res 1992, 38: 269-277 
337. Berge RK, Aarsland A, Kryvi H, Bremer J, Aarsaether N Alkylthioacetic acid (3-thia fatty acids) - a new 
group of non-oxidizable, peroxisome-inducing fatty acid analogues I. A study on the structural 
requirements for proliferation of peroxisomes and mitochondria m rat liver. Biochim Biophys Acta 1989, 
1004: 345-356 
338. Neat CE, Thomassen MS, Osmundsen H. Induction of peroxisomal B-oxidation in rat liver by high-fat 
diets. Biochem J 1980; 186: 369-371 
339. Neat CE, Thomassen MS, Osmundsen H. Effects of high-fat diets on hepatic fatty acid oxidation in the 
raL Isolation of rat liver peroxisomes by vertical-rotor centnfugation by using a self-generated, ïso-
osmotic, Percoli gradient. Biochem J 1981; 196: 149-159 
340. Norseth J, Thomassen MS. Stimulation of microperoxisomal B-oxidation in rat heart by high-fat diets. 
Biochim Biophys Acta 1983; 751: 312-320 
341. Bremer J, Norum KR. Metabolism of very long-chain monosaturated fatty acids (22:1) and the adaptation 
-65-
Chapter 2 
to their presence in the diet. J Lipid Res 1982, 23: 243-256 
342. Lock EA, Mitchell AM, Elcombe CR. Biochemical mechanisms of induction of hepatic peroxisome 
proliferation. Annu Rev Pharmacol Toxicol 1989; 29 145-163 
343. Hawkins JM, Jones WE, Bonner FW, Gibson GG. The effect of peroxisome proliferators on microsomal, 
peroxisomal, and mitochondrial enzyme activities in the liver and kidney. Drug Metabolism Rev 1987; 18: 
441-5 IS 
344. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome 
proliferators. Nature 1990; 347: 645-649 
345. Göttlicher M, Widmark E, Li Q, Gustafsson J-Α. Fatty acids activate a chimera of the clofibnc acid-
activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA 1992; 89: 4653-4657 
346 Dreyer C.Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal 6-oxidation 
pathway by a novel family of nuclear hormone receptors. Cell 1992; 68: 879-887 
347. Dreyer C, Keller H, Mahfoudi A, Laudet V, Krey G, Wahli W. Positive regulation of the peroxisomal B-
oxidation pathway by fatty acids through activation of peroxisome prohferator-activated receptors (PPAR). 
Biol Cell 1993; 77: 67-76 
348. Schmidt A, Endo Ν, Rutledge SJ, Vogel R, Shinar D, Rodan GA. Identification of a new member of the 
steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol 
Endocrinol 1992; 6: 1634-1641 
349. Wahli W, Martinez E. Superfamily of steroid nuclear receptors: positive and negative regulators of gene 
expression. FASEB J 1991; 5: 2243-2249 
350. Green S. Receptor-mediated mechanisms of peroxisome proliferators. Biochem Pharmacol 1992; 43° 393-
401 
351. Umesono K, Murakami KK, Thompson CC, Evans RM Direct repeats as selective response elements for 
the thyroid hormone, retinole acid and vitamin D3 receptors. Cell 1991; 65: 1255-1266 
352. Tugwood JD, Issemann I, Anderson RG, Bunded KR, McPheal WL, Green S. The mouse peroxisome 
proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl 
CoA oxidase gene. EMBO J 1992; 11: 433-439 
353. Issemann I, Pnnce RA, Tugwood JD, Green S. The peroxisome prohferator-activated receptor: retinoid X 
receptor heterodimer is activated by fatty acids and fibrate hypohpidaemic drugs. J Mol Endocrinol 1993; 
11: 37-47 
354. Osumi T, Wen JK, Hashimoto T. Two cis-acting regulatory sequences in the peroxisome proliferator 
responsive enhancer region of rat acyl-CoA oxidase gene. Biochem Biophys Res Commun 1991; 175: 866-
871 
355. Zhang B, Marcus SL, Sajjadi FG, Alvares К, Ready Ж, Subramani S, Rachubinski RA, Capone JP. 
Identification of a peroxisome proliferator-responsive element upstream of the gene encoding rat 
peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase. Proc Natl Acad Sci USA 1992; 89: 
7541-7545 
356. Issemann I, Pnnce R, Trugwood J, Green S. A role for fatty acids and liver fatty acid buiding protein in 
peroxisome proliferation? Biochem Sec Trans 1992; 20: 824-827 
357. Keller H, Dreyer C, Medio J, Mahfoudi A, Ozato K, Wahli W. Fatty acids and retinoids control lipid 
metabolism through activation of peroxisome prohferator-activated receptor-retinoid X receptor heterodi-
mers. Proc Natl Acad Sci USA 1993; 90: 2160-2164 
358. Keller H, Mahfoudi A, Dreyer С Hihi AK, Medin J, Ozato K, Wahli W. Peroxisome prohferator-
activated receptors and lipid metabolism Ann NY Acad Sci 1993; 368: 157-173 
359. Bass NM, Sadovsky Y, Appell R, Kushner PJ. Dicarboxylic fatty acids activate the peroxisome-
proliferator-activated receptor (PPAR) in rat HTC hepatoma cells. Hepatol 1993; IB: 125 
360. Marcus SL, Miyata KS, Zhang B, Subrarnam S, Rachubinski RA, Capone JP. Diverse peroxisome 
-66-
Introduction 
proliferator-activated receptors bind to the peroxisome prohferator-responsive elements of the rat 
hydratase/dehydrogenase and fatty acyl-CoA oxidase genes but differentially induce expression. Proc Natl 
Acad Sci USA 1993; 90: 5723-5727 
361. Hertz R, Bar-Tana J. Induction of peroxisomal B-oxidation genes by retinóte acid ш cultured rat 
hepatocytes. Biochem J 1992; 281: 41-43 
362. Castelein H, Declercq PE, Mannaerts GP, Baes MI. Peroxisome prohferators and T3 operate by way of 
distinct receptors FEBS Lett 1993; 332: 24-26 
363. Maatman RGHJ, Van Moerkerk НТВ, Nooren IMA, Van Zoelen EJJ, Veerkamp JH. Expression of 
human liver fatty acid-binding protein m Escherichia coli and comparative analysis of its binding 
characteristics with muscle fatty acid-binding protein Biochim Biophys Acta submitted 
364. Ketterer B, Tipping E, Hackney JF, Baele D. A low-molecular-weight protein from rat liver that 
resembles ligandm ш its bmding properties. Biochem J 1976; 155: 511-521 
365. Ockner RK, Lysenko N, Manning JA, Monroe SE. Sex steroid modulation of fatty acid utilization and 
fatty acid-binding protein concentration in rat liver. J Clin Invest 1980; 65: 1013-1023 
366. Trulzsch DV, Müller Τ, Treuner M, Spitzer E. Effect of estrogen on the expression of fatty acid-binding 
protein m hepatoma (HEPG2) cells. Hepatol 1993; 18: 137A 
367. Levin MS, Li E, Ong DE, Gordon JI. Comparison of the tissue-specific expression and developmental 
regulation of two closely linked rodent genes encoding cytosohc retinol-binding proteins. J Biol Chem 
1987; 262: 7118-7124 
368. Wei L-N, Mertz JR, Goodman DS, Nguyen-Huu MC. Cellular retinole acid- and cellular retinol-binding 
proteins: complementary deoxyribonucleic acid cloning, chromosomal assignment, and tissue specific 
expression. Mol Endocrinol 1987; 1: 526-538 
369. Smith WC, Nakshatn H, Leroy Ρ, Rees J, Chambón P. A retinole acid response element is present ш the 
mouse cellular retinol bmding protein I (mCRBP I) promoter. EMBO J 1991; 10: 2223-2230 
370. Husmann M, Hoffmann B, Stump DG, Chytil F, Pfahl M. A retinole acid response element from the rat 
CRBP I promoter is activated by an RAR/RXR heterodimer. Biochem Biophys Res Commun 1992, 187 
1558-1564 
371. Li E, Demmer LA, Sweetser DA, Ong DE, Gordon JI. Rat cellular retinol-binding protein II: use of a 
cloned cDNA to define its primary structure, tissue-specific expression, and developmental regulation. 
Proc Natl Acad Sci USA 1986; 83. 5779-5782 
372. Ong DE, Lucas PC, Kakkad B, Quick TC. Ontogeny of two vitamin A-metabolizmg enzymes and two 
retinol-binding proteins present m the small intestine of the rat. J Lipid Res 1991; 32: 1521-1527 
373. Mangelsdorf DJ, Umesono К, Kliewer SA, Borgmeyer U, Ong ES, Evans RM. A direct repeat m the 
cellular retinol-binding protein type Π gene confers differential regulation by RXR and RAR. Cell 1991; 
66: 555-561 
374. Wei L-N, Tsao J-L, Chu Y-S, Jeannotte L, Nguyen-Huu MC. Molecular cloning and transcriptional 
mapping of the mouse cellular retinole acid binding protein gene. DNA and Cell Biol 1990; 9: 471-478 
375. Nilsson MHL, Spurr NK, Saksena P, Busch С, Nordlinder H, Peterson PA, Rask L, Sundelin J. Isolation 
and characterization of a cDNA clone corresponding to bovine cellular retinoic-acid-binding protein and 
chromosomal localization of the corresponding human gene. Eur J Biochem 1988; 173: 45-51 
376. Shubeita HE, Sambrook JF, McCormick AM. Molecular cloning and analysis of functional cDNA and 
genomic clones encoding bovine cellular retinole acid-binding protein. Proc Natl Acad Sci USA 1987, 84-
5645-5649 
377. Bailey JS, Siu C-Η. Unique tissue distribution of two distmct cellular retinole acid binding proteins in 
neonatal and adult rat. Biochim Biophys Acta 1990; 1033: 267-272 
378. Durand В, Saunders M, Leroy Ρ, Leid Μ, Chambón P. All-trans and 9-cis retinole acid induction of 
CRABP Π transcription is mediated by RAR-RXR heterodimers bound to DR1 and DR2 repeated motifs. 
-67-
Chapter 2 
Cell 1992; 71: 73-85 
379. Petkovich M. Regulation of gene expression by vitamin A: The role of nuclear retinole acid receptors. 
Annu Rev Nutr 1992; 12: 443-471 
380. De Luca LM. Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. FASEB J 
1991; 5: 2924-2933 
381. Monss-Кау G Retinóte acid and development. Pathobiology 1992; 60: 264-270 
382. Mangelsdorf DJ, Umesono К, Evans RM. The retinoid receptors. In: Spom MB, Roberts AB, Goodman 
DS, eds. The retinoids: Biology, chemistry and medicine, 2nd edition. Raven Press Ltd, New York 1994 
319-349 
383. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM. Retinoid X receptor interacts with nuclear 
receptors m retinole acid, thyroid hormone and Vitamin D, signalling. Nature 1992; 355: 446-448 
384. Dollé Ρ, Ruberìe E, Leroy Ρ, Monss-Kay G, Chambón P. Retinóte acid receptors and cellular retinoid 
binding proteins. A systematic study of their differential pattern of transcription during mouse or-
ganogenesis. Development 1990; 110: 1133-1151 
385. Boylan JF, Gudas LJ. Overexpression of the cellular retinole acid binding protein-I (CRABP-I) results m a 
reduction ш differentiation-specific gene expression in F9 teratocarcmoma cells. J Cell Biol 1991; 112: 
965-979 
-68-
CHAPTER 3 
TWO TYPES OF FATTY ACID-BINDING PROTEIN IN HUMAN KIDNEY 
Isolation, characterization and localization 
R.G.H.J. Maatman, T.H.M.S.M. Van Kuppevelt and J.H. Veerkamp 
This chapter is an adapted version from 
Biochem. J. (1991) 273, 759-766 

Two types of fatty acid-binding protein in human kidney 
SUMMARY 
Two types of fatty acid-binding protein (FABP) were isolated from human kidney by gel 
filtration and ion-exchange chromatography. Characterization based on molecular mass, 
isoelectric point, fluorescence with dansylamino-undecanoic acid and immunological cross-
reactivity showed that one, type B, was fairly similar to human heart FABP. The other, type A, 
showed, like human liver FABP, a high fluorescence enhancement and a wavelength shift with 
dansylamino-undecanoic acid as well as the binding of a variety of ligands. Antibodies raised 
against FABP type A and against liver FABP markedly cross-reacted in e.l.i.s.a., in Western 
blotting and in indirect immuno-peroxidase staining on kidney and liver sections. Differences in 
amino acid composition and isoelectric points, however indicate that type A might be a kidney 
specific type. The FABP type A is more abundant in kidney than the В type and is predomi­
nantly localized in the cortex, especially in the cells of the proximal tubules. The FABP type В 
is mainly present in the cells of the distal tubules. 
In conclusion, this study shows the presence of two types of FABP in the kidney. One 
type seems to be related to heart FABP, while the other type resembles, but seems not identical 
to, liver FABP. Both types have a characteristic cellular distribution along the nephron. 
INTRODUCTION 
In many tissues a low-molecular mass fatty acid-binding protein (FABP) is present. A 
precise function of FABP has not yet been shown, but it is generally assumed that it is involved 
in fatty acid transport and metabolism [1-5]. In man three FABP types have been identified thus 
far: heart [6-8] liver [9,10] and intestinal FABP [11]. In rodents five distinct FABP types have 
been isolated and characterized. Immunochemical and molecular-biological studies show that 
heart FABP and/or its mRNA are present in skeletal muscle, kidney and many other tissues, but 
not in liver and intestine [2,4,5,12-14]. The liver type FABP is located in hepatocytes and 
shows in the intestine a gradient from duodenum to colon and from crypt to villus tip [15-17]. 
Intestinal FABP is similarly distributed within the intestine, but is not present in liver [18,19]. 
A specific lipid-binding protein is present in adipocytes [20]. Fujii et al. [21] isolated an FABP 
from rat kidney, which differed from rat liver FABP. Recently Lam et al. [22] showed the 
presence of a second renal-specific FABP in rat kidney and bladder, besides the heart type. 
In experimental hypertension the content of the renal FABP type is decreased in rat 
kidney in contrast with that of the heart type [22]. Other investigations showed that in this 
condition the content of heart FABP is also decreased in rat aorta [23]. In spontaneously 
hypertensive rats, however, the FABP content of kidney medulla is higher than in normal rats 
[24]. 
FABPs may play an important role in fatty acid metabolism of kidney, since fatty acids 
are a major source of energy in this organ [25-28]. Considerable differences in the FABP 
content were found between cortex and medulla of rat kidney, but both a higher content of 
cortex [22] and of medulla [24] were reported. Studies of mammalian nephron segments have 
shown a large diversity of transport functions [29] and a specific distribution of enzymes of 
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metabolic pathways [30]. These data suggest that the content and nature of the F ABP type may 
differ in the various cell types of the nephron. Therefore we decided in our series of studies on 
FABPs from human tissues [6,10,31] to investigate the presence of FABP in the human kidney. 
In the present study we describe the isolation, characterization and cellular distribution of two 
FABP types of human kidney. 
MATERIALS AND METHODS 
Materials 
Sephacryl S-200, CM-cellulose, DEAE-Sepharose CL-6B Fast Flow and Sephadex G-50 
(fine grade) were obtained from Pharmacia Biotechnologies (Int.), Uppsala, Sweden; Lipidex 
1000 from United Technologies Packard, Downers Grove, IL. USA; [l-14C]oleic and [1-
14C]palmitic acids from Amersham, Little Chalfont, Bucks, U.K.; 11-dansylamino-undecanoic 
acid from Molecular Probes, Junction City, OR, USA; polystyrene 96-well flat-bottom 
microtitre elisa plates from Greiner, Nürtingen, Germany; horseradish peroxidase-conjugated 
swine anti-rabbit IgG from Dakopatts A/S, Glostrup, Denmark; goat anti-(human Tamm-
Horsefall glycoprotein) from Cappel, West Chester, PA, USA; Diaflo YM-2 and YM-5 
membranes from Amicon Corporation, Lexington, KY, USA; nitrocellulose sheets (BA-85, pore 
size 0.45 μΜ) and electroelution membranes (BT1, BT2) from Schleicher &. Schuil, Dassel, 
Germany; Servalyt ultrathin 5% Polyacrylamide Precoates from Serva GMBH & Co, Heidel­
berg, Germany. Human kidneys were obtained after nephrectomy or at obduction within 15 h 
after death. Rat kidneys were obtained from 10 week old male Wistar rats. 
Methods 
Purification of fatty acid-binding proteins 
Renal cortex was separated from medulla using the junction of cortex and outer medulla 
as anatomical marker. Cortex (150-175 g) originating from 2 kidneys was homogenized (40%; 
w/v) in ice-cold 10 mM-potassium-phosphate/154 mM-potassiumCl (pH 7.4) with a polytron 
homogenizer. The homogenate was centrifuged for 10 min at 600 g and subsequently for 90 
min at 105,000 g. The supernatant (cytosol) was fivefold concentrated by ultrafiltration on a 
Diaflo YM-5 membrane. The concentrated cytosol was applied, in four portions of 9 ml, to a 
Sephacryl S-200 gel filtration column (2.6 χ 110 cm), equilibrated in 30 mM-Tris/HCl (pH 
8.0)/l mM-dithiothreitol/1 mM-EDTA and eluted with the same buffer. The fractions contai­
ning fatty acid-binding activity were combined, dialysed overnight against 5 mM- Tris/HCl (pH 
8.4) and applied to a DEAE-Sepharose Fast Flow column (2.5 χ 10 cm), equilibrated in the 
same buffer. The column was eluted stepwise with 0.6 1 of 15 mM, 30 mM- and 50 mM-
Tris/HCl (pH 8.0). The fractions containing fatty acid-binding activity were combined, 
concentrated on a Diaflo YM-2 membrane and applied to a CM-cellulose column (4.8 χ 4 cm), 
equilibrated in 20 mM-potassium-phosphate/1 mM-dithiothreitol (pH 5.4). The column was 
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eluted with 0.3 1 of the same buffer. The fatty acid-binding fractions were combined, concentra­
ted on a Diaflo YM-2 membrane and applied to a Sephadex G-50 (fine) column (l.S χ 70 cm), 
which was equilibrated and eluted with 10 mM-potassium-phosphate/1 mM-dithiothreitol (pH 
7.4). The purified FABPs were stored at -20°C. 
FABPs from human and rat liver [10], heart [11] and human skeletal muscle [31] were 
isolated as described. Heart and muscle FABPs were additionally purified by CM-cellulose 
chromatography. 
Electroelution 
F ABP preparations obtained from the Sephadex G-50 column, were fractionated by 
SDS/PAGE in 16 % gel at pH 8.8. After Coomassie Blue staining of the molecular-mass 
markers and a small strip of the protein sample, the major 15 kDa band was cut from gel. The 
gel slices were applied to the Biotrap electrophoresis chamber (Schleicher & Schuell, Dassel, 
FRG) filled with 0.05 M-Tris/25 mM-glycine/0.1 % SDS buffer (pH 6.8) [32]. Electroelution 
was executed for 2 h at a constant voltage of 200 V. The protein trapped between the BT1 and 
BT2 membrane was used. 
Immunocytochemistry 
Kidney slices were fixed in 4% paraformaldehyde in 0.01 M phosphate buffer (pH 7.4) 
and embedded in paraffin. All further procedures were done at room temperature. Sections were 
deparaffinized and treated for 30 min. with 1% (v/v) hydrogen peroxide in methanol to remove 
intrinsic peroxidase activity. After rehydration, sections were incubated with 20% (v/v) normal 
swine serum for 15 min followed by rabbit antiserum raised against one type of FABP (diluted 
1:250 or 1:500) for 90 min. The sites of immunoreaction were revealed with swine anti-rabbit 
IgG-peroxidase using diaminobenzidine as a substrate. Sections were counterstained with 
Harris's haematoxylin and embedded in glycerol/gelatin mounting medium. To localize distal 
tubules, an antiserum against Tamm-Horsefall glycoprotein was used [33,34]. Pre-immune sera 
and antisera raised against non-related antigens were applied as controls. 
Other procedures 
Fatty acid-binding activity of column fractions and isolated FABP preparations were 
determined as described by Peeters et al. [31]. Amino acid analysis, fluorescence measurements 
of ll-dansylamino-undecanoic acid binding to FABP and its displacement by various ligands 
were performed as previously described [6, 10]. Tryptophan determination in 6 M-guanidinium 
HCl (pH 6.5) and 5,5-dithiobis-(2-nitrobenzoic acid) analysis for determination of free cysteine 
were performed as described by Edelhoch [35] and Wilton [36], respectively. 
Polyacrylamide slab gel electrophoresis was performed in 0.1% SDS at pH 8.8 in 16% 
acrylamide gels. Reductive gels were run after addition of 10 тМ-2-mercaptoethanol in the 
upper reservoir buffer [37]. Gels were stained with Coomassie Brilliant Blue or silver [38]. 
Isoelectric focusing was performed on native 5 % ultrathin Polyacrylamide gels. Protein samples 
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(5-10 /ig) were subjected to focusing at 1000 
V in a Desaga Mediphor electrophoresis 
apparatus. Gels were fixed in 0.82 M-trichlo-
roacetic acid for 15 min and stained with 
Coomassie Brilliant Blue R250 in solution 
(methanol/acetic acid/water; 5:1:4 by vol.) 
for 15 min. Gels were de-stained in the same 
solution. 
Preparation and characterization of the 
rabbit antisera against the FABPs of kidney 
were performed as described for the FABPs 
from heart [6], liver [10] or muscle [31]. 
ELISA and immunoblotting were as previous­
ly described for rat FABPs [39]. 
RESULTS 
Purification of two FABP types 
The combined fractions of low-mole­
cular-mass proteins with fatty acid-binding 
activity obtained after Sephacryl S-200 gel 
filtration of cortex cytosol were separated on 
DEAE-Sepharose. After stepwise elution with 
15, 30 and 50 mM-Tris/HCl (pH 8.0), res­
pectively two peaks with fatty acid-binding 
activity were identified, peaks A and В (Fig. 
1). Both preparations were applied to a CM-
cellulose column to remove contamination 
with haemoglobin subunits. After CM-cellu-
lose, preparation В was pure by SDS/PAGE, 
preparation A contained only FABP and a 
protein of approximately 30 kDa. Gel filtra­
tion on Sephadex G-50 did not remove this 
latter protein. 
Therefore the sample was refractionated by 
preparative SDS/PAGE. After electrocution 
of FABP (15 kDa band) from the gel and re-
electrophoresis, the gel again showed FABP 
and the 30 kDa protein. These results in­
dicate that the contaminating protein is a 
100 200 
FractKxi no 
Fig. 1. Purification of FABPs from the low molecular-
mass fraction of the renal cortex cytosol by DEAE-
Sepharose anion-exchange chromatography. 
Bound proteins were eluted stepwise with 15, 30 and 50 
raM Tris/HCl (pH 8.0). Protein was monitored at 280 
nm ( ) and 300 μ\ samples were assayed for 
[l-"C]palmitic acid binding (o). 
kDa 
94 
68 
43 
30 · 
20,1 
14,4 
-«к 
"f 
•ш 
-
• 
mm-
Ik** Ê 
M 1 2 3 4 5 6 
Fig. 2 SDS-PAGE of preparations at different stages 
of the purification of FABP from human renal cortex. 
The gel was stained with Coomassie Brilliant Blue. 
Lanes labelled with "M" contain calibration proteins 
(Mr): Phosphorylase b (94000); BSA (67000); ovalbumin 
(43000); carbonic anhydrase (30000); soybean trypsin in-
hibitor (20100); and a-lactalbumin (14400). Lane 1; 
cytosolic protein (200 /*g); lane 2; combined FABP-
containing fractions after Sephacryl S200 gelfiltration 
(200 ^g); lane 3; peak A after DEAE-Sepharose chroma-
tography (40 /*g); lane 4; FABP type A after CM-cel-
lulose chromatography (15 /tg); lane 5; peak В after 
DEAE-Sepharose chromatography (40 μξ); lane 6; FABP 
type В after CM-cellulose (15 pg). 
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dimer of FABP, as was also observed previously with rat liver FABP [10,39,40]. 
The results of a typical purification procedure are summarized in Table I and Fig. 2. The yield 
of FABPs is rather low but is in the same order as for human liver [10] and human heart [6]. 
The ratio of preparations A and В was always approximately 4:1. Purification from kidney 
cortex of both female or male individuals showed the same results. Purification of FABP from 
the cytosol of kidney medulla yielded comparable amounts of the В preparation but only slight 
amounts of the A preparation. 
Characterization of the FABP preparations 
The FABP preparations obtained as peak A and В appeared to be no isoforms, but 
different FABP types (A and B). The molecular mass determined by gel electrophoresis is 14.7 
± 0.2 (mean ± SD, n=6) kDa for type A and 16.1 ± 0.2 kDa (n=6) for type B. Isoelectric 
focussing revealed an pi of 6.8 for type A and of 5.2 for type B, respectively. These isoelectric 
points agree with the different elution positions of the proteins from DEAE-Sepharose. 
Table 1 Isolation of FABPs from human renal corte. Protein was determined by the procedure of Lowry et 
al. [54] or by quantitative ammo acid analysis (after CM-cellulose and Sephadex G-50); fatty acid-binding 
activity was assayed at 1 μΜ-[1-"0] oleic acid. The supernatant was freed from albumin by affinity chromato­
graphy on Sepharose-anti-(human serum albumin) before assay of specific binding activity. 
Purification step 
105000 g supernatant 
Sephacryl S-200 
DEAE-Sepharose 
Preparation A 
Preparation В 
CM-cellulose 
Preparation A 
Preparation В 
Sephadex G-50 
Preparation A 
Protein 
ime) 
10298 
808 
49 
12 
21 
5 
5 
Specific binding 
activity (nmol/mg) 
0.55 
2.53 
5.52 
6.06 
17.5 
27.4 
16.4 
Purification 
(-fold) 
1.0 
4.6 
10.0 
11.0 
15.9 
24.9 
14.7 
Yield 
% 
100 
36 
4.8 
1.3 
3.3 
1.2 
0.7 
The amino acid compositions of both proteins were compared with each other and with our data 
on human liver and heart FABPs [6,10].The FABP type A differs slightly from liver FABP but 
is markedly different from heart FABP (Table 2). The FABP type В preparation had a 
composition, which differed from kidney type A FABP and from liver and heart FABPs. On 
base of a molecular mass of about 14.5 kDa, FABP type A and liver FABP contain one 
cysteine residue in contrast with the other FABPs. Determination of tryptophan however, 
showed that FABP type A contains two tryptophan residues, whereas liver FABP contains none. 
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'able 2 Amino acid composition of FABPs from kidney (A and В types), liver and heart 
'allies are given in residues/1000 amino acid residues and are means±S.D. for the number of preparations in 
arenthese. Data on human heart and liver FABPs were obtained from Paulussen et al. [6] and Peelers et al. [10] 
sspectively. Statistical significance: different from liver FABP: 'P<0.001, b P<0.01; different from heart FABP: 
><0.001, d P<0.01; different from kidney FABP type В: 'Р<0.001, 'P<0.01. 
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Kidney FABP 
typeA 
(n-8) 
106 ±5* 
67 ±2"·' 
61 ±6" 
152 ± 3 ' 
37 ± 3 ' 
100 ± 5 ' 
60±4· 
8 
71 ± 4 ' 
18±2 
65 ±7* 
67±3 
17±2· 
5 4 ± 3 ' 
16 ± 1 ' 
54 ± 3 " 
99 ±3"·' 
24±2* 
Liver FABP 
(n-5) 
94±5 
78±5 
59±7 
158±10 
31±6 
95±3 
51±9 
ND 
65±11 
15±3 
63±11 
69 ±5 
16±3 
56±2 
0 
15±3 
109±8 
24±3 
Heart FABP 
(n=3) 
108±4 
127 ±10 
54±5 
102±5 
18±4 
84±1 
57±3 
ND 
63±4 
17±4 
33+6 
104±3 
16±1 
46±4 
9 ± 1 
25±3 
107 ± 8 
32±2 
Kidney FABP 
type В 
(n=4) 
96 ±5 
73 ±T 
39 ±4" 
115±16 
62 ±2* 
153 ± 6 ' 
71 ±3" 
ND 
59 ± 2 
16±2 
44±2 
69 ±3' 
10 ± 1 ' 
39±2 
ND 
17 ±2" 
92±2 
44 ±1* 
r
atty acid-binding studies 
The binding affinities (Kd va­
nes) for oleic acid of type A and В were 
1.2 and 0.3 /xM, respectively. The maxi-
nal binding capacity of preparations of 
oth proteins obtained in different isola-
ion procedures was 16-30 pmol of oleic 
cid//tg FABP (0.24-0.45 mol/mol 
:ABP). The cause of the deviation of the 
inding ratio from 1.0 may be the loss of 
inding activity by the ion-exchange chro-
natography as previously observed with 
?ABPs isolated from other tissues [6,10, 
U.41]. 
Measurements of the interaction 
if FABP type A with 11-dansylamino-un-
lecanoic acid by fluorescence showed a 
narked shift of both excitation (328-345 
H u m a n k i d n e y FABP 
t y p e A 
S H u m a n k i d n e y FABP 
с І У » · В 
Fig. 4 Fluorescence emission spectra of 1 μΜ 11-
dansylamino-undecanoic acid with ( + ) or without (-) 
2.7 μΜ kidney FABP type A or В in 10 mM Tris/HCl 
(pH 8.0). Excitation wavelengths were 330 and 345 nm, 
respectively m the absence and presence of FABP type 
A. No shift in excitation wavelength was found for FABP 
typeB. 
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nm) and emission (545-505 nm) wave­
lengths and a large enhancement of fluore­
scence (Fig.4), similar to observations 
with liver FABPs [10]. Kidney FABP 
type В did not show the wavelength shifts 
and only a slight enhancement of fluores­
cence (Fig.4), comparable with heart 
FABP [10]. 
Displacement studies with 
various types of ligands were performed 
to investigate the binding specificity of the 
FABP preparations. Various ligands cau­
sed a displacement of the fluorescent 
probe from renal FABP type A similar to 
that from human liver FABP (Fig.5). The 
type В did not show this phenomenon and 
appeared to be more ligand-specific simi­
lar to heart FABP [6]. 
Oleic acid 
Palmiloyl-CoAil™^^P^ 
PelmiLc-ylcarniline 
2-HydroiypalmiLic acid 
Tetradecylglycidic acidff 
Bromophtalein 
40 SO 60 
Displacement (Я) 
Fig. 5 Displacement of ll-dansylamino-undecanoic 
acid from human liver FABP and kidney FABP type 
A by different ligands. Concentrations were 40 ¿ig 
FABP, 1.0 μΜ dansylamino-undecanoic acid and 1.0 μΜ 
fatty acid (1% ethanol) in 1 ml 10 mM Tns/HCl (pH 
8.0). Fluorescence was measured at 345 nm (excitation) 
and SOS nm (emission). Displacement (decrease of 
fluorescence) is given as a percentage of the control 
fluorescence. 
Table 3 Immunological cross-reactivity of FABP and FABP antisera of 
human kidney, heart and liver. Serum dilutions at which half-maximal 
binding was obtained in an elisa were taken as measures for the immuno­
logical cross- reactivity. Per well, 0.4 μg of FABP was used. Values are 
means ± S.D. of at least three experiments and are given as percentage of 
the binding of the specific antiserum to the specific antigen. 
Immunochemical studies 
The specificity of 
the antisera against the 
kidney FABPs was assayed 
on Western blots of cytosols 
from kidney cortex. They 
revealed only two bands at 
14.5 kDa and 30 kDa with 
anti-(FABP type A) anti­
serum and one band at 15.5 
kDa with anti-(FABP type 
B) antiserum. The former 
observation was in accor­
dance with the presence of a dimer, as indicated above. The cortex cytosol also reacted with 
antisera against FABPs from human liver and heart, similar to the anti-(type A) and anti-(type 
B) antisera respectively. The renal FABP types and their antisera showed slight cross-reactivity. 
Human liver and heart FABP reacted only with anti-(FABP type A) and anti-(FABP type B) 
antiserum respectively. 
The cross-reactivity of the renal FABP types and heart and liver FABP and their 
Origin 
of 
FABP 
Kidney type A 
Kidney type В 
Heart 
Liver 
Antiserum 
against 
FABP from: Kidney 
type A 
100 
22±5 
3 ± 1 
67 ±7 
Reactivity (%) 
Kidney 
type В 
2 ± 0 
100 
91±7 
2 ± 0 
Heart 
0 
88±1 
100 
4 ± 2 
Liver 
85 ± 8 
13±1 
8 ± 2 
100 
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antisera was also investigated in ELISA (Table 3). The renal FABP types show a low degree of 
crossreactivity. The FABP type A cross-reacts strongly with anti-(liver FABP) serum, while the 
FABP type В does so with anti-(heart FABP) serum. 
Tissue distribution of both FABP types 
We studied the distribution of both FABP types in sections of human kidney with the 
antisera against FABP type A and В by the immunoperoxidase procedure. Antisera against 
FABPs from human liver, heart or skeletal muscle were also applied. Sections of the cortex and 
medulla were used to study different parts of the nephron. Identification of renal tubules was 
based on their position and relative abundance and on the morphological characteristics of their 
epithelial cells such as cell shape, position of the nucleus, presence of a brush border, cell 
striatum and appearance of cell boundaries [42,43]. Distal-tubular cells were identified with the 
antiserum against Tamm-Horsfall glycoprotein, which is specific for distal tubular cells. The 
results of the immunolocalization studies are shown m Figs. 6-9 and summarized in Table 4. 
Pre-immune sera did not show significant staining. 
Table 4 Inununohistochonical localisation of FABP along the nephron using antisera raised against different 
FABP preparations. Stauung: + + , strong; +, moderate; -, weak or absent. Abbreviations: Glom, glomeruli; 
PCT, proximal convoluted tubules; PST, proximal straight tubules; IT, intermediate tubules; DST, distal straight 
tubules; DCT, distal convoluted tubules; CD, collecting ducts. 
Staining intensity along the nephron 
Antiserum against 
FABP from: G l o m ^ Τ P S T Π" D S T D C T C D 
+ +" + + 
+ +" + + 
+ +" + + 
In human kidney, anti-(FABP type A) antiserum immunoreacted strongly with the 
proximal convoluted tubules (Fig. 6a), moderately with the proximal straight tubules and weakly 
or not with the other tubules (Fig. 6b). A comparable distribution was found using anti-(human 
liver FABP) antiserum (Fig. 7). Interestingly, human fetal kidney contains already early FABP, 
like human liver [44]. We observed immunoreactivity of proximal convoluted tubules of the 
kidney of a 4 months-old fetus with anti-(FABP type A) antiserum. 
In contrast, the distal tubules were found strongly immunoreactive with anti-(FABP 
type B) antiserum, while the proximal convoluted tubules showed a moderate staining (Fig. 8). 
The macula densa, a plaque of specialized tubular cells situated within the end portion of the 
Kidney (type A) 
Liver 
Kidney (type B) 
Heart 
Psoas muscle 
" Macula densa was negative 
+ + 
+ + 
+ 
+ 
+ 
+ 
+ 
-
-
-
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distal straight tubule was found negative (Fig. 8a, inset). The other tubules stained weakly or 
not at all. Using anti-(human heart FABP) or anti-(human muscle FABP) antisera, a similar 
distribution was obtained (Fig. 9). This is also the case when rat kidney sections were incubated 
with anti-(rat heart FABP) antiserum. 
The cytoplasm of renal adipocytes was strongly immunoreactive with the antisera 
against renal FABP type B, heart and muscle FABP, but not with the other sera (not shown). 
On human liver sections, the antiserum against kidney FABP type A reacted strongly with 
hepatocytes as anti-(human liver FABP) antiserum did. Antisera against FABP type B, heart or 
muscle FABP gave only a weak or no reaction. 
Ш 
в 
CD 
LJö**»4 
• •--eje •••*:• 
CD «С 
<&: 
:*· * 
Fig. 6 Immunoperoxida.se staining of human 
renal cortex (a) and medulla (b) using an­
tiserum against type A FABP. Proximal 
convoluted tubules (PCT) are strongly immuno­
reactive, while proximal straight tubules (PST) 
react weakly. Glomeruli (G) and other tubules, 
e.g. collecting ducts (CD) and distal straight 
tubules (DST), are negative. The bar represents 
80 μτη. 
Fig. 7 Immunoperoxidase staining of human 
renal cortex (a) and medulla (b) using an­
tiserum against human liver FABP. A similar 
distribution is obtained as for anti-(FABP type 
A) antiserum (Fig. 6). The bar represents 80 
μπι. 
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Fig. 9 Immunoperoxida.se staining of human 
renal cortex (a) and medulla (b) using antise-
rum against human heart FABP.A similar 
distribution is obtained as for anti-(FABP type 
B) antiserum (Fig. 8). The bar represents 80 
/un. 
Fig. 8 Immunoperovida.se staining of the 
human renal cortex (a) and medulla (b) using 
antiserum against FABP type B. Distal tubules 
(DT) are strongly positive, while proximal 
convoluted tubules (PCT) show a moderate 
staining. Other tubules e.g. proximal straight 
tubules (PST), collecting ducts (CD) and glome-
ruli (G), are negative. Inset: the macula densa 
(MD), a specialized region of the distal straight 
tubule, does not stain. The bar represents 80 
/im. 
DISCUSSION 
Two types of FABP, type A and type B, were found in human kidney. FABP type A 
resembles human liver FABP [10] in many, but not all, respects. It has a molecular mass of 
14.5 kDa and shows a 30 kDa dimer band similar to human and rat liver FABPs [10,39,40]. 
The dimer may be caused by apolar interactions rather than by disulphide bridges since it is still 
present when SDS/PAGE is performed under strongly reductive conditions [37]. The Kd values 
for oleic acid are of the same order for type A and liver FABP. Fluorescence with 11-dansyla-
mino undecanoic acid and the displacement of this fatty acid by various ligands are similar to 
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those of liver FABP [10]. Both, FABP from human liver and kidney (type A) had a lower 
affinity for palmitoyl-CoA than for fatty acids, similar to rat and bovine liver FABP 
[10,45,46,47]. Preparations did not contain acyl-CoA binding protein (Mr 10 kDa). 
Antisera raised against renal FABP type A and liver FABP showed a high cross-reactivity with 
both FABPs and are immunoreactive with the same cells within the kidney and liver. Antisera 
raised against the FABPs from rat kidney, however, did not react with rat liver FABP [21,22]. 
Rat kidney FABP has been reported to be identical with a2u-globulin, which is only present in 
male rat kidney [48]. We isolated both FABP types from male as well as female kidney cortex. 
The amino acid composition as well as the isoelectric point differ between FABP type 
A and liver FABP. The former contains two tryptophan residues whereas the latter does not. 
The isoelectric point of type A is more neutral than that of human liver FABP (pi 5.8) [10]. We 
therefore conclude that FABP type A might be a new kidney specific FABP type. The human 
kidney FABP type A contains, similarly to the specific rat kidney FABP type both cysteine and 
tryptophan in contrast to the liver FABP type. 
The other type of renal FABP, type B, seems to be related to human heart FABP, but 
its amino acid composition differs. The molecular mass (15.5 kDa) and the Kd for oleic acid 
are similar for human heart FABP [6] and FABP type B. The pi is 5.2, which is comparable 
with that of the FABPs from human, rat, porcine and bovine heart [6,41,49] and the heart type 
FABP of rat kidney [22]. Antisera raised against FABP type В and human heart FABP give a 
high cross-reactivity and are immunoreactive with the same cells within the kidney. Both sera 
show also reactivity with the cytoplasm of adipocytes. Human adipocytes contain a specific 
lipid-binding protein, which has a high similarity to heart FABP [20]. The presence of a heart 
type FABP in human kidney is in agreement with the observations on rat heart FABP and its 
mRNA in rat kidney [12,14,22,38]. No data, however, are available on the ligand properties of 
the heart type FABP isolated from rat kidney [22]. 
On base of the yield of the isolation procedures, cortex and medulla of human kidney 
appear to differ in the proportion of both FABP types, similar to that observed in rat kidney 
[22]. Our immunohistochemical data demonstrate this more clearly. FABP type A is located 
predominantly in the proximal-tubular system, while FABP type В is mainly found in the distal-
tubular system. The epithelial cells of the proximal convoluted tubules, may, however, contain 
both types of FABP since they are also moderately reactive with anti-(FABP type B) antiserum. 
More evidence is necessary to prove if these cells are comparable with intestinal cells, which 
contain two types of FABP and, in addition, in the ileum a FABP counterpart, gastropin 
[18,50]. This is interesting since both cell types are highly polarized absorptive cells with well-
developed brush borders. Western-blot analysis of cytosolic protein from rat glomeruli and 
tubules showed that the specific kidney FABP is predominantly located in the proximal tubule 
[51]. In human kidney-specific staining with anti-(human liver FABP) antibodies was confined 
to cortical-tubular cells [9]. 
Concerning the functional significance of the two types of FABP in different cells of 
the kidney, we can only speculate. Metabolic functions are unevenly distributed along the 
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nephron. In the proximal tubules, fatty acids serve as energy supply. These cells have a nigh 
capacity for gluconeogenesis, but a low glycolytic capacity [27]. Depending on the serum 
concentration, the excess of fatty acids is incorporated in triacylglycerols [26,28]. In the distal 
part of the nephron triacylglycerol synthesis is low, gluconeogenesis is absent, but the capacity 
of glycolytic enzymes is much higher. In proximal tubules both mitochondrial and peroxisomal 
ß-oxidaüon of fatty acids take place, whereas in the distal tubules only mitochondrial oxidation 
occurs [26,32,53]. Proximal and distal tubules also differ in re-absorption and excretion 
processes [30]. In proximal tubules, a large variety of substrates are reabsorbed; in distal 
tubules they are predominantly electrolytes. In this respect the differences in ligand specificity 
of the FABP types may be important. The FABP type A may similarly to liver FABP, act as a 
rather general carrier for hydrophobic compounds, whereas the В type is specific for fatty acid 
transport. Thus, the regional distribution of the different types of renal FABP may be related to 
differences in fatty acid metabolism and/or in resorption or excretion processes. 
In conclusion, we isolated two FABP types from human renal cortex with different 
characteristics and distribution. FABP type В seems related to, and shows identity with heart 
FABP. FABP type A resembles liver FABP in many respects. The differences in isoelectric 
point and amino acid composition, however, indicate that it might be a kidney-specific FABP 
type. Definitive evidence about the structure of both FABPs has to await analysis of their amino 
acid and/or cDNA sequence. 
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Molecular identification of the liver- and heart-type FABPs in human and rat kidney 
SUMMARY 
The cDNAs of two types of fatty acid-binding protein (FABP) present in human kidney, 
previously described as types A and B, were isolated using reverse transcriptase-PCR (RT-PCR) 
with human kidney mRNA and various sets of primers. The cDNA fragments were cloned and 
sequenced. Renal FABP type A and В cDNA appeared to be completely identical with human 
liver- and heart-type FABP cDNA, respectively. 
In the second part of this study we demonstrated the presence of liver type FABP in rat 
kidney by chromatography, e.l.i.s.a. and immunocytcchemistry. The ratio and cellular 
distribution of the two FABP types varies markedly in human and rat kidney. Using RT-PCR 
we were also able to prepare and identify liver and heart type FABP cDNAs with mRNA from 
both male and female rat kidney. 
INTRODUCTION 
In mammalian cells, fatty acids are important molecules for energy delivery and for 
synthesis of membrane lipids and lipid mediators. Fatty acids are metabolized in mitochondria, 
peroxisomes and on the endoplasmic reticulum. The transport of fatty acids from the plasma 
membrane to these cellular organelles is believed to be performed by fatty acid-binding proteins 
(FABPs) [1-3]. On the basis of their primary structure at least five FABPs, with sequence 
similarities of 25-65%, have been identified [3]. These FABPs have been named, liver, heart, 
intestinal, adipocyte and myelin FABP, after the tissue from which they were initially isolated. 
The existence of different FABP types suggests a type-specific function. The presence of more 
than one FABP type in a tissue e.g. intestine [4], stomach [5] and kidney [6,7] supports this 
hypothesis. Since the first isolation of an FABP cDNA, the rat liver FABP cDNA [8], cDNAs 
of all five FABP types have been obtained [9-16]. 
In rat kidney two FABP types have been demonstrated. One was identified as heart type 
FABP, based on biochemical and immunological characterization [8,17,18] and mRNA 
detection [11,19]. The second type was biochemically and immunologically different from heart-
or liver-type FABP and was named renal-specific FABP [6,18,20]. Amino acid sequencing, 
however, demonstrated that this renal-type FABP was identical with «2U-globulin [18,21]. The 
latter protein is a secretory protein of the liver and undergoes endocytotic uptake into the 
proximal tubules [22]. The a2U-globulin molecule is structurally not a FABP but is more closely 
related to the lipocalins as lactoglobulin and serum retinol-binding protein [23,24]. Recently we 
isolated two FABP types from human kidney; one (type A) showed similarity with human liver 
FABP and the other (type B) with human heart FABP [7]. However, cDNA analysis has yet to 
prove the exact identity of both human kidney FABPs. 
In the present study we describe the preparation and identification of the two human 
renal FABP cDNA types by reverse transcriptase-PCR (RT-PCR). We also applied this PCR-
technique to investigate the FABP types of rat kidney, since we obtained evidence indicating the 
presence of liver type FABP in this tissue. 
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MATERIALS AND METHODS 
Materials 
Moloney Murine Leukemia virus [MMuLV] RNase H reverse transcriptase was obtained 
from Bethesda Research Laboratories, Life Technologies, Gaithersburg, MD, USA; recom-
binant Taq DNA polymerase Amplitaq from Perkin-Elmer Cetus, Norwalk, CT, USA; Sequena-
se version 2.0 from United States Biochemical, Cleveland, OH, USA; synthetic oligonucleotide 
primers from Pharmacia, Uppsala, Sweden; wheat germ extract, L-[35S]methionine, [a-35S]-
dATP [15 mCi/ml], [a-32P]-dATP [10 mCi/ml] from Amersham Int, Little Chalfont, Bucks., 
U.K.; SP6-RNA polymerase, RNasin and pGEM-5 Zf[+] from Promega Corporation, 
Madison, NY, USA; peroxidase-conjugated goat anti-(rabbit IgG) from Tago, Burlingama, CA, 
USA; rabbit peroxidase anti-peroxidase couples were from Dakopatts, Glostrup, Denmark; goat 
anti-(Tamm-Horsfall glycoprotein) from Cappel, West Chester, PA, USA. 
Human kidney tissue was obtained after nephrectomy. Rat kidneys were from 12-week-
old Wistar rats. 
Methods 
RNA isolation and blot hybridization 
Total RNA was extracted with LiCl/urea by a modification of the procedure of Auffray 
et al. [25]. Kidney tissue (1-2 g) was homogenized in a mixture of 3 M-LiCl/6 M-urea/20 mM-
sodium acetate (pH 5.2)/heparin (2 mg/ml) and left overnight at 0°C. The RNA precipitate was 
pelleted by centrifugation for 15 min at 16,000 g and washed once with 4 M-LiCl/8 M-urea. 
After centrifugation for 15 min at 16,000 g the pellet was dissolved in 50 mM-sodium acetate 
(pH 5.2)/0.2 % SDS/2 mM-EDTA and extracted successively with phenol, phenol/chloroform 
and chloroform. Subsequently the RNA was precipitated with ethanol and stored at - 20°C. 
Poly-(A)+-RNA was selected on oligo(dT)-cellulose [26]. 
For Northern blot analysis, RNA was electrophoresed on 1% agarose gels in the 
presence of formaldehyde. Prior to electrophoresis, ethidium bromide was added to the RNA 
samples in order to allow visualization of the rRNAs in the gel. In this way, it was ascertained 
that the amounts of RNA in the different lanes were approximately the same. Following 
electrophoresis the RNA was transferred to nitrocellulose filters [26]. DNA probes were 
labelled by the random priming method [27]. The RNA blot was hybridized at 37°C in 0.5 M-
sodium phosphate as described by Church & Gilbert[28]. The blots were finally washed in 0.05 
M-sodium phosphate at 65°C, dried and subjected to autoradiography at -70°C using intensi-
fying screens. 
RT-PCR-procedure 
Primers derived from the heart and liver FABP cDNA sequence were designed so as to 
amplify the coding region. The primers used are given in Table 1. 
-88-
Molecular identification of the liver- and heart-type FABPs in human and rat kidney 
Table 1. Frimas used in RT-PCR 
Primer Sequence 
1. Human heart FABP (forward) 
2. Human heart FABP (reverse) 
3. Rat heart FABP (forward) 
4. Rat heart FABP (reverse) 
5. Human liver FABP (forward) 
6. Human liver FABP (forward) 
7. Human liver FABP (reverse) 
8. Human liver FABP (reverse) 
9. Rat liver FABP (forward) 
10. Rat liver FABP (reverse) 
GCCAGCATCACCATGGTCGACGCTTTC 
ATCACCAGTGGATCCAGGTCATGCCTC 
TCTCATTGCACCATGGCGGACGCCTTT 
AGTGACGGCCGATCCAGGTCACGCCTCCTT 
AAGGGGGTGTCGGAAATCGTG 
ATTGCCCATATGAGTTTCTCCGGCAAGTAC 
GCGCTGCAGGGATCCGTCGАСГЛ „ 
AATGGGATCCTGTTTAAATTCTCTTGCTGATTCT 
GCCCATATGAACTTCTCCGGCAAGTAC 
CTGGGATCCCTAAATTCTCTTGCTGACTCTCTT 
First strand synthesis reactions were carried out with 50 μg total RNA or 2 μg poly-A+ 
RNA in a total volume of 20 μΐ containing 50 mM-Tris/HCl (pH 8.3)/75 mM-KCl/3 mM-
MgCl2/125 μΜ-αΝΤΡ$/40 units RNasin/0.5 μg primer and 400 units M-MuLV reverse 
transcriptase. A reverse primer was added to the RNA sample, heated for 10 min. at 70eC and 
quenched on ice. The reverse transcription reaction was carried out for 1 hr at 37 е С and 30 min 
at 45°C. 
The PCR amplification reactions were carried out in a total volume of 100 μΐ containing 2 μΐ 
of the reverse transcription reaction, 0.5 μg of the reverse and forward primer, 10 mM-
Tris/HCl (pH 8.3)/50 тМ-КСУІ.5 тМ-MgCyO.OOl % gelatin/250 μΜ-dNTPs and 2.5 units 
Amplitaq. The mixture was overlaid with mineral oil. After 8 min denaturation at 94°C, 40 
cycles of amplification were carried out by using a step program (94"C, 1 min; 50CC, 1.5 min; 
72°C, 1.5 min) followed by a 2 min final extension at 72°C. 
Cloning and sequencing of the cDNAs 
RT-PCR products were digested with restriction enzymes which recognize specific sites in 
the primers. The cDNA fragments were cloned in M13mpl8 and PGEM 5Zf(+). Plasmids with 
cDNA inserts were single and double strand sequenced in both directions with Sequenase, using 
the supplier's recommendations. 
In vitro transcription/translation assay 
The cDNA insert was ligated in PGEM 5Zf(+), as described above, grown in JM101 and 
afterwards linearized with BamHI. RNA transcripts were synthesized in vitro from the BamHI 
digested clone in the presence of SP6 RNA polymerase and the dinucleotide primer G-
(5')ppp(5')G [29]. In vitro translation in a nuclease-treated wheat germ extract was performed 
for 60 min at 25 "C in 30 μΐ of a reaction mixture, containing 1 mM-amino acids/1 mM-
["S]methionine and 0.65 M-KC1. 
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Immuiioprecipitation of newly synthesized FABP 
200 μΐ Protein-A Sepharose CL-4B in phosphate-buffered saline (10%, v/v) was incubated 
with 75 μΐ anti-(human liver FABP) serum for 2 h at room temperature under rotation. Non-
specifically bound proteins were removed by washing the gel suspension 4 times with 500 μ\ 
buffer A (500 mM-NaCl/10 mM-Tris/HCl (pH 7.4)/ 0.05% Nonidet P40). Subsequently, the 
gel suspension was incubated with 25 μ\ of the translation assay mix in 500 μΐ 150 mM-
NaCl/50 mM-Tris/HCl (pH 7.4)/0.05% Nonidet P40 for 3 h at 4°C, under rotation. Finally, 
the gel suspension was washed 4 times with buffer A and 50 μ\ of SDS gel electrophoresis 
loading buffer was added. SDS gel electrophoresis was performed on a 15% Polyacrylamide 
gel. 1 2 3 4 5 6 
Immunocytochemistry 
Kidney tissue from male and female Wistar 
rats (200 g) were fixed for 2 h in 2% periodate-
lysine-paraformaldehyde and embedded in paraf­
fin. Deparaffinized sections were treated with 1% 
(v/v) H 20 2 in methanol in order to remove intrin­
sic peroxidase activity. After rehydration and 
treatment with 20% (v/v) normal goat serum in 
Tris-buffered physiological saline for 30 min, 
sections were incubated with rabbit antisera raised 
against rat liver FABP or rat heart FABP, optimal 
dilutions being 1:25 - 1:50. Immunopositive sites 
were detected by subsequent incubations with goat 
anti-(rabbit IgG-peroxidase) and rabbit peroxidase 
anti-peroxidase complex. Peroxidase activity was 
visualized using diaminobenzidine as substrate. 
Sections were counterstained for 1 min with Har­
ris's heamatoxylin and embedded in glycerol/gela-
tine mounting medium. Preimmune sera and sera 
raised against unrelated antigens were used as 
controls. In addition, immune sera were absorbed 
(18 h, 20°C) with both FABPs, the optimal a-
mount being 25 μg of FABP/100 μΐ diluted serum. Antiserum against Tamm-Horsfall glycopro­
tein was used for the localization of distal tubules. 
Other procedures 
Preparation of rat kidney cytosol, Sephacryl S-200 gel filtration and DEAE-Sepharose 
chromatography were performed as described for human kidney [7]. The FABP contents of 
kidney cytosol were determined in e.l.i.s.a. as described [17]. 
τ» s 28! 
18 S - • «-»8 
• 
Fig. 1 Northern blot analysis of human renal 
FABP type A and В transcripts. Total RNA 
(50 /tg) (lanes 1, 3, 5) and poly-(A)+ RNA (20 
/tg) (lanes 2, 4, 6) from human renal tissue 
was fractionated by electrophoresis on 1% 
agarose-formaldehyde denaturing gels, transfer­
red to nitrocellulose and hybridized with 
random-primed labelled human liver FABP 
cDNA (lanes 1 and 2), human heart FABP 
cDNA (lanes 3 and 4) or human actin cDNA 
(lanes 5 and 6). 
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Rat liver and heart FABPs were isolated as described [30,31] and antisera were raised in rabbits 
[17,32]. cDNA probes of human heart (muscle) FABP and of human liver FABP were prepared 
as described previously [15] or during this study respectively. 
RESULTS AND DISCISSION 
Identification of two FABP transcripts in human kidney. 
Northern blot analysis of total RNA (50 /tg) and poly(A)+-mRNA (20 μg) from human 
kidney showed the presence of two transcripts using human liver and heart FABP cDNA as 
probe. The transcripts were 0.5 and 0.7 kb in length for the liver and heart types, respectively 
(Fig. 1). From the autoradiogram it can be concluded that the mRNA concentration of both 
FABP types is rather low in kidney, since 50 μg of total RNA only gave a faint band at the 
position of the FABP transcripts. 
Isolation of cDNAs of two FABP types of human kidney 
After the identification of two trans­
cripts, we attempted the isolation of both 
cDNAs, by RT-PCR using primers based 
on the cDNA sequences of human liver-
and heart-type FABP cDNAs. The struc­
tural and immunological data concerning 
the FABP type A from human kidney 
revealed many similarities but also some 
differences compared with human liver 
FABP [7]. The cDNA sequence was 
required to establish the structure. For the 
isolation of the FABP type A cDNA the 
RACE (rapid amplification of cDNA 
ends) protocol described by Frohman et 
al. [33] was followed. The reverse tran­
scription primer (primer 7) was an oligo­
nucleotide with 17 dT residues and an 
adaptor sequence containing three restric­
tion enzyme recognition sites. The for­
ward primer (primer 5) was derived from 
human liver FABP cDNA (nucleotides 
106-126) and is located in a highly conse­
rved region [10]. The DNA fragment 
isolated after RT-PCR was cloned in 
M13mpl8 and sequenced. This 350 bp 
Huernn Liver ГАВР cOHA 
H u » n Heart FABP cONA 
Type A/ Type B/ 
Liver Heart 
3 2 1 1 2 3 
0.39 kb 
43 kb 
Fig. 2 Reverse Transcriptase PCR isolation of human 
kidney FABP type A and В cDNA. Poly-(A)' RNA (2 
/tg) was reverse transcribed with З'-primers of human 
liver or heart FABP cDNA, amplified in PCR using 5'-
and З'-prímers and subjected to Polyacrylamide mini-gel 
electrophoresis. Lane 1 shows the ФХ174 χ Hae III 
marker and lane 2 and 3 contain the RT-PCR fragment 
prepared with 1 and 2 μg of poly(A+) RNA respectively. 
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fragment appeared to be completely identical with human liver FABP cDNA. Subsequently RT-
PCR was applied with a reverse and forward primer (primers 8 and 6) encoding the 3'- and 5'-
ends respectively of the human liver FABP cDNA coding region, respectively (Fig. 2). The 403 
bp fragment was isolated and cloned in pGEM-5 Zf(+) and sequenced. The sequence appeared 
to be identical with the liver FABP cDNA sequence described by Chan et al. [9]. 
Data on the protein have indicated that the FABP type В from human kidney is identical 
with the heart type FABP [7]. To establish this, we carried out a reverse transcription with 
primer 2, which encoded the З'-end of the coding region of the heart FABP cDNA. The reverse 
transcription mixture was amplified with the same reverse primer and primer 1, encoding the 
5'-end of the heart FABP cDNA coding region (Fig. 2). A DNA fragment of 432 bp was 
isolated, digested with restriction enzymes, which recognize sites present in the primers, and 
subcloned in M13mpl8. The sequence appeared to be fully identical with the heart- or muscle-
type FABP cDNA sequence published by Peeters et al. [15]. 
Both total RNA and mRNA from both males and females could be used for the isolation of 
the renal FABP cDNAs. The FABP mRNA concentrations appeared to be similar when RT-
PCR was applied with equal amounts of RNA of male or female kidney. 
In vitro transcription/translation of human renal type A FABP cDNA 
The identity of the cDNA fragment 
isolated with human liver FABP cDNA 
primers was confirmed by an in vitro 
transcription/translation assay followed by 
immunoprecipitation. The pGEM-5 Zf-
(+), containing the human renal FABP 
type A cDNA, was linearized with Bam 
HI, which is located 5 bp downstream of 
the stop codon. After linearization, the 
pGEM-5Zf(+)-FABP type A vector was 
used in an in vitro transcription assay. 
The RNA product yielded in an in vitro 
translation assay the 14.3 kDa product 
(Fig. 3). The smaller products are due to 
a start of translation at ATG codons lo­
cated further downstream. These ATG 
codons correspond with amino acid posi­
tions 19 and 74 [9,10]. Im­
munoprecipitation of the translation pro­
duct with antibodies against human liver FABP gave the same result (Fig. 3). 
Renal FABP type В cDNA was directly cloned in the expression vector pET8c. After expressi­
on in Escerichia coli the protein was identical with heart (muscle) FABP on the basis of various 
kDa 
200-
9 2 -
69-
46-
30-
14 
'^Щщ^' 
Fig. 3. SDS/PAGE and subsequent autoradiography of 
the products obtained after in vitro transcrip­
tion/translation of human liver FABP cDNA. pGEM 5 
Zf(+)-HL-FABP was Bam HI digested, transcribed with 
SP6-RNA polymerase and translated with wheat germ 
extract. The translation product was immunoprecipitated 
with antibodies against human liver FABP. Lane 1, 
molecular-mass markers; lane 2, total translation mixture 
(4 μΐ); lane 3, an equal amount of total translation mix­
ture after immunoprecipitation (15 μΐ). 
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biochemical and immunological tests (results not shown) [IS]. 
Identification of the FABP types and FABP RNA transcripts in rat kidney 
As already mentioned, male rat kidney contains the heart-type FABP and ot2UglobuIin, 
female kidney only contains the heart-type FABP [6,17,18,20]. The presence of liver FABP in 
rat kidney has never been demonstrated. We obtained evidence that the liver-type FABP is also 
present in rat kidney, as in human kidney. The low-molecular-mass fraction obtained by 
Sephacryl gel filtration of rat kidney cytosol revealed on DEAE-Sepharose chromatography two 
fractions with fatty acid-binding activity. The first fraction was not bound, like the liver-type 
FABP, whereas the second fraction was eluted from the column during the gradient, like the 
heart-type FABP. The first peak bound about 10% of the [14C]oleic acid bound by the second 
peak. 
E.l.i.s.a. showed low amounts of liver-type FABP in rat kidney cytosol (Table 2). The 
concentrations are much lower than those of the heart-type FABP and the ratio of liver- and 
heart-type FABP differs considerably from that in man. 
Immunocytochemistry on rat
 T a b ie 2 FABP content of kidney. Values (detennmed by e.l.i.s.a.) 
kidney sections also established are means±S.D. for five or six individuals. 
the presence of liver-type FABP. 
Using anti-(liver FABP) anti-se- Content (пдюі/mg of cylosolic protein) 
rum, proximal as well as distal Liver-type Heart-type 
tubules reacted positively, the ^ ^
 0.078±o.ooo5 o.79±o.io 
latter being more immunoreactive Rat female 0.051 ±o.ooo7 o.67±o.04 
(Fig 4a). In addition, the COllec- Human male 0.63 ±0.190 0.3B±0.26 
ting tubules and the papillary 
epithelium are also immunoreactive but glomeruli did not stain. Preabsorption of immune serum 
with liver FABP resulted in a complete abolition of staining (Fig. 4b). No difference could be 
observed between male and female rat kidneys. Distal tubules were the only structures strongly 
positive when stained with anti-(heart FABP) antiserum (Fig 5): proximal tubules were not 
distinctively positive and glomeruli were negative. Preabsorption of immune serum with liver 
FABP had no effect. Male and female rat kidneys reacted similarly. The cellular distribution of 
the heart type is similar in rat kidney to that previously found in human kidney [7]. The liver-
type FABP, however, is restricted to the proximal convoluted and straight tubules in human 
kidney [7]. Like the kidney, the rat stomach also shows the presence of both heart- and liver-
type FABP with a specific cellular distribution [5]. 
With RT-PCR we also investigated the presence of the transcripts of liver- and heart-type 
FABP in rat kidney. Poly(A)+ RNA was isolated and reverse-transcribed with a reverse pnmer 
(primer 4 or 10), which partially overlapped the З'-end of the coding region of the rat heart- or 
liver-type FABP cDNA respectively. PCR amplification was accomplished by using the reverse 
primer and the appropriate forward pnmer (primer 3 or 9), which partially overlapped the 5'-
end of the coding region of the FABP cDNA. Subsequently the RT-PCR products were sub-
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G 
Fig. 5. Immiinoperoxidase staining of rat renal 
tissue using antiserum against rat heart FABP. 
Distal tubules (DT) are strongly immunopositive. PT, 
proximal tubules; G, glomeruli. The bar represents 
100 ^m. 
jected to Polyacrylamide mini-gel electropho-
resis and electroblotting to Hybond N+. The 
DNA blots were probed with human heart and 
liver FABP cDNA. As a control RT-PCR was 
also applied on rat heart and liver mRNAs with 
both rat liver and heart FABP type cDNA pri-
mers. 
The rat heart FABP cDNA could be demon-
strated on the blot with the human muscle FABP 
cDNA probe, to be present in rat heart and kid-
ney mRNA, but not in rat liver mRNA (Fig. 6). 
The blot hybridized with human liver FABP 
cDNA showed the presence of liver FABP 
mRNA in both liver and kidney mRNA, but not 
in heart mRNA (Fig. 6). Bands at higher molecular masses may be due to reverse transcription 
of pre-mRNAs. Based on the RT-PCR and hybridization results, the content of the mRNAs of 
the liver and heart FABP types do not differ markedly in kidneys of male and female rats. 
Studies on transgenic animals expressing reporter genes under the control of the liver FABP 
gene promoter have revealed that expression of liver type FABP is possible in mouse kidney 
[34,35]. The heart-type FABP mRNA has been demonstrated in rat kidney by others [11,19] Its 
content shows marked variations from fetal to adult life [19]. Concerning the physiological 
relevance of the two FABP types in kidney we can only speculate. The liver-type FABP binds 
various ligands and may be involved in the renal excretion of exogenous and endogenous 
metabolites. The liver-type FABP also binds some drugs [2,3] and may in this way prevent 
Fig. 4. Immiinoperoxidase staining of rat renal 
tissue using antiserum against rat liver FABP 
before (a) and after (b) preabsorption with rat 
liver FABP. Proximal tubules (PT) and distal tubules 
(DT) are positive, the latter being more immunoreac-
tive. Glomeruli (G) and blood vessels (BV) are negati-
ve. The bar represents 100 firn. 
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nephrotoxicity. The heart-type FABP only binds 
fatty acids and seems to be involved in lipid 
metabolism. 
In conclusion, we have isolated the cDNAs 
of both human renal FABP types by RT-PCR. 
Human renal FABP type A and В cDNA ap­
peared to be fully identical with human liver 
and heart FABP cDNA respectively. The cDNA 
analysis gave the conclusive evidence for the 
presence of liver and heart type FABP in human 
kidney, in agreement with most or all of the 
physiochemical and immunochemical data on the 
protein [7]. Furthermore, we also demonstrated 
the presence of liver and heart FABP types and 
their mRNAs in kidneys from both male and 
female rats. The significance of the occurrence 
in kidney of two FABP types with different 
ligand specificities and cellular distributions 
requires further investigation. The availability of 
cDNAs and FABP preparations of both types 
from human and rat kidney will allow future 
work in this area. 
pn>t*;d with Ьмми п а я к f \BP ι DNA 
I 2 J 1 S 6 7 « « 
Fig. 6 Identification of the FABP RNA transcripts 
in rat tissues. Poly(A)+ RNA (2 /ig) from rat tissues 
including male kidney (lanes 2, 6), female kidney 
(lanes 3, 7), heart (lanes 4, 8) and liver (lanes 5, 9) 
were reverse transcribed with З'-pnmers of rat liver-
type FABP cDNA (lane 2-5) and rat heart-type FABP 
cDNA (lanes 6-9), respectively. The reverse tran­
scription mixture was amplified in PCR and subjected 
to Polyacrylamide mini-gel electrophoresis, electro-
blotted to Hybond N* and probed with human liver 
and heart FABP cDNA, respectively. Lane 1 shows 
the ΦΧ χ HaelH marker. 
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Expression of human L-FABP in E. coli and comparative binding studies 
SUMMARY 
Human liver fatty acid-binding protein (L-FABP) has been efficiently expressed in 
Escherichia coli. The cDNA encoding human liver FABP was under control of the T7 RNA 
polymerase promoter in the expression vector pET-3b. Expression required overnight induction 
with isopropyl β-D-thiogalactopyranoside in the presence of the bacterial RNA polymerase 
inhibitor, rifampicin. The protein could be punned by (N114)2504 fractionation, anion-exchange 
and gel filtration chromatography and was recognized by anti-(human L-FABP) antiserum. 
The binding characteristics of delipidated recombinant human L-FABP and muscle FABP 
(M-FABP) for fatty acids of different chain-length and saturation grade and for various hydro­
phobic ligands were determined by radiochemical analysis and for L-FABP also by fluorescen­
ce. The apparent binding affinity of the ligands was calculated by using displacement curves of 
oleic acid and dansylamino-undecanoic acid (DAUDA). L-FABP showed a preference for 
binding of long-chain saturated and unsaturated fatty acids up to C^, whereas the M-FABP has 
a preference for unsaturated fatty acids, especially with 18 С atoms. L-FABP also binds 
palmitoyl derivatives and many other hydrophobic ligands, generally however with a lower 
affinity than fatty acids. M-FABP binds besides fatty acids only oestradiol and testosterone with 
high affinity. Fatty acids with fluorescent reporter groups are also more tightly bound by L-
FABP. A direct assay and displacement studies of oleic acid gave the same K4 value of 
DAUDA for L-FABP. Fluorescence enhancement and displacement studies indicate that the 
binding of fluorescent fatty acids is determined by both the fluorescent reporter group and the 
carbon chain. 
INTRODUCTION 
All living cells utilize fatty acids as source of energy and/or for synthesis of membrane 
lipids and lipid mediators. Fatty acids may modulate various cellular processes by their 
interaction with enzymes, membranes, ion channels, receptors or genes. Utilization by cellular 
organelles requires facilitation of their solubility and transport, in which fatty acid-binding 
proteins (FABPs) are supposed to be involved. This group of low-molecular mass proteins with 
high sequence similarity is known to consist of seven different types at the moment [1-5]. 
Recently we isolated two types of FABPs from human kidney, which showed similar 
characteristics as L-FABP and M-FABP on base of molecular mass, isoelectric point, binding 
affinity for oleic acid, immunological crossreactivity and amino acid content [6]. Isolation of 
both cDNAs for these FABPs by reverse transcriptase PCR on kidney mRNA established the 
presence of L-FABP and M-FABP in human kidney [7]. The two types are differently distribu­
ted, L-FABP is present in the proximal tubules whereas M-FABP is predominantly present in 
the distal tubules [6]. 
M-FABP was expressed in E.coli [8], crystallized and its three-dimensional structure 
determined [9]. The structure of human M-FABP was found to be similar to that of other 
members of the FABP family; containing ten anti-parallel β-strands arranged in two orthogonal 
ß-sheets and two short α-helices located between the first and second B-strand [9]. In spite of 
-qp-
Chapter 5 
their high structural similarity, intestinal, adipocyte, myelin and muscle FABP types bind their 
fatty acid differently. The muscle and myelin FABP types bind the fatty acid in an U-shape 
[9,10] whereas the intestinal and adipocyte FABP types bind the fatty acid in an more extended 
conformation [11-14]. Amino acids involved with fatty acid binding are different between 
muscle and intestinal FABP [15]. 
The L-FABP, the other type present in human kidney, has not been expressed in E. coli 
until now. However the cDNA encoding rat L-FABP was expressed in E. coli and amounts of 
recombinant protein could be obtained [16,17]. Attempts to analyze the three-dimensional 
structure of the L-FABP failed thusfar [18]. Analysis of the binding characteristics revealed that 
the fluorescent probe DAUDA is bound by rat L-FABP. Binding is accompanied by a shift in 
wavelength of the fluorescence emission maximum and a large fluorescence enhancement [19]. 
The amount of L-FABP in various tissues could be calculated from the fluorescence signal [20]. 
Displacement of DAUDA could be determined for various ligands which revealed information 
about the binding characteristics and binding pocket of L-FABP [21]. Binding studies with 
fluorescent anthroyloxy-labeled fatty acids suggested that the binding pocket of L-FABP is more 
hydrophobic compared to M-FABP and adipocyte FABP [22-24]. However investigations with 
the fluorescent trinitrophenyladenosine-triphosphate [25] suggest that the fluorescent group is 
involved in binding rather than the fatty acid. 
The presence of two FABP types in human kidney [6,7] suggests a specific function and 
difference in binding characteristics of both proteins. Several independent binding studies have 
been carried out with L-FABP or M-FABP with fatty acids and some other hydrophobic 
compounds [for refs see 5 and 26], but simultaneous comparative studies of binding charcteris-
tics of both FABP types lack. Moreover, most studies have been carried out without delipi-
dation of the protein and with isolated tissue preparations, which may contain contaminating 
other lipid-binding proteins. Therefore we expressed for the first time the human L-FABP in E. 
coli and did extensive studies with delipidated recombinant L-FABP and M-FABP to analyse 
their binding affinities for various types of fatty acids and a large series of hydrophobic ligands. 
We used the radiochemical Lipidex procedure in combination with an equivalent competition 
method based on a newly developed procedure for analysis of ligand-protein binding data [27]. 
We also compared the interaction of various fluorescent fatty acids with both FABP types and 
determined the binding affinity of DAUDA for L-FABP by an analogous method [28]. For 
comparison with the radiochemical data we studied also the displacement of DAUDA from L-
FABP by various fatty acids and hydrophobic ligands and calculated the apparent K, values for 
these ligands, using a newly described mathematical approach. 
MATERIALS AND METHODS 
Materials 
Oligonucleotide primers and the FPLC Hiload Q Sepharose column were obtained from 
Pharmacia Biotechnologies Int., Uppsala, Sweden; rifampicin and saturated and unsaturated 
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fatty acids from Sigma Chemical Co., St. Louis, MO., U.S.A.; IPTG from Life Technologies 
Inc., Gaithersburg, MD, U.S.A.; Lipidex 1000 from Canberra-Packard, Groningen, The 
Netherlands; 11-dansylamino-undecanoic acid, 2-(9-anthroyloxy)palmitic acid, 12-(9-anthroyl-
oxy)oleic acid and 16-(9-anthroyloxy)palmitic acid were from Molecular Probes, Junction city, 
OR., U.S.A. and [l-C,4]oleic acid from Amersham International, Little Chalford, U.K.. All 
other reagents were of analytical grade. 
Methods 
Expression and purification of recombinant human liver FABP. 
Cloning of human liver FABP cDNA in expression vector pET-3b. 
Two single stranded complementary oligonucleotides homologous to the first 10 amino 
acid residues of human L-FABP with a Ndel-site at the start codon were synthesized: 5'-TAT-
GAGTTTCTCCGGCAAGTACCAACTGCA-3' and 3'-ACTCAAAGAGGCCGTTCATGGTTG-
5'. The oligonucleotides were purified by fast liquid chromatography. The human L-FABP 
cDNA isolated by us with reverse transcriptase PCR [7] was digested with PstI and BamHI. 
The single stranded oligonucleotides were hybridized and ligated in a 10-fold molar excess with 
the PstI/ВатШ partial human L-FABP cDNA fragment to create a Ndel site at the L-FABP 
cDNA. The nucleotide sequence of the FABP cDNA after primer ligation was verified using the 
dideoxy chain termination technique. The Ndel/BamHI L-FABP cDNA was ligated in the 
similar sites of the expression vector pET-3b (Fig. 1). 
Expression of L-FABP in E. coli 
The pET-3b/L-FABP construct was used to transform E. coli K12 strain BL21(DE3) 
pLys S [29]. Transformed cells were grown overnight on 2xTY plates containing 100 μg/ml 
ampicillin and 35 μg/ml chloramphenicol (2xTY/AC) [30]. A 80 ml overnight culture was 
grown from a freshly streaked out plate and 5 ml was used to inoculate 1.5 1 2xTY/AC in a 2 1 
flask. These were incubated at 37°C until the cell density reached an A «^, of 0.8-1.0. Expressi­
on by T7-RNA polymerase was induced by addition of 0.5 mM-IPTG and incubation for 45 
min at 37eC. Subsequently 175 μg/ml rifampicin was added to the culture and incubation 
continued for 16 h at 37°C. To improve expression, other media, ТВ and SBLH [30] were also 
evaluated. 
Purification of recombinant L-FABP 
The cells were harvested by centrifugation for 20 min at 5,000 g. The pellets were 
washed once with PBS, stored at -70°C to facilitate cell lysis and resuspended in 10 mM-
Tris/HCl (pH 8.5)/0.01 % sodium azide. The cells were passed through a French press cell and 
centrifuged for 30 min at 30,000 g. The supernatant was saturated with ammonium sulphate in 
two steps, the first step to 50% and the second to 70% ammonium sulphate. After each 
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saturation step the mixture was centrifugea for 30 min at 30,000 g and the ultimate supernatant 
was dialyzed for 48 h against 10 mM-Tris/HCl (pH 8.5)/0.01% sodium azide. The dialysate 
was bound to a FPLC ffiload Q-Sepharose column and eluted with a gradient of 10 to 100 mM-
Tris/HCl (pH 8.5). Recombinant L-FABP was purified from DNA traces by gel filtration on 
Sephadex G-50 (1.5cm χ 120cm). Immediately before binding assays, FABP preparations were 
delipidated with the Lipidex procedure [31]. 
Fatty acid-binding assays with oleic acid 
All binding assays were carried out in a volume of 0.5 ml 10 mM-Tris/HCl (pH 8.0)/ 
1% ethanol at 37 "C. K,, values for the binding of recombinant human L-FABP and M-FABP to 
[l-14C]oleic acid were determined with the Lipidex procedure and Scatchard analysis [31]. The 
K, values for binding of other fatty acids and hydrophobic ligands to FABP were determined by 
displacement analysis according to the method of van Zoelen [27]. Displacement curves were 
made with the Lipidex-procedure by addition of 1 дМ-[1-І4С]о1еіс acid in the presence of un­
labeled oleic acid (0-10 μΜ) to 0.2 μΜ-L-FABP or 0.28 μΜ-Μ-FABP. Subsequently the 
displacement percentage of [l-14C]oleic acid by various hydrophobic ligands was analyzed by 
addition of 1 μΜ-[1-'^]ο1είΰ acid and 1 μΜ-competitor to the same amount of FABP. From 
the displacement curve the concentration of unlabeled oleic acid was read which is needed to 
obtain the same percentage of displacement as with 1 μΜ-competitor. Van Zoelen [27] showed 
that the K, value of the competitor can be calculated with the formula: 
L.-L,' Κ,-Κ, 
L,u ( l - c p m ^ / c p r r O ~ K,, 
In this equation L, is the added concentration of competitor, L," is the concentration of 
non-labeled oleic acid required to obtain the same percentage of displacement as found with L¡, 
K, the dissociation constant for the competitor and Kj the dissociation constant for oleic acid. 
Van Zoelen [27] showed that if competition is complete a correction term (1 - cpm*dded/cpmb0,nd) 
is included to account for the fact that the free ligand concentration can be significantly lower 
than the ligand concentration added. 
Fatty acid-binding assays with fluorescent ligands 
Fluorescence enhancement of various fluorescent fatty acids with recombinant L-FABP and 
M-FABP. 
All fluorescence experiments were carried out at a Shimadzu-500 fluorometer. The 
fluorescence was analyzed for 1.0 μΜ-fluorescent fatty acid in the absence or presence of 2.0 
μΜ-L-FABP or 2.8 μΜ-Μ-FABP in 1 ml 10 mM Tris/HCl (pH 8.0)/l% ethanol at 25 °C. The 
emission spectrum between 480 and 550nm for DAUDA was determined at an excitation 
wavelength of 328 nm and for DAUDA in the presence of FABP at 345 nm. Maximum 
fluorescence of the other ligands with or without protein was obtained by scanning between 380 
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and 550 nm at the excitation wavelength indicated. 
Displacement studies with DAUDA 
All experiments were carried out in a volume of 1.0 ml 10 mM Tris/HCl (pH 8.0)/l% ethanol 
at 25 e C. Displacement studies with DAUDA were performed by addition of 1 μΜ-DAUDA 
with or without 1 μΜ-competitor to 0.2 μΜ-L-FABP. Emission spectra (480nm-550nm) were 
scanned at an excitation wavelength of 345 nm because the various competitors cause a different 
wavelength shift of the fluorescence emission maximum. The displacement percentage could be 
calculated with the equation: 
In this equation F¡ is the fluorescence of DAUDA in the presence of FABP and 
competitor at the wavelength of maximal emission, F0 is the fluorescence of DAUDA without 
protein at 545 nm and F,,^ is the fluorescence of DAUDA in the presence of FABP at 505 nm. 
To determine the Kd for DAUDA saturation curves were made by analysis of the 
fluorescence of 0.2 μΜ L-FABP with increasing concentrations of DAUDA (0-5 μΜ). Values 
were corrected for the fluorescence of the DAUDA solution itself. The saturation curves were 
converted mathematically into a displacement type of curve as described earlier [28], using 1 
μΜ DAUDA as the constant concentration of labelled ligand. This displacement curve was 
linearized as described by Van Zoelen et al. [28], and the K„ for DAUDA was obtained from 
the values of slope and intercept. In addition the parameter Z„ was determined from this 
linearity, which equals the fraction of DAUDA which becomes bound after incubation of 1 μΜ 
DAUDA with FABP. 
The K¡ values of competing ligands were subsequently determined by an equivalent 
competition principle, by reformulating equation [10C] of reference [27] according to 
L, - L.' Κ,-Κ, 
L." (1-Ζ..Φ) = K, 
In this equation L¡ is the added concentration of competitor, L,u is the concentration of 
DAUDA required to get the same percentage of displacement as found with L¡ in the mathe-
matically converted DAUDA saturation curve, K¡ the dissociation constant for the competitor 
and Kj the dissociation constant for DAUDA. The value of Φ is given by the fraction of 
fluorescence intensity, remaining after addition of competitor. The above equation assumes that 
DAUDA fluorescence can be fully competed by an excess concentration of competitor. 
Other procedures 
SDS-PAGE and Western blotting were performed as earlier described [32]. The rabbit 
anti-(human L-FABP) antiserum was obtained as given in [33]. Protein was determined with the 
Lowry procedure and corrected by amino acid analysis. Recombinant human M-FABP was 
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prepared as previously described [8]. 
Ndel Bern HI 
Hum» Liver ГАВР cDNA 
1 Digest with Pelt 
2 Isolate 460 bp frig ment 
Ndel Pill 1 3 Lígate 30 bp Ndel Pati dl oligo 
α 
1 
D l | » l wllh NJel. ВштШ 
Fig. 1: Strategy for the construction of the L-FABP expression vector pET-3b/L-FABP. The box represents the 
complete coding region of L-FABP cDNA. The sequence ATG of the native cDNA was changed by digestion at 
the PstI site and ligation of a 30 bp synthetic oligonucleotide containing at the 3'end a PstI sticky end and at the 
5'end a Ndel sticky end, as described in detail ш experimental procedures. The new sequence was hgated into 
pET-3b to create the pET-3b/L-FABP vector. This vector has the Shine Delgamo translation initiation signal slO 
between the unique Ndel site and the φΙΟ T7 promoter, a φΎ transcription terminator downstream of a BamHI site, 
and confers resistance to ampicillin. 
RESULTS AND DISCUSSION 
Synthesis and purification of recombinant L-FABP 
The strategy for constructing the expression vector pET-3b/L-FABP relied on modifying 
the 5' end of the L-FABP cDNA with a synthetic oligonucleotide to position an Ndel site at the 
ATG start site. This allowed the cloning of the complete coding region of the L-FABP cDNA 
downstream the T7-RNA polymerase promoter (Fig. 1). E. coli K12 strain BL21(DE3) 
transformed with pET-3b/L-FABP did not show recombinant L-FABP after 3 h and overnight 
induction with IPTG. In vitro transcription and translation of the L-FABP cDNA and im-
munoprecipitation of the in vitro translation mixture with antisera raised against L-FABP 
revealed, however, immunoreactive protein [7]. This indicates the cDNA has no out of frame 
mutations, but the expression of FABP in E. coli is undectable. A slight leakage of the lacUV5 
promoter upstream of the T7 RNA polymerase gene may cause a basal level of T7 RNA-
polymerase production and target gene transcription in uninduced cells [29]. Therefore it might 
be that in comparison to uninduced cells no L-FABP is visible in induced cells on SDS-PAGE. 
To overcome this problem we used E. coli strain K12 BL21(DE3)/pLys S for transformation 
-104-
Expression of human L-FABP in E. coli and comparative binding studies 
but got similar results. To reduce the syn­
thesis of bacterial proteins and improve L-
FABP expression rifampicin was added to 
cultures [29]. This resulted in low amounts of 
recombinant L-FABP only after overnight 
expression (Fig. 2 and 3). The use of more 
rich media like ТВ and SBLH medium, 
carbenicillin instead of ampicillin, induction 
at higher cell density, induction with 1 and 2 
mM-IPTG and growth at 30°C did not im­
prove L-FABP expression. 
The low expression might be explain­
ed by the fact that the Shine Delgarno ribo-
some binding site is not in optimal distance 
of the translational start. Studies on the ex­
pression of rat L-FABP revealed that no 
expression could be detected when the Shine 
Delgarno sequence was at 15 bp of the start 
codon. However within a distance of 6 bp of 
the start codon expression was found [16]. A 
second reason is that the L-FABP cDNA 
contains amino acid codons which are less 
preferential for the used bacterial strain [34]. 
Synthetic L-FABP cDNA prepared from 
oligonucleotide primers, using E. coli prefe­
rential codons, revealed a 20-fold higher 
expression than the isolated rat L-FABP 
cDNA [16,17]. 
For purification of the recombinant 
human L-FABP the bacterial lysate was 
precipitated with 50% and 70% ammonium 
sulphate and subsequently subjected to anion-
exchange and gel filtration chromatography 
(Fig. 2). The yield was 1-2 mg/1 culture. 
This is similar to the expression of rat L-
FABP in E. coli [16] but much lower than of 
human M-FABP [8]. The recombinant pro­
tein was recognized by an antiserum evoked 
against isolated human L-FABP (Fig. 3). 
2 3 4 5 6 kDa 
94 
68 
43 
30 
20.1 
14.4 
Fig. 2: Analysis of the expression and purification of 
recombinant L-FABP. Samples were fractionated on a 
15% SDS-PAGE and stained with Coomassie Brilliant 
Blue. Lane 1, molecular mass markers; lane 2, whole 
cell lysate of noninduced cells ( 100 ^g); lane 3, whole 
cell lysate after 3 h of induction (125 μg)·, lane 4, whole 
cell lysate after overnight induction (125 ßg); lane 5, 
supernatant after 70% saturation with ammonium sulphate 
(100 /xg); lane 6, pure L-FABP after anion exchange 
chromatography and gel filtration (15 /tg). 
kDa 
Fig. 3: Immunostained Western blot of recombinant 
L-FABP. Samples were fractionated on a 15% SDS-
PAGE and transferred to nitrocellulose. The blot was 
stained with anti-(human L-FABP) antiserum. Lane 1, 
molecular mass markers; lane 2, whole cell lysate of non 
induced cells ( 100 Mg); lane 3, whole cell lysate after 3 
h of induction (125 ¿ig); lane 4, whole cell lysate after 
overnight induction (125 μg); lane 5, supernatant after 
70% saturation with ammonium sulphate (100 /ig); lane 
6, pure L-FABP after anion exchange chromatography 
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Analysis of the binding characteristics of recombinant L-FABP and M-FABP. 
Analysis by radiochemical assay. 
First the binding affinity for [l-14C]oleic acid was analyzed with the Lipidex method. 
Scatchard plots revealed a Kj of 0.90 ± 0.04 μΜ and 0.43 ± 0.03 μΜ (means ± S.D. of 4 
experiments) for human L-FABP and M-FABP, respectively. These values are in good 
agreement with earlier found values for isolated or recombinant proteins [8,33,35]. Delipidation 
was essential, since without this procedure apparent K¿ values of oleic acid of 0.51 ± 0.05 μΜ 
and 0.20 ± 0.03 μΜ were found for human L-FABP and M-FABP, respectively. 
To obtain the binding affinity for various ligands the displacement percentage of [1-
uC]oleic acid by these ligands was determined for both L-FABP and M-FABP. From displace­
ment curves, obtained by addition of 1-10 μΜ unlabeled oleic acid to 1 μΜ [l-uC]oleic acid 
and protein samples, the oleic acid concentration required to obtain the same displacement 
percentage as with the specific competitor, could be established. With the formula described in 
the experimental procedures the K, for the specific competitor was calculated. Table 1 gives the 
K, values of L-FABP and M-FABP binding to fatty acids varying in chain length and the 
number and place of double bonds and for various hydrophobic ligands. Although the differen­
ces in K, values of fatty acids are relatively small data show that the recombinant L-FABP and 
M-FABP have both a specific preference. L-FABP shows a high affinity for all saturated and 
unsaturated fatty acids with a chain of 15 С atoms and longer up to C14l. M-FABP shows a 
high preference for binding unsaturated fatty acids, especially with 18 С atoms. Both proteins 
have similar Kj values for cis- and trans-parinaric acid. Remarkable is the difference in K¡ for 
these ligands which suggests that a cis double bound at C-15 causes a weaker interaction. A cis 
double bond at C-6 in petroselenic acid shows a similar effect for both FABP types. 
Comparison of our data on delipidated L-FABP with those found by others, who usually 
did not delipidate, shows some differences. Takikawa and Kaplowitz estimated a much higher 
affinity of human L-FABP for oleic acid [36]. Bass et al. found similar K„ values of stearic, 
linoleic and archidonic acid binding to rat L-FABP but their values for palmitic, oleic and 
erucic acid differ from ours [37]. Miller and Cistola [38] reported affinities of rat L-FABP to 
oleic acid in a similar range as we found for human L-FABP. Nemecz et al. [39] found a much 
lower affinity of rat L-FABP for stearic, oleic and linoleic acid, but a higher for cis-parinaric 
acid. Their K^  value for trans-parinaric acid does not significantly differ from our value. Lowe 
et al. [40] also found higher Kd values of palmitic, oleic and archidonic acid with rat L-FABP 
than we [33]. The displacement percentages observed for human M-FABP are in good agree-
ment with those found by Peeters et al. [8,35]. 
Several reports [for refs see 5 and 26] describe the interaction of FABPs with other 
ligands than ratty acids. Our data (Table 2) indicate that M-FABP binds besides fatty acids only 
testosterone and oestradiol with high affinity. However the human L-FABP binds cellular 
metabolites like the palmitoyl derivatives, lysolecithin, deoxycholic acid, prostaglandins, steroid 
hormones, hexadecanedioic acid and eicosanol. Also retinoids, 1,25-dihydroxy vitamin D3, 
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clofibric acid, bromothalein and inhibitors of camtine palmitoyltransferase (tetradecylglycidic 
acid and POCA) are bound by L-FABP. Their affinities are generally weaker than those of the 
long-chain fatty acids. Only bromothalein and prostaglandin A! show a higher affinity than oleic 
acid.Takikawa and Kaplowitz found binding of deoxycholic acid by human L-FABP with a 
lower affinity [36]. For palmitoyl-CoA binding to rat L-FABP, lower K¿ values were found by 
others [37,41,42], but their FABP preparations isolated from rat liver may contain some acyl-
CoA binding protein [43]. The binding affinity of prostaglandins for human liver FABP 
decreases in the order PGA, > PGE2 and PGE, > PGF^, prostacyclin and thromboxane Bj. 
These data agree with the preferential binding of growth-inhibitory prostaglandins to rat liver 
FABP [44]. Testosterone binds more avidly than oestradiol and ethynyloestradiol in contrast to 
previous observations [45]. Retinol, retinole acid and 1,25-dihydroxy vitamin D3 show a 
moderate affinity to liver FABP, but vitamin E and K3 only a low affinity. The displacement of 
oleic acid by hexadecanedioic acid, but not by dodecanedioic acid is of interest in relation to the 
differences in their inducing activity of both FABP and peroxisomes in cultured hepatocytes 
[46]. In spite of the generally lower affinity for the other hydrophobic ligands than for fatty 
acids, L-FABP might be involved in their transport and biotransformation in liver, intestine and 
kidney and also protect the cell against toxicity of these ligands. 
The fatty acids with a fluorescent reporter group, DAUDA and the anthroyloxy fatty 
acids, are bound with higher affinity by L-FABP than by M-FABP, except 12-(9-anthroyloxy)-
oleic acid (Table 1). Storch et al. reported a similar K¿ value of 2-(9 anthroyloxy)palmitic acid 
for binding to rat L-FABP [22]. The location of the fluorescent group at C-12 seems to 
decrease the affinity for L-FABP whereas location at the end of the fatty acid increases the 
affinity in comparison to the native fatty acid. L-FABP is suggested to have a more open and 
hydrophobic binding pocket than M-FABP [22-24] which explains the difference in K¡ values of 
the fluorescent fatty acids between both proteins. The fluorescent reporter group rather than the 
fatty acid may interact with the protein which might explain the differences in affinity with the 
native fatty acid. 
The tertiary structure of M-FABP and intestinal FABP show a large extent of similarity 
[15]. For L-FABP the three-dimensional structure is not known up to now. NMR studies with 
l3C-carboxy-labeled fatty acids indicated a more solvent-accessible binding environment for L-
FABP than for intestinal FABP [47]. The location of the carboxylic group near the aqueous 
surface of L-FABP was also suggested by the variations of quantum yields in the interaction of 
L-FABP with a series of fluorescent fatty acids with the anthroyl group attached at different С 
atoms [22]. The carbon chain is present in a nonpolar environment in a fairly constrained 
configuration. The constraint at the C-6/C-7 position of the acyl chain would be higher than at 
the methyl or carboxyl end [22]. Our results with the anthroyloxy-labeled fatty acids sustain this 
latter conclusion. The 12-(9-anthroyloxy)oleic acid has the lowest K¡ value. The comparable 
fluorescence enhancement indicates, however, a similar interaction of the anthroylgroup of 2-(9-
anthroyloxy)palmitic acid and 12-(9-anthroyloxy)oleic acid with L-FABP. 
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Table 1 Displacement of [l-"C]oleic acid and binding affinity of human recombinant L-FABP and M-FABP 
for various fatty acids. Displacement is given as the percentage of [l-,4C]oleic acid binding to F ABP ш the 
absence of competitor. Concentrations were 0.2 μΜ L-FABP or 0.28 μΜ M-FABP, 1 μΜ [l-'*C]oleic acid and 1 
μΜ competitor. The Kj for [l-,4C]oleic acid was determined by Scatchard analysis of binding data, the K, for the 
competitors by the method of Van Zoelen [27] as described in detail in expérimental procedures. Values are means 
± S.D. of four independent experiments. 
L-FABP M-FABP 
Ligand 
Undecanoic acid (11:0) 
Laune acid (12:0) 
Mynstic acid (14:0) 
Pentadecanoic acid (15:0) 
Palmitic acid (16:0) 
Stearic acid (18:0) 
Nonadecanoic acid (19:0) 
Palmitoleic acid (c9, 16:1) 
Petroselenic acid (c6, 18:1) 
Oleic acid (c9, 18:1) 
Elaidicacid (t9, 18:1) 
Lmoleicacid (c9,12, 18:2) 
Lmolemcacid (c9,12,15, 18:3) 
Cis-pannanc acid (c9,15,tll,13, 18:4) 
Trans-pannanc acid (t9,ll,13,15, 18:4) 
Arachidomc acid (c5,8,ll,14, 20:4) 
Eructe acid (cl3, 22:1) 
Cervomcacid (c4,7,10,13,16,19, 22:6) 
Nervomc acid (cl5, 24:1) 
2-Br-palmitic acid 
2-Hydroxy-paImitic acid 
2-(9-Anthroyloxy) palmitic acid 
12-(9-Anthroyloxy) oleic acid 
16-(9-Anthroyloxy) palmitic acid 
Π-Dansylamino undecanoic acid 
% displacement 
24 ± 1 
33 ± 1 
26 ± 5 
34 ± 3 
30 ± 3 
35 ± 2 
17 ± 3 
29 ± 1 
25 ± 3 
39 ± 7 
31 ± 2 
34 ± 1 
38 ± 1 
31 ± 2 
53 ± 3 
39 ± 3 
58 ± 1 
39 ± 3 
50 ± 1 
35 ± 1 
34 ± 1 
63 ± 4 
14 ± 1 
92 ± 3 
73 ± 2 
Κ,(μΜ) 
1.68 ± 0.45 
1.08 ± 0.36 
1.42 ± 0.43 
1.02 ± 0.26 
1.23 ± 0.31 
0.97 ± 0.26 
1.24 ± 0.48 
1.34 ± 0.40 
1.67 ± 0.41 
0.90 ± 0.04 
1.23 ± 0.33 
1.05 ± 0.37 
0.86 ± 0.25 
1.32 ± 0.33 
0.46 ± 0.14 
0.84 ± 0.23 
0.39 ± 0.14 
0.82 ± 0.23 
0.55 ± 0.22 
0.95 ± 0.30 
1.03 ± 0.31 
0.29 ± 0.07 
4 34 ± 1.03 
< 0.05 
0.15 ± 0 08 
% displacement 
19 ± 6 
19 ± 4 
15 ± 4 
20 ± 5 
20 ± 8 
14 ± 3 
2 ± 2 
28 ± 5 
19 ± 8 
37 ± 1 
48 ± 7 
34 ± 6 
35 ± 7 
18 ± 1 
35 ± 1 
21 ± 7 
28 ± 7 
15 ± 4 
19 ± 7 
26 ± 1 
15 ± 5 
17 ± 2 
25 ± 1 
24 ± 1 
19 ± 2 
Κ,(μΜ) 
1.18 ± 0.41 
1.09 ± 0.14 
1.45 ± 0.26 
1.05 ± 0.21 
1.11 ± 0 . 3 7 
1.64 ± 0.44 
> 10 
0.67 ± 0.12 
1.36 ± 0.74 
0.43 ± 0.03 
0.28 ± 0.05 
0.51 ± 0.09 
0.48 ± 0.10 
1.26 ± 0.23 
0.49 ± 0.03 
0.95 ± 0.35 
0.70 ± 0.19 
1.43 ± 0.28 
1.20 ± 0.37 
0.64 ± 0.05 
1.52 ± 0.50 
1.36 ± 0.33 
0.80 ± 0.07 
0.83 ± 0.08 
1.11 ± 0.18 
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Table 2 Displacement of [l-"C]olcic acid and binding affinity of human recombinant L-FABP and M-FABP for 
various ligands. Displacement is given as the percentage of [l-"C]oleic acid binding to FABP ш the absence of 
competitor. Concentrations were 0.2 μΜ L-FABP or 0.28 μΜ M-FABP, Ι μΜ [l-l4C]oleic acid and 1 μΜ competitor. 
The K, values were determined by analysis of binding data for the competitors by the method of Van Zoelen [27] as 
described in detail in experimental procedures. Values are means ± S.D. of at least three independent experiments. N.D., 
not determined. 
L-FABP M-FABP 
Ligand 
Palmi toyl-CoA 
Palmi toylcami tine 
Palmi toylglycerol 
Lysolecithm 
Deoxycholic acid 
Prostaglandin E, 
Prostaglandin Ej 
Prostaglandin A, 
Prostaglandin F ,^ 
Prostacyclm 
Thromboxane B, 
Testosterone 
Oestradiol 
Ethynyl oestradiol 
Dodecanedioic acid 
Hexadecanedioic acid 
Eicosanol 
Retinol 
Reunoic acid 
1,25 Dihydroxy vitamin D, 
Vitamin E 
VitammKj 
Clofibnc acid 
Bromothalem 
Tetradecylglycidic acid 
POCA 
% displacement 
26 ± 2 
35 ± 3 
30 ± 3 
29 ± 3 
20 ± 3 
21 ± 6 
27 ± 10 
46 ± 11 
15 ± 4 
10 ± 8 
8 ± 7 
25 ± 6 
11 ± 6 
6 ± 6 
3 ± 3 
24 ± 7 
29 ± 1 
27 ± 5 
20 ± 6 
21 ± 8 
6 ± 4 
12 ± 6 
30 ± 3 
49 ± 2 
31 ± 5 
32 ± 1 
Κ,ΟιΜ) 
1.55 ± 0.40 
0.96 ± 0.25 
1.26 ± 0.30 
1.30 ± 0.32 
2.23 ± 0.57 
2.08 ± 0.75 
1.08 ± 1.05 
0.67 ± 0.33 
3.01 ± 0.84 
4.33 ± 3.27 
5.17 ± 3.34 
1.58 ± 0.49 
6.85 ± 3.59 
7.30 ± 0.27 
> 10 
2.27 ± 1.02 
1.34 ± 0.40 
1.40 ± 0.36 
2.66 ± 1.24 
1.85 ± 1.56 
7.90 ± 3.50 
4.17 ± 3.39 
1.23 ± 0.31 
0.56 ± 0 . 1 7 
1.17 ± 0.35 
1.15 ± 0.36 
% displacement 
11 ± 2 
2 ± 2 
12 ± 6 
1 ± 1 
1 ± 1 
3 ± 2 
5 ± 4 
3 ± 3 
4 ± 1 
2 ± 1 
2 ± 1 
30 ± 10 
29 ± 6 
N.D. 
N.D. 
17 ± 5 
8 ± 6 
11 ± 9 
2 ± 2 
5 ± 5 
10 ± 4 
9 ± 5 
11 ± 6 
6 ± 6 
4 ± 4 
11 ± 6 
Κ,ΟιΜ) 
2.03 ± 0.23 
> 10 
2.09 ± 0.68 
> 10 
> 10 
> 10 
4.4 ± 1.7 
> 10 
> 10 
> 10 
> 10 
0.63 ± 0.30 
0.63 ± 0.15 
N.D. 
N.D. 
1.24 ± 0.50 
3.4 ± 1.5 
2.7 ± 2.0 
> 10 
5.3 ± 4.6 
2.5 ± 1.0 
3.2 ± 1.6 
2.6 ± 1.2 
3.9 ± 1.5 
> 10 
2.09 ± 0.68 
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Liffand 
DAUDA 
2-(9-anthroyloxy)parmitic acid 
12-(9-anthroyloxy)oleie acid 
16-(9-anthroyloxy)palmitic acid 
Cis-рагшалс acid 
Trans-рагшапс acid 
Xex 
345 
365 
365 
365 
306 
306 
L-FABP 
18.3 ± 0.2 
20.0 ± 0.2 
21.8 ± 0.9 
8.2 ± 0.6 
15.3 ± 0.7 
22.0 ± 0 . 4 
M-FABP 
3.4 ± 0.2 
13.3 ± 0.2 
5.8 ± 0.4 
2.5 ± 0.6 
5.7 ± 0.4 
5.5 ± 0.5 
Analysis by fluorescence assay. 
The relative fluo- Table 3 Fluorescence increase of different fatty acids in reaction with human 
. L-FABP and M-FABP. Experiments were performed with 1.0 μΜ fatty acid in 
rescence ennancemeni
 Ш в a b s e n c e o r p r e s e n c e o f 2.0 μΜ L-FABP or 2.8 μΜ M-FABP. Optimal 
was for all fluorescent excitation wavelength λ„ is given in run. The fluorescence increase is calculated 
fattv acids markedly ** " ^ n i , ° °^ fluorescence with and without protein. Fluorescence values of 
DAUDA are relative to the emission without protein at 545 run (excitation at 328 
higher With L-FABP than „„,)
 s i n c e a 5 0 5 „„, (excitation 345 am) no fluorescence without protein is 
with M-FABP (Table 3). observed. Maximum fluorescence of the other hgands was obtained by scanning 
__ . . of emission between 380 and 550 nm. Values are means ± S.D. of three 
There is as expected no . . . , 
r
 independent experiments, 
correlation of the K, 
values of the fluorescent 
fatty acids (Table 1) and 
the fluorescence enhance­
ment data (Table 3) for 
both L-FABP and M-
FABP. Although the K, 
values of the pannane 
acids are similar for both 
FABPs, the fluorescence 
increase is much higher with L-FABP. The interaction with the anthroyloxy-labeled fatty acids 
depends on the location of the fluorescent reporter group e.g. the 16-AP shows the strongest 
affinity but the lowest fluorescence increase with L-FABP. These differences relate to the 
different protein-ligand interactions studied in the two assays. The radiochemical displacement 
assay is based on the interference with the binding of the oleic acid carbon chain, whereas the 
fluorescence enhancement assay indicates a hydrophobic interaction of the fluorescent reporter 
group with the protein. The latter is clear from the interaction of rat L-FABP with the 
fluorescent trinitrophenyladenosine-triphosphate, but not with ATP itself [25]. The more 
hydrophobic binding pocket of L-FABP than of M-FABP might explain the difference in 
fluorescence increase of both proteins as suggested [22-24]. 
The low fluorescence enhancement does not allow displacement studies and determina­
tion of the K, value of the fluorescent fatty acids with M-FABP. In our experiments with 
fluorescent probes we noticed that DAUDA is most stable and most suitable for displacement 
studies. First the optimal L-FABP concentration was determined to get a fluorescence signal 
which is sensitive enough to study displacement and at which the fatty acid concentration is 
saturating. With 0.2 μΜ L-FABP the displacement percentage with oleic acid is identical with 
that at lower FABP concentrations and the signal is most optimal (Fig. 4). 
The binding affinity of recombinant human L-FABP for DAUDA was determined by 
analysis of its binding and displacement curves [28]. The К* was established at 0.17 ± 0.05 μΜ 
(mean ± S.D. of four ex-periments) which is in excellent accordance with the K, determined 
from the displacement of [l-,4C]oleic acid (Table 1) and the reported IQ values for binding of 
DAUDA to isolated rat and porcine L-FABP [17,28]. This Kd value is used in the calculation of 
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ILFABP <|iM)l 
Fig. 4 Analysis of the optimal L-FABP concentration for 
fluorescence displacement studies with DAUDA. The 
fluorescence of 1 μΜ DAUDA with ( · ) or without (O) 1 
μΜ oleic acid is given for the range of 0-1 μΜ L-FABP. 
The displacement percentage (D) is also given. 
the K¡ values of competing ligands (Table 
The same fatty acids and other 
hydrophobic ligands as used in radioche-
mical analysis were applied in DAUDA 
displacement studies with L-FABP. The 
displacement percentages are given for all 
ligands in Table 4. The preference for 
long-chain fatty acids is similar as in the 
oleic acid displacement studies. A peculiar 
finding was the result with petroselenic 
acid which does not displace DAUDA 
although from oleic acid displacement it 
appeared that this acid is bound by L-
FABP. Displacement studies with 
DAUDA on isolated human and rat L-
FABP showed a similar binding preference although the values differ a little [21,33]. Other 
ligands as palmitoyl-CoA, lysolecithin, bromothalein and tetradecylglycidic acid also inhibit the 
binding of DAUDA to L-FABP (Table 4) as previously found for isolated human and rat L-
FABP [21,33]. However, palmitoylglycerol, deoxycholic acid, POCA, clofibric acid, eicosanol, 
prostaglandin E, and b¡ and retinol did not inhibit DAUDA fluorescence with human L-FABP 
(data not shown) in contrast to their interference with oleic acid binding. 
Comparison of the data of Table 4 with the radiochemical studies (Table 1) shows that 
the displacement percentages of DAUDA by various fatty acids are markedly higher than of 
oleic acid although the Kd value of DAUDA is considerably lower. The K^ value for [1-
14C]oleic acid binding was 0.90 μΜ but displacement of DAUDA gave a K, value of 0.19 μΜ. 
The apparent K¡ values of the competing ligands calculated from their displacement percentage 
and the DAUDA displacement curves (Table 4) appear also to differ from the K¡ values 
obtained with [l-I4C]oleic acid displacement. The long-chain saturated and unsaturated fatty 
acids and palmitoyl-CoA, and tetradecylglycidic acid show generally a lower K„ the other 
ligands a markedly higher K, value in the DAUDA displacement studies (Table 4, and data not 
shown). These distinct differences between the results of both displacement assays reflect the 
different kind and location of interaction of the acyl carbon chain and the fluorescent reporter 
group with the L-FABP. The decrease of bound radioactivity is based on the competitive 
interaction with the binding of the acyl chain of oleic acid to L-FABP, whereas the decrease of 
the fluorescence signal gives only information on the competition with the fluorescent reporter 
group of DAUDA in its interaction with the protein. 
In conclusion, we obtained only good expression of human L-FABP in Exoli after 
overnight incubation with IPTG and rifampicin. We showed that with the oleic acid displace-
ment method the K, values of L-FABP and M-FABP for a large series of fatty acids and other 
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ligands can be determined. Our results indicate that binding assays with fatty acids with 
fluorescent groups do not well reflect the interaction of the acyl carbon chain with the FABP. 
The Kd value for DAUDA was found to be similar in assays based on [l-14C]oleic acid 
displacement and DAUDA saturation. The type-specific ligand preference of L-FABP and M-
FABP might relate to the presence of both FABP types in one organ, like the kidney [6,7]. 
Table 4 Displacement of DAUDA and binding affinity of human recombinant L-FABP for various hydro­
phobic ligands. Recombinant human L-FABP (0.2 μΜ) was incubated with 1 μΜ DAUDA with or without 1 μΜ 
competitor. Fluorescence spectra were measured between 475 and 550 nm at an excitation wavelength of 345 nm. 
The fall in fluorescence due to the displacement of DAUDA from L-FABP by competing ligand is expressed as a 
percentage of the initial protein-bound DAUDA fluorescence. The K, values of the competing ligands were 
calculated from their displacement percentage and the DAUDA displacement curve. All values are means ± S.D. 
for at least four independent experiments. 
Lieand 
Undecanoic acid (11:0) 
Laune acid (12:0) 
Mynstic acid (14:0) 
Pentadecanoic acid (15:0) 
Palmitic acid (16:0) 
Stearic acid (18:0) 
Nonadecanoic acid (19:0) 
Palmitoleic acid (c9, 16:1) 
Petroselemc acid (c6, 18:1) 
Oleic acid (c9, 18:1) 
Elaidicacid (t9, 18:1) 
Linoleicacid (c9,12, 18:2) 
Lmolemcacid (c9,12,15, 18:3) 
Arachidonic acid (c5,8,11,14, 20:4) 
Erucic acid (cl3, 22:1) 
Cervonicacid (04,7,10,13,16,19,22.6) 
Nervonic acid (cl5, 24:1) 
2-Br-palnutic acid 
2-Hydroxy-palmioc acid 
Palmi toyl-CoA 
Palmi toylcanu tine 
Lysolecithine 
Bromothalem 
Tetradecvlslvcidic acid 
% displacement 
1 ± 3 
1 ± 2 
21 ± 4 
53 ± 3 
73 ± 5 
76 ± 5 
71 ± 2 
61 ± 2 
1 ± 1 
78 ± 5 
80 ± 3 
70 ± 5 
60 ± 2 
52 ± 4 
84 ± 3 
41 ± 3 
84 ± 1 
78 ± 5 
39 ± 4 
50 ± 2 
9 ± 7 
25 ± 6 
38 ± 6 
66 + 2 
Κ, (μΜ) 
> 10 
> 10 
2.94 ± 0.55 
0.70 ± 0.06 
0 26 ± 0 07 
0.21 ± 0.04 
0.32 ± 0.05 
0.52 ± 0.04 
> 10 
0.19 ± 0.04 
0.17 ± 0.02 
0.32 ± 0.08 
0.54 ± 0.03 
0.70 ± 0.08 
0.15 ± 0.05 
1.28 ± 0 20 
0.15 ± 0.01 
0.19 ± 0.04 
1.48 ± 0.30 
0.77 ± 0.05 
6.40 ± 2.70 
2.44 ± 0.58 
1 59 ± 0.49 
0.39 + 0.03 
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Structure and binding characteristics of locust and human M-FABP 
SUMMARY 
The conservation between M-FABP of Locusta migratoria (Lm) flight muscle and of 
human skeletal muscle was investigated. The locust M-FABP cDNA (632 bp) was isolated by 5' 
and 3' rapid amplification of cDNA ends. The identity of the locust and human M-FABP on the 
cDNA and the protein level is 54% and 42%, respectively. The predicted amino acid sequence 
of locust M-FABP indicates a molecular mass of 14,935 Da and an isoelectric point of 6.1. The 
locust M-FABP was expressed in Escherichia coli, purified by (N114)2804 precipitation, anion-
exchange and gel filtration chromatography and compared with the recombinant human M-
FABP with respect to immunological and binding properties. In spite of the high sequence 
similarity, the proteins did not show immunological cross-reactivity. The binding parameters of 
locust M-FABP were analyzed with radiolabeled oleic acid by the Lipidex assay and titration 
microcalorimetry. Both methods revealed a K¿ for oleic acid of 0.5 μΜ and a binding stochio-
metry of 1 mol fatty acid/mol FABP. The ΔΗ, AG and AS for oleic acid binding are -146 and -
36 kJ/mol and -369 J/mol K, respectively. All information obtained from binding, fluorescence 
and displacement studies indicated that locust M-FABP has binding characteristics similar to 
human M-FABP. Finally the recombinant locust M-FABP was crystallized with and without 
oleic acid. All crystals are trigonal in the P3,21 space group. The unit cell dimensions are 
a=b=5.89 nm and c=14.42 nm. 
INTRODUCTION 
Fatty acids are important molecules for energy generation and synthesis of membrane 
lipids. Moreover, they may function as lipid mediators and influence various cellular processes 
by their interaction with enzymes, membranes, ion channels, receptors or genes. In the 
cytoplasm of tissues the flux of fatty acids between plasma membrane and organelles, where 
fatty acids are converted, seems to be contraled by a group of low-molecular mass proteins, the 
fatty acid-binding proteins (FABPs). Until now, seven vertebrate FABPs, with a amino acid 
sequence similarity of 25-65%, have been identified: liver, intestinal, heart or muscle, 
adipocyte, myelin, ileal and epidermal FABP types [1-5]. 
Previously we isolated human M-FABP, a protein of a 15 kDa molecular mass, a 
isoelectric point of 5.2 and a high immunological crossreactivity with human heart FABP [6]. 
Analysis of a full-length human M-FABP cDNA clone and amino acid sequencing of human M-
FABP proved that muscle and heart FABPs are identical [7]. The human M-FABP has a more 
general tissue distribution than all other FABP types [1-5]. The recombinant human M-FABP 
showed preference for binding of palmitic and C1S-CU unsaturated fatty acids [8]. The recombi­
nant protein was crystallized and its three-dimensional structure solved [9]. The structure of 
human M-FABP was found to be similar to that of other members of the FABP family; 
containing ten anti-parallel ß-strands arranged in two orthogonal ß-sheets and two short a-
helices located between the first and second ß-strand [9]. In spite of their high conformational 
similarity, intestinal, adipocyte, myelin and muscle FABP types bind their fatty acid differently. 
The muscle and myelin FABP types bind the fatty acid in an U-shape [9,10] whereas the 
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intestinal and adipocyte F ABP types bind the fatty acid in an more extended conformation [11-
14]. Amino acids involved with fatty acid binding are also different between muscle and 
intestinal FABP [IS]. Additionally, evidence has been obtained that adipocyte and muscle 
FABPs contain a tyrosine phosphorylation recognition sequence [16-18]. 
Recently FABPs have been isolated from the invertebrate species Schistosoma monsoni 
[19], Schistocerca gregaria [20] and Locusta migratoria [21,22]. One FABP preparation 
obtained from midgut of Manduca sexta [23] was used to determine the three-dimensional 
overall structure. The overall structure of the protein is similar to that of the mammalian 
intestinal, myelin and adipocyte FABP types [24]. Locust flight muscle uses exclusively fatty 
acids as energy source for sustained flight activity and it is likely that FABP is involved in the 
intracellular fatty acid transport [21]. Immunochemical studies revealed that in the desert locust 
S. gregaria this protein is only present in adult flight muscle and comprises 18% of the total 
cytosolic protein [20,25]. The amino acid sequence of flight muscle FABP from S. gregaria 
seems to be highly conserved during evolution and the highest similarity of amino acid sequence 
(46%) was found with human M-FABP [26]. 
As an extension of our isolation of flight muscle FABP from Locusta migratoria [21,22] 
we determined its complete cDNA sequence and expressed the protein in E. coli. Since locust 
and human M-FABP showed a high primary structure identity we studied subsequently the 
immunological and binding properties of both proteins to obtain more information about a 
similarity of their tertiary structure. Finally we crystallized the recombinant locust M-FABP in 
order to begin the three-dimensional structure analysis. 
MATERIALS AND METHODS 
Materials 
Oligonucleotide primers and the FPLC Hiload Q Sepharose column were obtained from 
Pharmacia Biotechnologies Int., Uppsala, Sweden; RNasin and terminal deoxynucleotidyl 
transferase from Promega Corporation, Madison, WI, USA; recombinant Taq DNA polymerase 
Amplitaq from Perkin Elmer Cetus, Norwalk, CT, USA; Moloney Murine Leukemia virus 
[MMuLV] RNase H~ reverse transcriptase and isopropyl B-D-thiogalactopyranoside from Life 
Technologies Inc., Gaithersburg, MD, U.S.A.; Geneclean from BIO101 Inc., La Jolla, CA, 
U.S.A.; Klenow DNA polymerase, T4 polynucleotide kinase; proteinase К and calf alkaline 
intestinal phosphatase from Boehringer Mannheim, Germany; Sequenase version 2.0 from 
United States Biochemical, Cleveland, OH, USA; Lipidex 1000 from Canberra-Packard, 
Groningen, The Netherlands; 11-dansylamino-undecanoic acid, 2-(9-anthroyloxy)palmiuc acid, 
12-(9-anthroyloxy)oleic acid and 16-(9-anthroyloxy)paImitic acid from Molecular Probes, 
Junction City, OR, U.S.A.; polyethylene glycol 4000 from J.T. Baker Chem. Co., Phillips-
burg, N.J., U.S.A.; [9,10-3H]oleic acid [2-10 Ci/mmol], [l-,4C]oleic acid [55 mCi/mmol] and 
£K-["S]thio-dATP [1000 Ci/mmol], from Amersham International, Little Chalford, U.K.. All 
other reagents were of analytical grade. 
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Methods 
Isolation and cloning of a full-length cDNA of locust M-FABP 
Locusta migratoria was reared in the laboratory under crowded conditions as described 
[27]. Locust flight muscle FABP was isolated as described by Van der Horst et al.[22]. The N-
terminal amino acid sequence of purified locust FABP was determined by automated Edman 
degradation. The amino acid sequence of the first 41 residues is as follows H2N-Val-Lys-Glu-
Phe-Ala-Gly-Ile-Lys-Tyr-Lys-Leu-Asp-Ser-Gln-Thr-Asn-Phe-Glu-Glu-Tyr-Met-Lys-Ala-Ile-Gly-
Val-Gly-Ala-De-Glu-Arg-Lys-Ala-Gly-Leu-Ala-Leu-Ser-Pro- аі-Пе [22]. 
Total RNA was extracted from 6.4 g flight muscle by the procedure of Auffray et al. 
and Puissant et al. [28,29]. Poly(A)-rich RNA was selected on oligo(dT)-cellulose [30]. 
Northern blot analysis was carried out as previously described [31]. The principles of 5' and 3' 
RACE procedures are given in refs 32 and 33. The sequence of the primers used is given in 
Fig. 1. 
First strand synthesis of 3' RACE was carried out with 20 μg total RNA in a total 
volume of 20 μί containing 50 mM Tris/HCl (pH 8.3)/75 mM KC1/3 mM MgCyi25 μΜ 
dNTPs/40 units RNasin/0.5 μg oligo-dT primer and 400 units M-MuLV reverse transcriptase. 
The reverse oligo-dT primer was added to the RNA sample, the mixture was heated for 10 min 
at 70°C and quenched on ice. The reverse transcription reaction was carried out for 1 h at 37°C 
and for 30 min at 45 e C. 
The PCR amplification reactions were carried out in a total volume of 100 μί containing 
2 μί of the reverse transcription reaction mixture, 0.5 μg reverse oligo-dT and 0.5 μg forward 
degenerate primer, 10 mM Tris/HCl (pH 8.3)/50 mM KC1/1.5 mM MgCyO.001 % gelatin/250 
μΜ-dNTPs and 2.5 units Amplitaq. After 8 min denaturation at 94°C, 40 cycles of amplifi­
cation were carried out by using a step program (94eC, 1 min; 37°C, 1.5 min; 72°C, 2 min) 
followed by a 2 min final extension at 72°C. 
First strand synthesis of 5' RACE with reverse primer 1 was carried out as described 
above using instead of 20 μg total RNA, 10 μg poly(A)-rich RNA. The RNA was hydrolyzed 
by adding an equal volume of 0.3 M NaOH/30 mM EDTA and boiling for 5 min. The first 
strand of cDNA was purified with Geneclean. A quarter of the purified first strand was used 
directly for dG-tailing. The first strand cDNA was denatured at 70eC for 5 min, chilled on ice, 
and the remainder of the reaction components was added. The final composition was 10 mM 
Tris/HCl (pH 8.4), 25 mM KCl, 1.25 mM MgCl2, 50 μg/ml bovine serum albumin, 0.2 mM 
dGTP and 10 units terminal deoxynucleotidyl transferase. Reaction mixtures were incubated for 
10 min at 37eC, then for 10 min at 65 °C. Tailed cDNA was purified with Geneclean and 14 of 
the volume was used for amplification during PCR with an anchor and a nested reverse primer 
2. PCR reaction buffer was the same as described above, but the cycling conditions were 94"C 
1 min; 55eC 1 min; 72eC 2 min. 
The PCR products were subjected to electrophoresis on 1.5% agarose gel and bands of 
expected length were cut out. The agarose was removed by the phenol freeze fracture method 
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[34]. The DNA was subsequently treated with proteinase К to remove Taq polymerase con­
tamination, with Klenow DNA polymerase to fill in the protruding ends and with T4 polynu­
cleotide kinase to phosphorylate the 5' terminus of the cDNA ends [35,36]. The cDNA 
fragments were initially ligated to each other and subsequently digested with Ncol and BamHI. 
The digestion product was ligated with a modified PGEM5 Zf(+) vector, which had previously 
been digested with the same enzymes. Nucleotide sequencing was performed using the dideoxy 
chain termination technique using [35S]thio-dATP and the Sequenase kit either on double 
stranded or single stranded PGEM vectors. The nucleotide sequence from each strand was 
determined to confirm the data. 
Expression of locust M-FABP in Escherichia coli and purification 
The primers used during 3' RACE amplification by PCR contain recognition sites for the 
restriction enzymes Ncol and BamHI, which facilitate cloning in pET3d. The sequenced locust 
M-FABP cDNA was isolated after digestion with Ncol and BamHI and ligated with pET3d 
vector previously digested with the same enzymes. 
The plasmid pET3d/locust M-FABP was used to transform the E.coli K12 strain BL21-
(DE3) [37]. The transformed cells were plated onto agar plates constituted with 2x TY medium 
containing 100 ¿tg/ml ampicillin. An overnight culture of 50 ml 2x TY/ampicillin medium was 
made from a freshly streaked plate and 1 ml was used to inoculate 80 ml 2x TY/ampicillin 
medium. This was incubated at 37°С until cell density (А
ш
) was 0.5. From this culture 5 ml 
were used to inoculate 12 χ 1.5 1 of 2x TY/ampicillin. When А^ ю was between 0.7-0.9, 
isopropyl β-D-thiogalactopyranoside at a final concentration of 0.5 mM was added to induce the 
synthesis of T7 RNA polymerase. The cultures were grown for 4 h at 37е С 
Purification of recombinant locust M-FABP 
Induced cells were harvested by centrifugation at 5000 χ g for 20 min. The pellets were 
washed with 150 mM NaCl/5.4 mM Na-phosphate/1.3 mM K-phosphate (pH 7.4), frozen at -80 
°C to facilitate cell lysis and «suspended in 50 mM Tris/HCl (pH 7.5). The «suspended pellets 
were freeze-thawed 3 times and sonified 3 times for 30 sec with the broad tip of a Branson 
sonifier. The suspension was centrifugea for 20 min at 30,000 χ g, the supernatant was 
saturated to 50% with ammonium sulphate and stirred for 1 h at 4 eC. After centrifugation for 
20 min at 30,000 χ g the supernatant was dialyzed for 48 h against 10 mM Tris/HCl (pH 7.5). 
After batchwise delipidation with Lipidex 1000 the dialysate was passed through a Q Sepharose 
HR 26/10 FPLC column. The M-FABP was eluted with 50 mM Tris/HCl (pH 8.0). Column 
fractions were analyzed by SDS-PAGE and Western blotting. Pure locust M-FABP fractions 
were pooled. Gel filtration on Sephacryl S-100 (100x3 cm) was applied to obtain M-FABP from 
impure fractions. 
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Characterization of recombinant locust M-FABP 
Titration calorimetry 
Titration calorimetry was performed using a MicroCal OMEGA differential titration 
calorimeter (MicroCal Inc., Northampton, MA, U.S.A.) [38]. Twenty five 4^1-aliquots of 
delipidated locust M-FABP sample (0.55 mM) were injected into 1.4 ml 15-25 μΜ [9,10-
3H]oleic acid solution in 20 mM Tris/HCl (pH 8.0). All titrations were executed at 25°C. The 
fatty acid concentration was determined after the experiment by analysis of the radioactivity. 
The data were processed using the software package ORIGIN (provided with the MicroCal 
instrument). A function that modelled one class of independent binding sites was used to fit the 
data [38]. The association and dissociation constants (K, and KJ, molar binding stoichiometry 
and enthalpy change (ΔΗ) were determined from the fitted curve. The changes of Gibbs free 
energy and entropy were calculated using the equations AG=-RTlnK, and AS=(AH-AG)/T, 
respectively, where R is the gas constant and Τ is the absolute temperature in K. 
Fatty acid-binding assays 
Immediately before binding assays, FABP preparations were delipidated with the Lipidex 
procedure [39]. All binding assays were carried out in a volume of 0.5 ml 10 mM Tris/HCl 
(pH 8.0)/ 1% ethanol at 37 °C. K¿ values for the binding of recombinant locust and human M-
FABP to [l-,4C]oleic acid were determined with the Lipidex procedure and Scatchard analysis 
[39]. The K¡ values for binding of other fatty acids were determined by displacement analysis 
according to the method of van Zoelen [40]. Displacement curves were made with the Lipidex 
procedure by addition of 1 /iM [l-14C]oleic acid in the presence of unlabeled oleic acid (0-10 
μΜ) to 0.4 μΜ locust M-FABP or 0.28 μΜ human M-FABP. Subsequently the displacement 
percentage of [l-14C]oleic acid by various hydrophobic ligands was analyzed by addition of 1 
μΜ [l-14C]oleic acid and 1 μΜ competitor to the same amount of FABP. From the displace­
ment curve the concentration of unlabeled oleic acid was read which is needed to obtain the 
same percentage of displacement as with 1 μΜ competitor. Van Zoelen [40] showed that the K, 
value of the competitor can be calculated with the formula: 
L, - L," K.-K, 
L,u (l-cprn'-'-'/cpm^") ~ K„ 
In this equation L, is the added concentration of competitor, L,u is the concentration of 
non-labeled oleic acid required to obtain the same percentage of displacement as found with L,, 
Kj the dissociation constant for the competitor and K¿ the dissociation constant for oleic acid. 
The correction term (1 - cpm"Ual/cpmb0U°d) is included to account for the fact that the free ligand 
concentration can be significantly lower than the ligand concentration added. 
-121-
Chapter 6 
Fluorescence enhancement of various fluorescent fatty acids with recombinant locust and 
human M-FABP. 
All fluorescence experiments were carried out at a Shimadzu-500 fluorometer. The 
fluorescence was analyzed for 1.0 μΜ fluorescent fatty acid in the absence or presence of 4.0 
μΜ locust M-FABP or 2.8 μΜ human M-FABP in 1 ml 10 mM Tris/HCl (pH 8.0)/l% ethanol 
at 25 °C. Excitation and emission wavelengths are given in the table. 
Other procedures 
Standard procedures were used for SDS-PAGE and Western blotting [41]. In the latter 
procedure we used AMPPD (Tropix) instead of 4-chloro-l-naphtol. The antisera used were 
rabbit polyclonal antisera against recombinant human M-FABP and liver FABP and a monoclo­
nal and polyclonal antiserum against locust M-FABP. Recombinant human M-FABP was 
prepared as previously described [8]. Protein was determined by the Lowry procedure and 
corrected on the basis of amino acid analysis. 
Crystallization and X-ray diffraction studies on recombinant locust M-FABP 
Crystals were obtained using the hanging drop vapor diffusion method [42]. Four μΐ of 
protein solution 40 mg/ml in 100 mM PIPES buffer (pH 7.1), 0.05% sodium azide were mixed 
with 4 μΐ of a solution of 30% polyethylene glycol 4000 in the same buffer (precipitant 
solution). The resulting 8 μΐ drop was placed on a silanized coverslip, inverted and sealed over 
a well containing 1 ml of the precipitant solution. The first crystals appeared after three days at 
a temperature of 20°C. After seven days the maximum dimensions of the crystals were 0.4 χ 
0.3 χ 0.2 mm. 
A crystal mounted in a quartz capillary was subjected to X-ray diffraction. The data 
were collected on a Siemens Area Detector system coupled to a Rigaku RU-200 rotating anode 
X-ray generator, operating at 50 kV and 85 mA. A copper anode was used to produce X-rays 
and a graphite monochromator was employed to select the Cu-Ka radiation (λ=0.1542 nm). A 
0.3 mm collimator was chosen and the crystal-to-detector distance was set at 14 cm. Four runs, 
one phi scan and three omega scans, were performed with a frame width of 0.25 degrees and an 
exposure time of 90 s per frame. 
The diffraction data were analyzed using the XENGEN V.2.0 programs package 
(Siemens Analytical X-rays Instruments Inc., Madison, WI, U.S.A.) running on a Silicon 
Graphics IRIS workstation. The 720 frames processed resulted in the integration of 23,729 
observed reflections. The program PRECESS contained in the PHASES package was used to 
visualize pseudo-precession pictures of the unreduced diffraction in order to determine the space 
group. 
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RESULTS AND DISCUSSION 
Isolation of a full length cDNA of locust flight muscle FABP 
The amino acid sequence of locust flight muscle FABP, isolated from adult male insects, 
was determined by automated Edman degradation. The N-terminal sequence was not blocked in 
contrast to most FABPs purified from tissue extracts. Total RNA was reverse transcribed with 
an oligo-(dT),7 adaptor primer and subsequently this primer and a degenerate primer deduced 
from the first 10 N-terminal amino acids of locust M-FABP was used in a 3' RACE (Fig. 1 
upper panel). The cloned PCR fragment revealed the complete coding region and the 3' untrans­
lated region. Northern blot analysis, using this partial cDNA as a probe, indicated that the 
transcript was approximately 0.6 kb in length and that the 5' untranslated region will be short. 
The 5' untranslated region and the coding region encoded by the degenerate primer was isolated 
by 5' RACE. After first strand synthesis with primer 1, hydrolysis of the RNA and purification 
of the first strand, a dG-tail was attached. After a second purification the 5' RACE PCR was 
applied with an oligo-(dC) adaptor primer and the nested primer 2 (Fig. 1 lower panel). The 
PCR product encoded a 54 bp 5' untranslated region and nearly the complete coding region of 
the cDNA. The 5' and 3' RACE as described above resulted in the isolation of a full length 
cDNA (632 bp) encoding the locust M-FABP (Fig. 2). The start codon is located on position 
67. The stop codon and polyadenylation signal are at position 469 and 603, respectively. The 
sequence predicts a protein of 133 amino acids with a calculated molecular mass of 14,935 Da 
and isoelectric point of 6.13. 
3' RACE 
Degenerate primer > 
Coding region locust M-FABP 
< Oligo-dT pnmer 
Τ T T 
С C C T 
G G G T G G C G T 
Degenerate primer-5'-GGGCCATGGTAAAAGAATTCGCAGGAATAAAATAC-3' 
Oügo-dTpnmer:5'-GCGCTGCAGGGATCCGTCGAC(T)„-3' 
5' RACE 
Coding region locust M-FABP 
< Reverse pnmer 1 
< Reverse pnmer 2 
Anchor pnmerrS'-AAGGAATTCÍC),,^' 
Reverse pnmer l:5'-GGGTTGGATCCCCGTTTACTGGGCCTTG-3' 
Reverse pnmer 2:5'-CTTGTATATTCTCGTCGCCACCAAG-3· 
Fig. 1 Procedure of cDNA isolation. The procedure of isolation of the full-length cDNA of locust M-FABP 
and the pnmers used are given. 
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GGGGGGGGCCGGGAClTCTCAGCabGITCCTGTCTACTCCACTGCCACAGCCCCACAGCCGCCGCC 
1 
M G GTC AAG GAG TTC GCC GGC АТС AAO TAC AAG CTC GAC TCG CAG ACC ЧАС TTC 
Met Val Lys Glu Phe Ala Gly Ile Lys Туг Lye Leu Aap ser Gin Thr Aan Phe 
GAG GAG TAC ATG AAG GCC АТС GCT CTG GGC GCC ATT GAG CCA AAG С CT GGT CTG 
Glu Glu Тут Het Lye Ale Ile Gly Val Gly Ala Ile Glu Arq Lye Ala Gly Leu 
CCG CTG ТСС CCG <ГГО АТС GAA CTC GAG GTC CTG GAC GGT GAC AAG TTC AAG CTC 
Ala Leu Ser Pro Val Ile Glu Leu Glu Val Leu Aep Gly Aep Lye Phe Lya Leu 
ACC TCC AAG ACC GCC АТС AAG AAC ACC GAG TTC ACC TTC AAG CTG GGC GAG GAG 
Thr S e r Lye Thr Ala I l e Lye Asn Thr Clu Phe Thr Phe Lye Leu Gly Glu Glu 
TTC GAC GAG GAC ACC TTC GAC GGC CGC AAG GTC AAG TCT АТС АТС ACC CAG GAC 
Phe Aep Glu Asp Tar Leu Aep Gly Ara Lye Val Lye 9 e r I l e I l e Thr Gin Aep 
GGG CCC AAC AAG CTG GTC CAC GAG CAG AAG GGT GAC CAC CCC ACT АТС АТС АТС 
Gly Pro Aen Lye Leu Val H i s Glu Gin Lys S l y Asp H i s Pro Thr I l a I l e I l e 
CGC GAG TTC TCC AAG GAG CAG TGC GTC АТС ACG ATT Αλλ CTG GGC GAC TTC CTG 
Ara Glu Phe S e r Lye Glu Gin Cys Val I l e Thr I l e Lye Leu Gly Aep Leu Val 
GCG ACG АСА ATA TAC AAG GCC CAG Веж^СССССМССААСССАСССАСЧЧТІЛ ПЧ.ГГГГСА 
Αία Thr Arg I l e Туг Lys Ala Gin End 
GOlTTAAACGTAATTTTCACTTTACTCTGTCATCAGAAGeTTTCGTTTCCTTTTTTAAGTAATATGAGCTT 
CGTGTCTTTCTAï]Ue№CATTTTTTACAATTTCACAAAAAJbAAAAAJUUUUU 
™ 632 
Fig. 2 Full-length cDNA sequence of locust (light muscle FABP. The position of the start (67), termination 
(469) and polyadenylation (603) are shaded. 
omparison of cDNA and amino acid sequence of locust M-FABF with other FABPs 
In order to make a comparison between the primary structure of the locust M-FABP and 
ther M-FABPs, we aligned both the cDNA and amino acid sequences (Table 1, Fig.3). The 
irtially elucidated cDNA sequence encoding Che M-FABP of Schistocerca gregaria [26] is the 
lost similar to that of locust M-FABP with 92% identity. The identity displayed is higher, 
i%, if the two amino acid sequences are compared. The identity of the human M-FABP [7] 
Table 1 The identity/similarity between invertebrati: FABPs and human muscle FABP 
The percentage of identity/similarity is given on amino acid and cDNA level for M-FABPs from Locusta 
migratoria (Lm), Schistocerca gregaria (Sg) [26], Schistosoma monsoni (Sm) [19] and Homo sapiens (Hs) [7] 
and for midgut FABPs from Manduca sexta (Ms) [23]. 
The percentage identity with Sg M-FABP cDNA could not be determined (nd) since only a part of it was 
isolated and sequenced [26]. For the elucidated part the identity with Lm M-FABP cDNA is 92%. 
Percent identity/similarity for amino acid alignment 
Lm M-FABP 
Sg M-FABP 
Sm M-FABP 
Hs M-FABP 
Ms FABP1 
MsFABP2 
Lm M-FABP 
-
nd 
48.3 
54.3 
48.9 
49.3 
Lm M-FABP 
Sg M-FABP 
97.7/97.7 
-
nd 
nd 
nd 
nd 
Sg M-FABP 
Sm M-FABP 
36.3/38.2 
36.3/38.2 
-
S0.7 
4S.0 
4S.4 
Sm M-FABP 
Hs M-FABP 
41.9/46.4 
41.2/45.7 
43.0/44.5 
-
43.0 
48.1 
Hs M-FABP 
Ms FABP1 
26.5/30.9 
26.5/30.9 
23.5/26.5 
26.6/29.2 
-
61.4 
Ms FABP1 
MsFABP2 
32.6/34.1 
32.6/34.1 
24.8/30.4 
32.6/35.0 
55.7/56.8 
-
MsFABP2 
Percent identity for cDNA alignment 
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Lm-M-FABP -VKEFACIKYltlDSQTIfrEEYUKAIGSGAIESKAGLALSI^IELEVLDGDiKFKLTSKTAI 5Θ 
Sg-M-FABP -VKEFAGIKYKtDSQTHFEEYMKAIÖVGAIEBKAGLALSPVIELEILDGDKFKLTSKTAI 58 
Sm-M-FABP M-SSÏII3-KWKLSESHMrDAV4SiaiSVSWATBQIGNTVTPTVTFT-MDGDKMTMLTESTF 55 
Hs-M-FABP MVDAELG-TWÎXVDSKUFDDYlIKSLSVGFATSQVASMTKPTTIIE-KNGDILTLKTHSTF 56 
* * ** * * . * . * * . * . . * . + * 
Lm-M-FABP Е»ГЕГТРХІЛЕ^ВІЕОТ1ЛСИПЖдіІТ0ОСРМКЬ НЕ0К-СОНРТІІІ8ЕГЗКЕ0С І'Е 117 
Sg-M-FABP {»TEFTjrKLGEEFOEETLOGSKVKSTITQDGPNKEVHEQK-GDHPTIIIREFSKEQCVIT 117 
Sm-M-FABP KlILSCTTKFqEEFOEJCTSEKÎiUWKS^ AŒKNSESKLTQTQVDPKNTTVIVREVDGDTMKTT 115 
Hs-M-FABP K^EISFKI^VEFWTTADDeKVSSIVTLDG-GKEVHLQiaiDGQETTLVItELIDGKLILT 115 
** . * * . * **** * * , * . * * * . . . * * . + + . . * * * 
Lm-M-FABP IKLODLVATSIÏ-KAQ 132 
Sg-M-FABP IKLGDLVAT8IV-KAQ 132 
Sm-M-FABP VTVGDVTAIBNÍKRLS 131 
Hs-M-FABP LTHGTAVCTjynÇEKEA 131 
* * * . 
Fig. 3 Alignment of M-FABPs from three invertebrates ала human. The amino acid sequence of Locusta 
migratoria (Lm), Schistocarca gregaria (Sg) [26], Schistosoma monsoni (Sm) [19] and Homo sapiens (Hs) [7] 
M-FABP are compared on similar residues. Ammo acids which are identical or are conservatively substituted 
are marked by asterisks or points, respectively. 
Table 2 Amino acid side chains of human M-FABP within 0.45 nm from the fatty acid carbon atoms and 
their counterpart in locust M-FABP. 
Carbon atom 
fatty acid 
C-2 
C-3 
C-4 
C-5 
C-6 
C-7 
C-8 
C-9 
C-10 
C-ll 
C-12 
C-13 
C-14 
C-15 
C-16 
Human 
Phel6, Argl26 
-
РЬеІб 
-
Asp76 
Asp76 
AU75, Asp76 
РЬеІб, Met20, 
MetíO, Thr29 
Phel6, Met20, 
АІаЗЭ, Ala7S 
АІаЗЗ. Phe57 
Lys58 
Pro38 
Pro38. Thr53. 
Val25, 
Thr29 
Ser55 
Amino acid M-FABP 
Asp76 
Locust 
Phel6, Argl26 
-
Phel6 
-
Asp76 
Asp76 
Leu77, Asp76 
Phel6, Met20, Val25, Asp76 
Met20, Glu30 
Phel6, Met20, Glu30 
Gly34, Leu77 
Gly34, IIe59 
Lys58 
Pro38 
Pro38. SerSS, Thr57 
with the locust M-FABP is 5 4 % and 4 2 % based on the c D N A and amino acid sequence, 
respectively. Moreover, the locust M-FABP has a significantly higher identity with the human 
M-FABP than with the other studied invertebrate FABPs, the M-FABP of Schistosoma monsoni 
and both midgut FABPs of Manduca sexta. This indicates that the muscle FABP type is highly 
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conserved. The recently solved three-dimensional structure of human M-FABP [9] and the 
alignment with the amino acid sequence of locust M-FABP (Fig.3) show that the residues 
involved in fatty acid binding in the human protein, are highly conserved in the locust M-FABP 
(Table 2). In human M-FABP residues Argl26 and Tyrl28 form hydrogen bonds with one 
oxygen of the fatty acid carboxylate, these residues are identical in the locust M-FABP. 
Moreover Argl06, which interacts with a highly ordered water molecule that is hydrogen 
bonded with the other oxygen of the carboxylate of the fatty acid, is also identical. In human 
M-FABP Thr40 hydrogen bonds with the same ordered water molecule; in the locust M-FABP 
this residue is substituted with a Val. Eight out of the fourteen amino acid residues located in 
the human M-FABP within 0.45 nm of the fatty acid, that have been proposed to interact with 
the methylenes of the hydrocarbon chain, namely Phel6, Met20, Val25, АІаЗЗ, Pro38, Lys58, 
Asp76 and Arg 126, are identical. The six other side chains within the same distance from the 
fatty acid are conserved and structurally comparable, as shown in Table 2, except for Thr29 
which is replaced by a Glu. The residue Phe57, that has been suggested to act as a lid covering 
the entry of the cavity where the Iigand is bound and is within van der Waals distance from the 
C-13 of the fatty acid in human M-FABP, is an lie residue in locust M-FABP. 
In the human M-FABP the residue Tyrl9 has been proposed to be a target for phospho­
rylation [9], in an analogous way to the Tyrl9 in the adipocyte FABP [16,17]. There is a 
comparable tyrosine residue in the locust M-FABP. Furthermore, the sequence prior to this 
amino acid, Asnl5-Phe-Asp-Aspl8, present in both human adipocyte FABP and M-FABP is 
highly conserved in the locust M-FABP, the Asp residues (17 and 18) being replaced with two 
Glu residues. 
The high overall sequence similarity and the presence of most of the amino acids 
involved in the fatty acid binding may indicate that the three-dimensional structure and the 
Iigand binding of locust M-FABP are analogous to human M-FABP. 
Expression, purification and characterization of the recombinant locust M-FABP 
The 3' RACE cDNA fragment, encoding the complete locust M-FABP, was cloned in 
pET-3d downstream of the T7 RNA polymerase promoter. The 15 kDa locust M-FABP was 
highly expressed in E. coli upon induction with isopropyl Д-D-thiogalactopyranoside and was 
not detected in uninduced cells. This was verified by SDS-PAGE and Western blotting (results 
not shown). Recombinant locust M-FABP could be isolated from bacterial lysate by 
precipitation with 50% ammonium sulphate, delipidation, anion-exchange and gel filtration 
chromatography (Fig. 4). The yield was 26 mg/1 culture. Analysis by SDS-PAGE revealed that 
the molecular mass of the recombinant protein is identical to the one of the protein isolated 
from locust flight muscle. The amino acid analysis of the purified protein revealed the quantities 
of specific amino acids expected on base of the cDNA sequence. In contrast to the protein 
isolated from locust muscle, the recombinant protein contains the N-terminal methionine. This 
amino acid seems not to be removed by bacterial processing. Despite their high overall amino 
acid similarity locust and human M-FABP show no immunological cross-reactivity, indicating 
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that the amino acids 
located on the surface of 
both proteins differ (Fig 
5). Both M-FABPs do 
not react with anti-
(human liver FABP) 
antiserum and human 
liver FABP does not 
react with all antí-(M-
FABP) antisera (data not 
shown). 
We established 
binding characteristics of 
locust M-FABP with 
oleic acid and various 
fluorescent ligands and compared these 
results with new data on human M-
FABP. First we determined the 
apparent K,, values for [l-14C]oleic acid 
with the Lipidex procedure. The Kd 
value for recombinant locust and human 
M-FABP are 0.47 ± 0.16 μΜ and 0.43 
± 0.03 μΜ (mean ± SD of 5 
independent experiments), respectively. 
The latter value agrees with previous 
data on isolated and recombinant human 
M-FABP [6,8]. The K„ value for the 
isolated locust M-FABP was also 
assayed and now established to be 0.59 
± 0.06 μΜ (mean ± SD of 3 
experiments). All K,, values found for 
21 
14 
Fig. 4 SDS-PAGE at different stages of purification of recombinant locust 
M-FABP. Lanes 1 and 5, molecular mass markers (kDa); lane 2, bacterial lysate 
4 h after induction (125 μg protein); lane 3, supernatant after 50% ammonium 
sulphate precipitation (50 μ%); lane 4 purified locust M-FABP (15 /ig). The 
proteins were stained with Coomassie Brilliant Blue. 
1 2 3 1 2 3 
Fig. 5 Immunological cross-reactivity of FABPs and FABP-
antisera. Preparations of recombinant M-FABPs (5 /xg) were 
run on SDS-PAGE, transferred to nitrocellulose and immunos-
tained with a polyclonal antiserum against human M-FABP 
(panel A) and a monoclonal antiserum against locust M-FABP 
(panel B). Lane 1, human M-FABP; lane 2, locust M-FABP and 
lane 3, molecular mass markers. A polyclonal rabbit and-(locust 
M-FABP) antiserum also only reacted with locust M-FABP (not 
recombinant and native locust M-FABP 
are similar, but lower than previously reported [22]. 
With titration microcalorimetry various parameters related to the binding of oleic acid to 
recombinant locust M-FABP were determined. The locust M-FABP solution was injected into 
[9,10-3H]oleic acid solution in the sample cell in contrast to previous investigations whereby the 
fatty acid was injected [43,44]. With our procedure the real concentration of oleic acid present 
could be determined after the experiment. The loss of fatty acid sticking to the equipment used 
during the experiment is approximately 60% but does not affect the experiment in this case. The 
results of a typical titration experiment of oleic acid with locust M-FABP are shown in Fig. 6. 
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The data were fitted to a 
mathematical model that 
assumes one class of 
binding sites and revealed 
a molar b ind ing 
stoichiometry of 1.03 ± 
0.13 and a Kt of 0.47 ± 
0.08 μΜ (n=3). This K< 
value is in excellent 
accordance with the value 
determined with the 
Lipidex procedure for 
locust M-FABP. The 
calculated AG, ΔΗ and 
AS value were -36.1 ± 
0.4 kJ/mol, -146 ± 7.5 
kJ/mol and 369 ± 26 
J/mol K, respectively. 
The obtained AG 
value is in good 
agreement with the AG 
values for fatty acid 
binding on rat intestinal 
FABP [43,44] and liver 
FABP [44] (Table 3). 
However the AH and AS 
values differ markedly 
from the values found for 
intestinal FABP [43,44] 
and liver FABP [44]. 
These differences may in 
part be due to the effect 
of the high fatty acid 
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Fig. 6 Titration calorimetry data for the binding of oleic acid to locust M-
FABP. The upper panel illustrates (he data ш the form of an injection diagram. 
In the lower panel, the filled circles represent the normalized areas under each 
injection spüce. The curve was mathematically fitted assuming one affinity class 
of binding sites. The fatty acid concentration m the sample cell was between IS 
and 25 μΜ for different experiments, and 25 4-¿il-portions of a 0.55 mM locust 
M-FABP solution were injected. The figure is representative for one out of three 
experiments. 
concentration and the methanol as used in these latter experiments. A potential problem using 
fatty acid as the titrant is the locally high concentration which will lead to the formation of acid-
soaps or micelles. After injection the dissociation of micelles into monomers might affect the 
thermodynamic parameters. Methanol has been claimed to give a carrier signal, that increases 
the signal-noise ratio in the measurements [44]. However it also increases the amount of fatty 
acid in solution, and the real fatty acid concentration was not determined. Moreover the 
interactions of the methanol with the protein may affect the conformation of the protein and/or 
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its binding characteristics. It has been shown for the crystal structure of human M-FABP that 
ordered solvent closely interacts with bound fatty acid [9]. These two combined effects could 
have led to an inadequate estimation of the enthalpy and entropy values for intestinal and liver 
FABP. 
Table 3 Fluorescence increase of différent fatty acids in reaction with human or locust M-FABP. 
Experiments were performed with 2.8 μΜ human M-FABP or 4.0 μΜ locust M-FABP and 1.0 μΜ fatty acid. 
The fluorescence increase is the ratio of the fluorescence with and without protein. Fluorescence increase of 11-
dansylamino-undecanoic acid is relative to the emission without protein at 545 nm (excitation at 328 run), since 
at 505 nm (excitation 345 nm) no fluorescence without protein is observed. Values are means ± S.D. of three 
independent experiments. 
Wavelength Fluorescence increase 
Ligand 
ll-Dansylamino-undecanoic acid 
2-(9-Anthroyloxy) palmitic acid 
16-(9-Anthroyloxy) oleic acid 
16-(9-Anthroyloxy) palmitic acid 
Cis-pannaric acid 
Trans-pannanc acid 
excitation 
run 
340 
365 
365 
365 
306 
306 
emission 
nm 
505 
452 
452 
452 
410 
410 
human 
M-FABP 
3.4 ± 0.2 
13.3 ± 0 2 
5.8 ± 0.4 
2.5 ± 0 6 
5.7 ± 0.4 
5 5 ± 0.5 
locust 
M-FABP 
5.0 ± 0.1 
8.8 ± 0.2 
7.9 ± 0.1 
1.5 ± 0.3 
7.9 ± 0.6 
9 2 ± 0.3 
Table 4 The K, values for various fatty acids with human and locust M-FABP. The K, values were derived 
from data of competitive inhibition of [>4C]oleic acid binding determined with the Lipidex procedure. To 0.28 
μΜ human M-FABP or 0.4 μΜ locust M-FABP, equal amounts (1 μΜ) of [l-'4C]oleic acid and competitor were 
added. The K, values were determined with displacement analysis as described in Materials and Methods. Values 
are means ± S.D. of at least three experiments. 
Competitor Human M-FABP Locust M-FABP 
Palmitic acid 
Linoleic acid 
Ілпоіешс acid 
Archidonic acid 
Cis-pannanc acid 
Trans-pannanc acid 
ll-Dansylanuno-undecanoic acid 
2-(9-Anthroyloxy) palmitic acid 
12-(9-Anthroyloxy) oleic acid 
1649-Anthrovloxy) palmitic acid 
μΜ 
1.11 ± 0.37 
0 51 ± 0.09 
0.48 ± 0.10 
0.95 ± 0.35 
1.26 ± 0.23 
0.49 ± 0 03 
1.11 ± 0.18 
1.36 ± 0.33 
0.80 ± 0.07 
0.83 -t 0.08 
μΜ 
0.49 ± 0.06 
1.15 ± 0.41 
1.08 ± 0.20 
2.56 ± 0.38 
1.32 ± 0.35 
0.58 ± 0.05 
0 90 ± 0.19 
2.12 ± 1.06 
1.25 ± 0.48 
0 81 ± 0 05 
Fluorescent probes were used to analyze the relative fluorescence increase upon binding 
of fatty acid by recombinant locust and human M-FABP (Table 3). The muscle type FABPs 
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react similarly with the fluorescent probes and give a markedly lower fluorescence increase than 
human liver FABP [45]. This large difference in fluorescence increase is due to the more 
hydrophobic binding site of the liver FABP [45-47]. The differences between the fluorescence 
increase of both muscle types with 2-(9-anthroyloxy)palmitic acid and 16-(9-anthroyloxy)palmi-
tìc acid, 13.3 and 2.5, respectively for human M-FABP and 8.8 and 1.5, respectively for locust 
M-FABP, in spite of its higher concentration suggest a weaker interaction of locust M-FABP 
with the fluorescent reporter group. 
The low fluorescence enhancement does not allow determination of an apparent K¿ value 
of the fluorescent fatty acids with muscle FABPs. Moreover this parameter may indicate only 
the interaction of the reporter group with the protein for 11-dansylamino-undecanoic acid and 
the anthroyloxy fatty acids. We used another method, the displacement of [14C]oleic acid in 
combination with the Lipidex procedure to determine the K¡ values of these fatty acids and of 
the parinaric acids. The same procedure we applied for four natural long-chain fatty acids 
(Table 4). In comparison to human M-FABP, the locust M-FABP appears to have a lower K¡ 
value for palmitic acid and a higher K, value for the C-18 unsaturated fatty acids and especially 
for arachidonic acid. This may be due to the substitution of Phe57 by Ile59, but also to other 
differences of the binding cavity. Both M-FABPs have a higher affinity to trans-parinaric than 
to cis-parinaric acid, in contrast with recombinant rat liver and intestinal FABP [48]. The fatty 
acids with the anthroyloxy group at the C-2- and C-12-position of the carbon chain show a 
slightly higher affinity with human M-FABP than with locust M-FABP. Others reported 
comparable apparent K¿ values for the binding of anthroyloxy fatty acids to rodent adipocyte 
and heart FABPs (17, 49, 50), molecules with a similar tertiary structure as human M-FABP. 
Generally, the interactions of all fatty acids with both M-FABP types are rather similar, 
indicating that the locations where the fatty acids bind present the same overall characteristics. 
Crystallization and preliminary X-ray diffraction studies of recombinant locust M-FABP 
Crystals of locust M-FABP diffract to a maximum resolution of about 0.22 nm. Analysis 
of the data revealed a primitive trigonal unit cell with dimensions of a=b=5.89 nm, c=14.42 
nm and a=90°, 0=90", γ=120°. The volume of the unit cell is 4.33 χ IO4 nm3. A total of 
23,729 reflections over 27,423 possible within the resolution range from 2.0-0.22 nm were 
collected from a single crystal. The data set showed an R . ^ based on intensity of 10.2%, a 
86.5% completeness in the considered resolution range and a б-fold redundancy. Further 
examination of the unreduced diffraction data revealed the absence of all reflections along the 
reciprocal с axis except the ones with Miller indices (0, 0, 3n). The inspection of the pseudo-
precession pictures obtained from the data reduced with a P3 symmetry indicated the presence 
of a three-fold symmetry axis along с This finding indicates that the space group is P3,21 
(P3221). Since there are 6 asymmetric units in the P3,21 unit cell, the total volume of the 
asymmetric unit is 7.2 χ IO3 nm3. Assuming the presence of two protein molecules per asym­
metric unit and a molecular mass of the locust M-FABP of 15 kDa, the volume per unit 
molecular weight is 0.24 nmVDalton, which is a value in the range expected for a protein 
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crystal [51]. The high amino acid sequence similarity should allow us to use the human M-
FABP as a starting model for the determination of the tertiary structure of the locust M-FABP 
using molecular replacement methods [52]. 
In conclusion, the structure of M-FABP is highly conserved during evolution. The 
primary structure of locust M-FABP shows a high similarity with that of human M-FABP. The 
conservation of the amino acids relevant for fatty acid binding is reflected in the similar binding 
characteristics. No immunological relation is however present. Elucidation of the three-dimen-
sional structure will give more information about the position of the relevant amino acid 
residues. 
Chapter 6 
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Survey and summary/samenvatting 
Many organs of all kinds of species utilize fatty acids as their main fuel. Fatty acids 
form also important compounds of membrane components as phospho- and glycerosphingoli-
pids. In addition, fatty acids and their Coenzyme A esters may influence directly or indirectly 
various cellular processes by interference with cell signaling, gene regulation, membrane 
transport systems or enzyme actions. Fatty acid-binding proteins (FABPs) are supposed to be 
involved in the intracellular transport of fatty acids and the modulation of fatty acid concentrati­
on. These molecules have a low molecular mass (IS kDa) and are present in the cytoplasm. The 
existence of at least seven F ABP types with differences in tissue and cellular distribution and in 
physicochemical and binding properties is of large interest with respect to their function. 
We especially performed our studies on FABPs of kidney since the various parts of the 
nephron show a marked biochemical and physiological heterogeneity. Marked differences are 
present in the permeability and transport properties, the oxygen consumption and dependence, 
the excretion of and sensibility for drugs and the fatty acid metabolism of the nephron 
segments. 
An additional comparative study was performed on the primary structure and binding 
properties of muscle FABP of Locusta migratoria and human to study evolutionary aspects of 
this protein. 
In Chapter 2 an overview is given on the structural and functional aspects of the seven 
FABP types isolated thus far. Data are presented on their cellular and subcellular distribution. 
Structural data on the FABP types and on the related members of the FABP family, the cellular 
retinol- and cellular retinoic acid-binding proteins are compared. The variations in the three-
dimensional structure and the protein-fatty acid interaction are discussed together with the 
methods applied to obtain the information. Variations in ligand specificity and stoichiometry are 
observed for the different FABP types. The function of FABPs as transfer proteins and their 
possible modulatory role in various cellular processes as cell signaling, gene regulation, ion 
transport and lipid metabolism are considered. The gene structure of the members of the FABP 
family is compared. The regulation of the FABP expression in various conditions has become of 
interest since in the upstream 5' flanking region of the various FABP genes several sequence 
elements have been identified that influence the expression level. 
In our studies on renal FABPs we started with the purification of the protein from 
human kidney (Chapter 3). Using ion-exchange and gel filtration chromatography we isolated 
two FABP types. Characterization based on molecular mass, isoelectric point, fluorescence with 
DAUDA and immunological crossreactivity showed that type A had much in common with the 
liver FABP type. The other, type B, was highly identical with the heart/muscle FABP type. 
Type A, with a molecular mass of 14.5 kDa and a pi of 6.8 showed a fluorescence enhance­
ment and a emission wavelength shift in reaction with DAUDA. Type B, with a molecular mass 
of 1S.5 kDa and a pi of 5.2 showed only a slight fluorescence enhancement and no wavelength 
shift with DAUDA. Type A is present in the proximal tubules whereas type В is predominantly 
present in the distal tubules of man. The presence of two FABP types within kidney with a dif­
ferent localization was not described before. In intestine two FABP types, the liver and the 
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intestinal type, were found but with a similar localization, in stomach four FABP types 
appeared to be present with a different cellular distribution. 
Definitive evidence of the primary structure of the two FABP types present in human 
kidney was obtained by elucidation of the cDNA sequence (Chapter 4). Based on the protein 
data we used primers deduced from the liver and heart FABP cDNA sequence in a reverse 
transcriptase PCR. The cDNAs isolated revealed that type A and В from human kidney are 
identical with the liver and heart FABP type, respectively. Results with enzyme-linked 
immunosorbent assay and ion-exchange chromatography suggested that the liver FABP is also 
present in rat kidney. Using reverse transcriptase PCR we showed that rat kidney also contains 
both FABP types. Immunolocalization showed that the heart FABP type is similarly distributed 
in rat kidney as in human kidney. The liver FABP type however is not only present in the 
proximal tubules but also in the distal and collecting tubules of the rat but its concentration is 
much less than in human kidney. 
The presence of two FABP types in kidney and their different localization suggest a 
type-specific function. Binding studies indicated that the liver FABP type is a more general 
carrier and might be involved in excretion processes. The heart FABP type only binds fatty 
acids and seems to be involved in lipid metabolism. To gain more insight in their possible role, 
both proteins were expressed in E. coli and their binding affinities determined for various 
hydrophobic ligands (Chapter 5). We obtained efficient expression of human liver FABP in E. 
colt. However the expression was low in comparison with the heart/muscle FABP type and 
required overnight induction in the presence of the bacterial RNA polymerase inhibitor, 
rifampicin. The binding characteristics of delipidated recombinant liver FABP and muscle 
FABP for fatty acids of different chain-length and saturation grade and for various hydrophobic 
ligands were determined by radiochemical analysis and for liver FABP also by fluorescence. 
The apparent binding affinity of the ligands was calculated by using displacement curves of 
oleic acid and DAUDA. Liver FABP showed a preference for binding of long-chain saturated 
and unsaturated fatty acids up to C24i whereas the muscle FABP has a preference for un­
saturated fatty acids, especially with 18 С atoms. Liver FABP also binds palmitoyl derivatives 
and other hydrophobic ligands as prostaglandins, 1,25 dihydroxy vitamin D3, steroid hormone, 
retinoids and hexadecanedioic acid, generally however with a lower affinity than fatty acids. 
Muscle FABP only binds fatty acids, testosterone and oestradiol with high affinity. Fatty acids 
with fluorescent reporter groups are also more tightly bound by liver FABP. A direct assay and 
displacement studies of oleic acid gave the same Kd value of DAUDA for liver FABP. 
Fluorescence enhancement and displacement studies indicate that the binding of fluorescent fatty 
acids is presumably determined by a different kind and location of interaction with both the 
fluorescent reporter group and the acyl carbon chain (Chapter 5). 
In conclusion we established, based on protein and cDNA data, the presence of both the 
liver and heart FABP type in the kidney. The distribution along the nephron suggests that the 
liver FABP type, predominantly present in the proximal part, is a more general carrier involved 
in transport and excretion of all kinds of hydrophobic ligands. The heart FABP type, predomi-
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nantly present in the distal part only binds fatty acids and is involved in lipid metabolism. For 
the continuation of this research, proximal tubule cells cultured on niters offer a good model to 
study the function of liver FABP in kidney. It is of high relevance to check if nephrotoxic 
agents are bound by the liver FABP type and really transported in the intact cell. The effect of 
tiansfection of those cells with liver FABP cDNA or antísense RNA could give more informati-
on on the role of this protein in uptake, transfer and excretion of various ligands. The expressi-
on of liver FABP in the cultured proximal tubule cells in the absence or presence of various 
fatty acids might give information about possible direct regulation of the FABP gene by these 
ligands. 
In an additional project we did a comparative analysis on flight muscle FABP of Locusta 
migratoria and human muscle FABP (Chapter 6). A full-length cDNA of locust muscle FABP 
was isolated by 3' and 5' rapid amplification of cDNA ends. By comparison of the primary 
structure of Lm and human muscle FABPs we obtained information about identical and 
functionally relevant amino acids. The primary structure of muscle FABP appeared to be highly 
conserved during evolution. The locust muscle FABP was expressed in E. coli and analyzed for 
its immunological behaviour and binding properties. Remarkable was the low immunological 
cross-reactivity with human muscle FABP in spite of the high similarity. The binding properties 
were studied by radiochemical displacement assays, titration microcalorimetry and binding 
assays of fluorescent fatty acids. Generally, the binding characteristics for oleic acid and 
fluorescent fatty acids of human and locust muscle FABP were similar indicating that the 
cavities where the fatty acid binds present the same overall characteristics. The recombinant 
locust protein was crystallized and analysis of the three-dimensional structure was started. The 
results of this analysis will give additional information to the known three-dimensional structure 
of human muscle FABP and data obtained in studies on site-directed mutants of this protein. 
Functional analysis of muscle FABP is complicated since transport of fatty acids from 
plasma membrane to cellular organelles cannot adequately be measured or visualized with 
fluorescent or radiochemical markers. A possibility to determine the function of muscle FABP 
is to transfect muscle cells with muscle FABP cDNA or antisense RNA or to inactivate the 
FABP gene by homologous recombination and generate mice which are deficient or partially 
deficient for this protein. 
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SAMENVATTING 
Veel organen van verschillende diersoorten benutten vetzuren als hoofdbron van energie. 
Vetzuren zijn ook belangrijke verbindingen van membraan bestanddelen als fosfolipiden en 
sfingoglycolipiden. Bovendien kunnen vetzuren en hun coenzym A esters direct of indirect 
verscheidene cellulaire processen beïnvloeden door interferentie met signaal transductie, 
genregulatie, membraantransport systemen of enzymactiviteiten. Vetzuurbindende eiwitten 
worden verondersteld betrokken te zijn bij het intracellulair transport van vetzuren en de 
modulering van de vetzuur concentratie. Deze moleculen hebben een laag moluculair gewicht 
(15 kDa) en zijn aanwezig in het cytoplasma. Het bestaan van minstens zeven FABP typen met 
verschillen in weefsel en cellulaire verspreiding en in fysisch-chemische en bindingseigenschap-
pen is van groot belang met betrekking tot hun functie. 
Wij hebben in het bijzonder onze studies uitgevoerd aan FABPs uit de nier omdat de 
verscheidene delen van het nefron een duidelijke biochemische en fysiologische heterogeniteit 
vertonen. Duidelijke verschillen zijn aanwezig in de permeabiliteit en transporteigenschappen, 
het zuurstofverbruik en -afhankelijkheid, de uitscheiding van en gevoeligheid voor medicijnen 
en het vetzuurmetabolisme van de nefron segmenten. Bovendien werd een vergelijkende studie 
uitgevoerd aan de primaire structuur en bindingseigenschappen van spier FABP van Locusta 
migratoria en mens om de evolutionaire aspecten van dit eiwit te bestuderen. 
In hoofdstuk 2 wordt een overzicht gegeven van de structurele en functionele aspecten 
van de zeven FABP typen die tot dusver zijn geïsoleerd. Hun cellulaire en subcellulaire 
verspreiding wordt besproken. Structurele gegevens van de FABP typen en verwante leden van 
de FABP-familie, de cellulaire retinol- en cellulaire retinolzuur-bindende eiwitten worden 
vergeleken. De variatie in de driedimensionale structuur en de eiwit-vetzuur interactie worden 
bediscusieerd samen met de methoden die gebruikt zijn om deze informatie te verkrijgen. 
Verschillen in ligandspecificiteit en -stoichiometric zijn waargenomen voor de verschillende 
FABP typen. De functie van FABPs als transport eiwitten en hun mogelijk modulerende rol bij 
verscheidene cellulaire processen als signaaltransductie, genregulatie, iontransport en lipidenme-
tabolisme worden beschouwd. De genstructuur van de leden van de FABP familie is vergeleken. 
De regulatie van de FABP expressie onder verschillende omstandigheden is blijkt van belang 
omdat in de 5' regio stroomopwaarts van de verscheidene FABP genen meerdere DNA elemen-
ten zijn geïdentificeerd die het expressie niveau beïnvloeden. 
In onze studies aan nier FABPs zijn we gestart met de zuivering van het eiwit uit 
humane nier (Hoofdstuk 3). Met behulp van ionenwisseling chromatografie en gelfiltratie 
hebben we twee FABP typen geïsoleerd. Karakterisering op basis van het molecuulgewicht, 
isoelectrisch punt, fluorescentie met 11-dansylamino-undecaanzuur (DAUDA) en immunologi-
sche kruisreactìviteit toonden aan dat type A veel overeenkomsten heeft met het lever FABP 
type. Het andere, type B, was zeer identiek met het hart/spier FABP type. Type A, met een 
molecuulgewicht van 14,5 kDa en een isoelectrisch punt van 6,8 toonde een fluorescentie 
toename en een emissie golflengte verschuiving bij interactie met DAUDA. Type B, met een 
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molecuulgewicht van 15,5 kDa en een isoelectrisch punt van 5.2 toonde een geringe fluorescen­
tie toename en geen emissie golflengte verschuiving met DAUDA. Type A is aanwezig in de 
proximale tubuli van de mens terwijl type В voornamelijk aanwezig is in de distale tubuli. De 
aanwezigheid van twee F ABP typen in één orgaan met een verschillende localisatie was nog niet 
eerder beschreven. In darm werden twee FABP typen, het lever en het darm type, gevonden 
met eenzelfde localisatie. 
Het definitieve bewijs voor de primaire structuur van de twee FABP typen aanwezig in 
humane nier werd verkregen door opheldering van de cDNA nucleotidenvolgorde (Hoofdstuk 
4). Gebaseerd on de eiwitgegevens werden primers, afgeleid van het lever en hart FABP 
cDNA, gebruikt in een reverse transcriptase polymerase ketting reactie. De nucleotidenvolgorde 
van de geïsoleerde cDNAs toonden aan dat type A en В uit humane nier hetzelfde zijn als het 
lever en hart FABP type, respectievelijk. Resultaten verkregen uit ELISA en ionenwisseling 
chromatografie suggereerden dat het lever FABP ook aanwezig is in de nier van rat. Met behulp 
van de reverse transcriptase polymerase ketting reactie toonden we aan dat rat nier ook beide 
typen bevat. Immunohistochemische analyse toonde aan dat het hart FABP type op dezelfde 
wijze verspreid is in rattenier als humane nier. Echter het lever FABP type is niet alleen 
aanwezig in de proximale tubuli van de rat maar ook in de distale tubuli en verzamelbuizen 
maar de concentratie is veel lager dan in humane nier. 
De aanwezigheid van twee FABP typen in nier en hun verschillende localisatie sugge­
reert een type specifieke functie. Bindingsstudies toonden aan dat het lever FABP type meerdere 
soorten van liganden bindt en betrokken zou kunnen zijn in uitscheidingsprocessen. Het hart 
FABP type bindt bijna uitsluitend vetzuren en lijkt betrokken bij het lipiden metabolisme. Om 
meer inzicht te krijgen in deze mogelijke rol werden beide eiwitten tot expressie gebracht in 
Escherichia coli en werd de bindingsaffiniteit voor verscheidene hydrofobe liganden bepaald 
(Hoofdstuk 5). We bewerkstelligden een efficiente expressie van humaan lever FABP in E.coli. 
De expressie was echter laag in vergelijking met hart/spier FABP en vereiste overnacht inductie 
in aanwezigheid van de bacteriële RNA polymerase remmer, rifampicine. De bindingskarakte-
ristieken van gedelipideerd recombinant lever FABP en spier FABP voor vetzuren met een 
verschillende ketenlengte en verzadigingsgraad en voor verscheidene hydrofobe liganden werden 
bepaald via radiochemische analyse en voor lever FABP ook met behulp van fluorescentie. De 
bindingsaffiniteit voor de liganden werd berekend met behulp van verdringingscurves met 
oliezuur en DAUDA. Lever FABP toonde een een voorkeur in binding van langketen, verzadig-
de en overzadigde, vetzuren tot C24:l toe terwijl het spier FABP een voorkeur heeft voor 
onverzadigde vetzuren in het bijzonder met 18 С atomen. Lever FABP bindt ook palmitoyl 
derivaten en andere hydrofobe liganden zoals Prostaglandines, 1,25 dihydroxy-vitamine D3, 
testosteron, retinoiden en hexadecaandicarbonzuur, echter in het algemeen met lagere affiniteit 
dan vetzuren. Spier FABP bindt alleen vetzuren, testosteron en oestradiol met hoge affiniteit. 
Vetzuren met fluorescente reporter groepen worden ook beter door lever FABP gebonden. Een 
directe analyse en verdringingsstudies met oliezuur leverden een zelfde dissociatieconstante van 
DAUDA voor lever FABP op. Fluorescentie toename en verdringingsstudies geven aan dat de 
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binding van fluorescente vetzuren waarschijnlijk wordt bepaald door verschillen in plaats en 
type van interactie tussen de fluorescente reporter groep en de acyl koolstofketen (Hoofdstuk 5). 
Samengevat, we toonden de aanwezigheid van zowel lever als hart F ABP type aan in de 
nier op basis van eiwit en cDNA studies. Hun verdeling over het nefron suggereert dat het lever 
F ABP, voornamelijk aanwezig in het proximale deel, betrokken is bij transport en uitscheiding 
van allerlei hydrofobe liganden. Het hart FABP type, voornamelijk aanwezig in het distale deel, 
is betrokken bij het lipiden metabolisme. 
In een ander project hebben we een vergelijkende analyse uitgevoerd aan vliegspier 
FABP van Locusta migratoria en humaan spier FABP (Hoofdstuk 6). Een volledige cDNA van 
locust spier FABP werd geïsoleerd via 3' en 5' snelle amplificering van cDNA einden. Door 
vergelijking van de primaire structuur van locust en humaan spier FABP verkregen we 
informatie over identieke en functioneel relevante aminozuren. De primaire structuur van spier 
FABP bleek zeer sterk geconserveerd tijdens de evolutie. Het locust spier FABP werd tot 
expressie gebracht in E.coli en het immunologische gedrag werd geanalyseerd. Opvallend was 
de lage immunologische kruisreactiviteit met humaan spier FABP in tegenstelling tot de grote 
overeenkomst in primaire structuur. De bindingseigenschappen werden bestudeerd via radioche-
mische verdringingsstudies, titratie microcalorimetrie en bindings analysen met fluorescente 
vetzuren. In het algemeen was er een grote overeenkomst tussen de bindingskarakteristieken 
voor oliezuur en fluorescente vetzuren van humaan en locust spier FABP, hetgeen aangeeft dat 
de holte waarin het vetzuur bindt een zelfde structuur vertoont. Het locust spier FABP werd 
gekristaliseerd en opheldering van de drie-dimensionale structuur werd begonnen. De resultaten 
van deze analyse zullen aanvullende informatie geven bij de bekende structuur van het humaan 
spier FABP en gegevens verkregen in studies aan mutanten van dit eiwit. 
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